詳細

甲斐田　勇人 （カイダ　ハヤト）

  • 医学科　准教授
Last Updated :2024/04/23

コミュニケーション情報 byコメンテータガイド

  • コメント

    PETやSPECTによる核医学診断を中心に診療と多施共同研究を行っています。PETによる腫瘍診断がメインテーマです。

研究者情報

学位

  • 博士（医学）（2005年11月 久留米大学）

ホームページURL

科研費研究者番号

  • 40299425

J-Global ID

プロフィール

  • 日本医学放射線診断専門医

    日本核医学会専門医

    PET核医学認定医

    日本がん治療認定医

研究キーワード

  • PET   CT   FDG PET   核医学(PETを含む)   FDG-PET/CT   心臓CT   癌増殖シグナル伝達因子   SUV max   不安定プラーク   肺癌   冠動脈疾患   血清マーカー   頸動脈硬化   放射線   循環器・高血圧   PET/CT   GLUT 1   GLUT 3   腫瘍核医学   癌   卵巣癌   悪性胸膜中皮腫   GLUT family   ERK MAPK   分子病理学   分子病理   VEGF   細胞増殖   乳癌   婦人科癌   

現在の研究分野（キーワード）

    PETやSPECTによる核医学診断を中心に診療と多施共同研究を行っています。PETによる腫瘍診断がメインテーマです。

研究分野

  • ライフサイエンス / 放射線科学

経歴

  • 2023年04月 - 現在  近畿大学高度先端総合医療センターPET分子イメージング部准教授
  • 2020年04月 - 2023年03月  近畿大学高度先端総合医療センターPET分子イメージング部講師
  • 2015年04月 - 2020年03月  近畿大学医学部医学部講師
  • 1999年04月 - 2015年03月  久留米大学医学部助教

学歴

  • 1991年04月 - 1997年03月   近畿大学   医学部   医学科

研究活動情報

論文

  • Tetsuya Kobayashi; Yui Shigeki; Yoshiyuki Yamakawa; Yumi Tsutsumida; Tetsuro Mizuta; Kohei Hanaoka; Shota Watanabe; Daisuke Morimoto‐Ishikawa; Takahiro Yamada; Hayato Kaida; Kazunari Ishii
    Journal of Imaging Informatics in Medicine 37 1 167 - 179 2024年01月 [査読有り]
  • Nakamoto Y; Baba S; Kaida H; Manabe O; Uehara T
    Ann Nucl Med 38 1 10 - 19 2023年10月 [査読有り]
  • Kohei Hanaoka; Shota Watanabe; Daisuke Ishikawa; Hayato Kaida; Takahiro Yamada; Masakazu Yasuda; Yoshitaka Iwanaga; Gaku Nakazawa; Kazunari Ishii
    Journal of Nuclear Cardiology 30 5 1879 - 1885 2023年10月 [査読有り]
     
    Background The aim of this study was to estimate the impact of respiratory and electrocardiogram (ECG)-gated FDG positron emission tomography (PET)/computed tomography (CT) on the diagnosis of cardiac sarcoidosis (CS). Methods and Results Imaging from thirty-one patients was acquired on a PET/CT scanner equipped with a respiratory- and ECG-gating system. Non-gated PET images and three kinds of gated PET/CT images were created from identical list-mode clinical PET data: respiratory-gated PET during expiration (EX), ECG-gated PET at end diastole (ED), and ECG-gated PET at end systole (ES). The maximum standardized uptake value (SUVmax) and cardiac metabolic volume (CMV) were measured, and the locations of FDG accumulation were analyzed using a polar map. The mean SUVmax of the subjects was significantly higher after application of either respiratory-gated or ECG-gated reconstruction. Conversely, the mean CMV was significantly lower following the application of respiratory-gated or ECG-gated reconstruction. The segment showing maximum accumulation was shifted to the adjacent segment in 25.8%, 38.7%, and 41.9% of cases in EX, ED, and ES images, respectively. Conclusion In FDG PET/CT scanning for the diagnosis of CS, gated scanning is likely to increase quantitative accuracy, but the effect depends on the location and synchronization method.
  • Effects of CT-based attenuation correction on quantitative SPECT/CT of jawbone
    Tsuchitani T; Kitajima K; Takahashi Y; Yoshida R; Kaida H; Tsurusaki M; Minami T; Kotura N
    Hell J Nucl Med 26 2 108 - 113 2023年08月 [査読有り]
  • Asymmetric diffuse thyroid uptake on 18F-FDG PET/CT in patient with subacute thyroiditis: Case report and literature review
    Kaida H; Wakana M; Yoshida S; Matsukubo Y; Ishii K
    Hell J Nucl Med 26 2 150 - 154 2023年08月 [査読有り]
  • Kaida H; Kitajima K; Sekine T; Ito K; Daisaki H; Kimura T; Sato MP; Enomoto A; Otsuki N; Ishii K
    Dentomaxillofac Radiol 52 7 20230083  2023年07月 [査読有り]
     
    OBJECTIVES: To investigate the usefulness of harmonized 18F-FDG-PET/CT parameters for predicting the postoperative recurrence and prognosis of oral tongue squamous cell carcinoma (OTSCC). METHODS: We retrospectively analyzed the cases of 107 OTSCC patients who underwent surgical resection at four institutions in Japan in 2010-2016 and evaluated the harmonized PET parameters of the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) for the primary tumor as the pSUVmax, pMTV, and pTLG. For lymph node metastasis, we used harmonized PET parameters of nodal-SUVmax, nodal-total MTV (tMTV), and nodal-total TLG (tTLG). The associations between the harmonized PET parameters and the patients' relapse-free survival (RFS) and overall survival (OS) were evaluated by the Kaplan-Meier method and Cox proportional hazard regression analysis for model 1 (preoperative stage) and model 2 (preoperative   +  postoperative stages). RESULTS: The harmonized SUVmax values were significantly lower than those before harmonization (p=0.012). The pSUVmax was revealed as a significant preoperative risk factor for RFS and OS. Nodal-SUVmax, nodal-tMTV, and nodal-tTLG were significant preoperative risk factors for OS. The combination of pSUVmax + nodal-SUVmax significantly stratified the patients into a low-risk group (pSUVmax <3.97 + nodal-SUVmax <2.85 or ≥2.85) and a high-risk group (pSUVmax ≥3.97 + nodal-SUVmax <2.85 or pSUVmax ≥3.97 + nodal-SUVmax ≥2.85) for recurrence and prognosis (RFS: p=0.001; OS: p<0.001). CONCLUSIONS: The harmonized pSUVmax is a significant prognostic factor for the survival of OTSCC patients. The combination of pSUVmax and nodal-SUVmax identified OTSCC patients at high risk for recurrence and poor prognosis at the preoperative stage.
  • Hayato Kaida; Yuko Matsukubo; Sung-Woon Im; Nobuo Kashiwagi; Kazunari Ishii
    Clinical Nuclear Medicine 48 3 245 - 247 2023年03月 [査読有り]
  • Inada M; Nishimura Y; Hanaoka K; Nakamatsu K; Doi H; Uehara T; Komanishi M; Ishii K; Kaida H; Hosono M
    Radiotherapy and Oncology 180 109491  2023年03月 [査読有り]
  • Prognostic role of preoperative fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography with an image-based harmonization technique: A multicenter retrospective study
    Hamada A; Kitajima K; Suda K; Koga T; Soh J; Kaida H; Ito K; Sekine T; Takegahara K; Daisaki H; Hashimoto M; Yoshida Y; Kabasawa T; Yamasaki T; Hirota S; Usuda J; Ishii K; Mitsudomi T
    JTCVS Open. 14 502 - 552 2023年02月 [査読有り]
  • Daisuke Morimoto-Ishikawa; Kohei Hanaoka; Shota Watanabe; Takahiro Yamada; Yoshiyuki Yamakawa; Suzuka Minagawa; Shiho Takenouchi; Atsushi Ohtani; Tetsuro Mizuta; Hayato Kaida; Kazunari Ishii
    EJNMMI physics 9 1 88 - 88 2022年12月 [査読有り]
     
    BACKGROUND: This study evaluated the physical performance of a positron emission tomography (PET) system dedicated to the head and breast according to the National Electrical Manufacturers Association (NEMA) NU2-2012 standard. METHODS: The spatial resolution, sensitivity, scatter fraction, count rate characteristics, corrections for count losses and randoms, and image quality of the system were determined. All measurements were performed according to the NEMA NU2-2012 acquisition protocols, but image quality was assessed using a brain-sized phantom. Furthermore, scans of the three-dimensional (3D) Hoffmann brain phantom and mini-Derenzo phantom were acquired to allow visual evaluation of the imaging performance for small structures. RESULTS: The tangential, radial, and axial full width at half maximum (FWHM) at a 10-mm offset in half the axial field of view were measured as 2.3, 2.5, and 2.9 mm, respectively. The average system sensitivity at the center of the field of view and at a 10-cm radial offset was 7.18 and 8.65 cps/kBq, respectively. The peak noise-equivalent counting rate was 35.2 kcps at 4.8 kBq/ml. The corresponding scatter fraction at the peak noise-equivalent counting rate was 46.8%. The peak true rate and scatter fraction at 8.6 kBq/ml were 127.8 kcps and 54.3%, respectively. The percent contrast value for a 10-mm sphere was approximately 50%. On the 3D Hoffman brain phantom image, the structures of the thin layers composing the phantom were visualized on the sagittal and coronal images. On the mini-Derenzo phantom, each of the 1.6-mm rods was clearly visualized. CONCLUSION: Taken together, these results indicate that the head- and breast-dedicated PET system has high resolution and is well suited for clinical PET imaging.
  • Kazunari Ishii; Kohei Hanaoka; Shota Watanabe; Daisuke Morimoto-Ishikawa; Takahiro Yamada; Hayato Kaida; Yoshiyuki Yamakawa; Suzuka Minagawa; Shiho Takenouchi; Atsushi Ohtani; Tetsuro Mizuta
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 64 1 153 - 158 2022年12月 [査読有り]
     
    We acquired brain positron emission tomography (PET) images of fluorodeoxyglucose (FDG) and flutemetamol PET using a time-of-flight-PET system dedicated for the head (dhPET) and a conventional whole-body PET/computed tomography (wbPET) system and evaluated the clinical superiority of dhPET over wbPET. Methods: There were 18 subjects for the FDG-PET study and 17 subjects for the flutemetamol PET study. FDG-PET images were first obtained using wbPET, followed by dhPET. Flutemetamol PET images were first obtained using wbPET, followed by dhPET. Images acquired using dhPET and wbPET were compared by visual inspection, voxel-wise analysis, and standard uptake value ratio (SUVR). Results: All FDG and flutemetamol images acquired using dhPET were judged as better by visual inspection than those acquired using wbPET. The voxel-wise analysis demonstrated that accumulations in the cerebellum, lateral occipital cortices, and around the central sulcus area in dhPET FDG images were lower than those in wbPET FDG images, whereas accumulations around the ventricle systems were higher in dhPET FDG images than those in wbPET FDG images. Accumulations in the cerebellar dentate nucleus, midbrain, lateral occipital cortices, and around the central sulcus area in dhPET images were lower than those in wbPET images, whereas accumulations around the ventricle systems were higher in dhPET flutemetamol images than those in wbPET flutemetamol images. Mean cortical SUVRs of FDG and flutemetamol dhPET images were significantly higher than those of FDG and flutemetamol wbPET images, respectively. Conclusion: The dhPET images had better image quality by visual inspection and higher SUVRs than wbPET images. Although there were several regional accumulation differences between dhPET and wbPET images, understanding this phenomenon will enable full use of the features of this dhPET system in clinical practice.
  • Kaida H; Yasuda T; Shiraishi O; Kato H; Kimura Y; Hanaoka K; Yamada M; Matsukubo Y; Tsurusaki M; Kitajima K; Hattori S; Ishii K
    BMC Cancer 22 1 1176  2022年11月 [査読有り]
     
    BACKGROUND: Induction or adjuvant therapies are not always beneficial for thoracic esophageal squamous cell carcinoma (ESCC) patients, and it is thus important to identify patients at high risk for postoperative ESCC recurrence. We investigated the usefulness of the total metabolic tumor volume (TMTV) for predicting the postoperative recurrence of thoracic ESCC. METHODS: We retrospectively analyzed the cases of 163 thoracic ESCC patients (135 men, 28 women; median age of 66 [range 34-82] years) treated at our hospital in 2007-2012. The TMTV was calculated from the fluorine-18 fluorodeoxyglucose (18F-FDG) uptake in the primary lesion and lymph node metastases. The optimal cut-off values for relapse and non-relapse were obtained by the time-dependent receiver operating curve analyses. Relapse-free survival (RFS) was evaluated by the Kaplan-Meier method, and between-subgroup differences in survival were analyzed by log-rank test. The prognostic significance of metabolic parameters and clinicopathological variables was assessed by a Cox proportional hazard regression analysis. The difference in the failure patterns after surgical resection was evaluated using the χ2-test. RESULTS: The optimal cut-off value of TMTV for discriminating relapse from non-relapse was 3.82. The patients with a TMTV ≥3.82 showed significantly worse prognoses than those with low values (p < 0.001). The TMTV was significantly related to RFS (model 1 for preoperative risk factors: TMTV: hazard ratio [HR] =2.574, p = 0.004; model 2 for preoperative and postoperative risk factors: HR = 1.989, p = 0.044). The combination of the TMTV and cN0-1 or pN0-1 stage significantly stratified the patients into low-and high-risk recurrence groups (TMTV cN0-1, p < 0.001; TMTV pN0-1, p = 0.004). The rates of hematogenous and regional lymph node metastasis were significantly higher in the patients with TMTV ≥3.82 than those with low values (hematogenous metastasis, p < 0.001, regional lymph node metastasis, p = 0.011). CONCLUSIONS: The TMTV was a more significantly independent prognostic factor for RFS than any other PET parameter in patients with resectable thoracic ESCC. The TMTV may be useful for the identifying thoracic ESCC patients at high risk for postoperative recurrence and for deciding the patient management.
  • Nemoto M; Tanaka A; Kaida H; Kimura Y; Nagaoka T; Yamada T; Hanaoka K; Kitajima K; Tsuchitani T; Ishii K
    Phys Med Biol 67 19 2022年09月 [査読有り]
     
    Abstract We propose a method to detect primary and metastatic lesions with Fluorine−18 fluorodeoxyglucose (FDG) accumulation in the lung field, neck, mediastinum, and bony regions on the FDG-PET/CT images. To search for systemic lesions, various anatomical structures must be considered. The proposed method is addressed by using an extraction process for anatomical regions and a uniform lesion detection approach. The uniform approach does not utilize processes that reflect any region-specific anatomical aspects but has a machine-learnable framework. Therefore, it can work as a lesion detection process for a specific anatomical region if it machine-learns the specific region data. In this study, three lesion detection processes for the whole-body bone region, lung field, or neck-mediastinum region are obtained. These detection processes include lesion candidate detection and false positive (FP) candidate elimination. The lesion candidate detection is based on a voxel anomaly detection with a one-class support vector machine. The FP candidate elimination is performed using an AdaBoost classifier ensemble. The image features used by the ensemble are selected sequentially during training and are optimal for candidate classification. Three-fold cross-validation was used to detect performance with the 54 diseased FDG-PET/CT images. The mean sensitivity for detecting primary and metastatic lesions at 3 FPs per case was 0.89 with a 0.10 standard deviation (SD) in the bone region, 0.80 with a 0.10 SD in the lung field, and 0.87 with a 0.10 SD in the neck region. The average areas under the ROC curve were 0.887 with a 0.125 SD for detecting bone metastases, 0.900 with a 0.063 SD for detecting pulmonary lesions, and 0.927 with a 0.035 SD for detecting the neck-mediastinum lesions. These detection performances indicate that the proposed method could be applied clinically. These results also show that the uniform approach has high versatility for providing various lesion detection processes.
  • Hayato Kaida; Takeshi Okuda; Kohei Hanaoka; Kazunari Ishii
    Clinical nuclear medicine 47 11 965 - 967 2022年06月 [査読有り]
     
    ABSTRACT: A 20-year-old man had left visual impairment and homonymous hemianopsia. MRI findings suggested enlargement of an optic glioma, because optic glioma was indicated by MRI 14 years earlier without a definite pathological diagnosis. 11C-methionine (MET) PET showed high uptake in the tumor in the parasellar region. Transnasal endoscopic biopsy was performed, and an inflammatory pseudotumor (IPT) was diagnosed based on histopathological findings. High MET uptake in a parasellar IPT has apparently not been previously reported. Clinicians should be aware of the possibility of high MET uptake in IPT, because this image could provide an interpretation pitfall.
  • Tetsuro Mizuta; Tetsuya Kobayashi; Yoshiyuki Yamakawa; Kohei Hanaoka; Shota Watanabe; Daisuke Morimoto-Ishikawa; Takahiro Yamada; Hayato Kaida; Kazunari Ishii
    Annals of nuclear medicine 36 4 420 - 426 2022年04月 [査読有り]
     
    AIM: The aim of this study was to evaluate an image reconstruction algorithm, including a new maximum-likelihood attenuation correction factor (ML-ACF) for time of flight (TOF) brain positron emission tomography (PET). METHODS: The implemented algorithm combines an ML-ACF method that simultaneously estimates both the emission image and attenuation sinogram from TOF emission data, and a scaling method based on anatomical features. To evaluate the algorithm's quantitative accuracy, three-dimensional brain phantom images were acquired and soft-tissue attenuation coefficients and emission values were analyzed. RESULTS: The heterogeneous distributions of attenuation coefficients in soft tissue, skull, and nasal cavity were sufficiently visualized. The attenuation coefficient of soft tissue remained within 5% of theoretical value. Attenuation-corrected emission showed no lateral differences, and significant differences among soft tissue were within the error range. CONCLUSION: The ML-ACF-based attenuation correction implemented for TOF brain PET worked well and obtained practical levels of accuracy.
  • Mana Okune; Masakazu Yasuda; Naoko Soejima; Yoshinori Kagioka; Kazuyoshi Kakehi; Takayuki Kawamura; Kohei Hanaoka; Hayato Kaida; Kazunari Ishii; Gaku Nakazawa; Shunichi Miyazaki; Yoshitaka Iwanaga
    Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 29 2 753 - 764 2022年04月 [査読有り]
     
    BACKGROUND: Although each 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and cardiac magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE) has been used to diagnose cardiac sarcoidosis (CS), active CS is still misdiagnosed. METHODS: Active CS, diagnosed by PET alone, was defined as focal or focal on diffuse FDG uptake pattern. In fusion PET/CMR imaging, using a regional analysis with AHA 17-segment model, the patients were categorized into four groups: (1) PET-/LGE-, (2) PET+/LGE-, (3) PET+/LGE+, and (4) PET-/LGE+. PET+/LGE+ was defined as active CS. RESULTS: 74 Patients with suspected CS were enrolled. Between PET alone and fusion PET/CMR imaging, 20 cases had mismatch evaluations of active CS, and most had diffuse or focal on diffuse FDG uptake pattern on PET alone imaging. 40 Patients fulfilled the 2016 the Japanese Circulation Society diagnostic criteria for CS. The interobserver diagnostic agreement was excellent (κ statistics 0.89) and the overall accuracy for diagnosing CS was 87.8% in fusion PET/CMR imaging, which were superior to those in PET alone imaging (0.57 and 82.4%, respectively). In a sub-analysis of diffuse and focal on diffuse patterns, the agreement (κ statistics 0.86) and overall accuracy (81.8%) in fusion PET/CMR imaging were still better. CONCLUSIONS: Fusion PET/CMR imaging with regional analysis offered reliable and accurate diagnosis of CS, covering low diagnostic area by FDG-PET alone.
  • Mizuta T; Yamakawa Y; Minagawa S; Kobayashi T; Ohtani A; Takenouchi S; Hanaoka K; Watanabe S; Morimoto-Ishikawa D; Yamada T; Kaida H; Ishii K
    Ann Nucl Med 36 11 998 - 1006 2022年 [査読有り]
     
    OBJECTIVES: This study evaluates the phantom attenuation correction (PAC) method as an alternative to maximum-likelihood attenuation correction factor (ML-ACF) correction in time-of-flight (TOF) brain positron emission tomography (PET) studies. METHODS: In the PAC algorithm, a template emission image [Formula: see text] and a template attenuation coefficient image [Formula: see text] are prepared as a data set based on phantom geometry. Position-aligned attenuation coefficient image [Formula: see text] is derived by aligning [Formula: see text] using parameters that match the template emission image [Formula: see text] to measured emission image [Formula: see text]. Then, attenuation coefficient image [Formula: see text] combined with a headrest image is used for scatter and attenuation correction in the image reconstruction. To evaluate the PAC algorithm as an alternative to ML-ACF, Hoffman 3D brain and cylindrical phantoms were measured to obtain the image quality indexes of contrast and uniformity. These phantoms were also wrapped with a radioactive sheet to obtain attenuation coefficient images using ML-ACF. Emission images were reconstructed with attenuation correction by PAC and ML-ACF, and the results were compared using contrast and uniformity as well as visual assessment. CT attenuation correction (CT-AC) was also applied as a reference. RESULTS: The contrast obtained by ML-ACF was slightly overestimated due to its unique experimental condition for applying ML-ACF in Hoffman 3D brain phantom but the uniformity was almost equivalent among ML-ACF, CT-AC, and PAC. PAC showed reasonable result without overestimation compared to ML-ACF and CT-AC. CONCLUSIONS: PAC is an attenuation correction method that can ensure the performance in phantom test, and is considered to be a reasonable alternative to clinically used ML-ACF-based attenuation correction.
  • Munehisa Bekki; Nobuhiro Tahara; Atsuko Tahara; Yoichi Sugiyama; Shoko Maeda-Ogata; Akihiro Honda; Sachiyo Igata; Mika Enomoto; Tatsuyuki Kakuma; Hayato Kaida; Toshi Abe; Yoshihiro Fukumoto
    Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 29 5 2132 - 2144 2022年 [査読有り]
     
    BACKGROUND: The localization of myocardial 18F-fluorodeoxyglucose (FDG) uptake affecting long-term clinical outcomes has not been elucidated in patients with corticosteroid-naïve cardiac sarcoidosis (CS). OBJECTIVES: This study sought to investigate the localization of myocardial FDG uptake on positron emission tomography (PET) and myocardial perfusion abnormality to predict adverse events (AEs) for a long-term follow-up in patients with corticosteroid-naïve CS. METHODS: Consecutive 90 patients with clinical suspicion of CS who underwent FDG-PET imaging to assess for inflammation were enrolled. AEs were defined as a composite of sustained ventricular tachycardia (VT), heart transplantation, and all-cause death, which were ascertained by medical records, defibrillator interrogation, and telephone interviews. RESULTS: Of 90 patients, 42 patients (mean age 62.9 ± 12.0 years; 76.2% females) were confirmed active cardiac involvement. Over a median follow-up of 4.9 years, 15 patients with CS experienced AEs including 6 sustained ventricular tachycardias (VT) and 9 deaths. Cox proportional-hazards model after adjustment for left ventricular systolic dysfunction revealed that FDG uptake in the right ventricle (RV) or basal anterolateral area of the left ventricle (LV) with myocardial perfusion abnormality was predictive of AEs. CONCLUSIONS: FDG uptake in the RV or basal anterolateral area of the LV with myocardial perfusion abnormality provides long-term prognostic risk stratification in patients with corticosteroid-naïve CS.
  • Shinichi Imai; Nobuhiro Tahara; Sachiyo Igata; Atsuko Tahara; Munehisa Bekki; Yoichi Sugiyama; Shoko Maeda-Ogata; Akihiro Honda; Hiroyuki Otsuka; Tomoyuki Ushijima; Yoshinobu Okabe; Hayato Kaida; Toshi Abe; Hiroyuki Tanaka; Yoshihiro Fukumoto; Eiki Tayama
    Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2021年10月 [査読有り]
     
    BACKGROUND: Immunoglobulin G4-related disease (IgG4-RD) is characterized by the infiltration of IgG4-positive plasma cells and fibrosclerotic inflammation in multiple organs. Although vascular complications are present in some patients with IgG4-RD, vascular and/or perivascular inflammatory activity compared to control subjects remains unknown. This study sought to investigate vascular/perivascular inflammation in IgG4-RD patients compared to control subjects using 18F-fluorodeoxyglucose-positron emission tomography combined with computed tomography (FDG-PET/CT). METHODS: We examined 37 consecutive patients diagnosed as IgG4-RD (29 males, mean age of 64.3 ± 8.3 years old), who underwent FDG-PET/CT. Thirty-seven age- and gender-matched subjects without IgG4-RD were employed as controls. Vascular/perivascular inflammation was quantified by blood-normalized standardized uptake value, known as a target-to-background ratio (TBR). RESULTS: All IgG4-RD patients presented with multiple region involvements. Twelve (32.4%) of the IgG4-RD patients had vascular complications, all of which appeared in the abdominal aorta. IgG4-RD patients had significantly higher TBR values in the descending aorta, abdominal aorta, and common iliac artery than control subjects. Also, IgG4-RD patients with vascular complication exhibited higher TBR values in the infra-renal aorta and common iliac artery than those without vascular complication. CONCLUSIONS: We found that vascular FDG activity is significantly elevated in IgG4-RD patients regardless of vascular complication than control subjects. FDG-PET/CT is a useful modality for assessing vascular/perivascular inflammation, which may contribute vascular complication in IgG4-RD patients.
  • Hayato Kaida; Kazuhiro Kitajima; Masatoyo Nakajo; Mana Ishibashi; Tomoyuki Matsunaga; Ryogo Minamimoto; Kenji Hirata; Koya Nakatani; Ao Hung; Satoshi Hattori; Takushi Yasuda; Kazunari Ishii
    European journal of nuclear medicine and molecular imaging 48 11 3666 - 3682 2021年10月 [査読有り]
     
    PURPOSE: To investigate the usefulness of the positron emission tomography response criteria in solid tumors 1.0 (PERCIST1.0) for predicting tumor response to neoadjuvant chemotherapy and prognosis and determine whether PERCIST improvements are necessary for esophageal squamous cell carcinoma (ESCC) patients. PATIENTS AND METHODS: We analyzed the cases of 177 ESCC patients and examined the association between PERCIST and their pathological responses. Associations of whole-PERCIST with progression-free survival (PFS) and overall survival (OS) were evaluated by a Kaplan-Meier analysis and Cox proportional hazards model. To investigate potential PERCIST improvements, we used the survival tree technique to understand patients' prognoses. RESULTS: There were significant correlations between the pathologic response and PERCIST of primary tumor (p < 0.001). The optimal cutoff value of the primary tumors' SULpeak response to classify pathologic responses was -50.0%. The diagnostic accuracy of SULpeak response was 87.3% sensitivity, 54.1% specificity, 68.9% accuracy, positive predictive value 60.5%, and negative predictive value 84.1%. Whole-PERCIST was significantly associated with PFS and OS. The survival tree results indicated that a high reduction of the whole SULpeak response was significantly correlated with the patients' prognoses. The cutoff values for the separation of prognoses were - 52.5 for PFS and - 47.1% for OS. CONCLUSION: PERCIST1.0 can help predict tumor responses and prognoses. However, 18F-FDG-PET/CT tends to underestimate residual tumors in histopathological response evaluations. Modified PERCIST, in which the partial metabolic response is further classified by the SULpeak response (-50%), might be more appropriate than PERCIST1.0 for evaluating tumor responses and stratifying high-risk patients for recurrence and poor prognosis.
  • Kenta Sakaguchi; Hayato Kaida; Shuhei Yoshida; Kazunari Ishii
    Annals of nuclear medicine 35 5 589 - 599 2021年05月 [査読有り]
     
    OBJECTIVE: Non-uniform attenuation correction using computed tomography (CT) improves the image quality and quantification of single-photon emission computed tomography (SPECT). However, it is not widely used because it requires a SPECT/CT scanner. This study constructs a convolutional neural network (CNN) to generate attenuation-corrected SPECT images directly from non-attenuation-corrected SPECT images. METHODS: We constructed an auto-encoder (AE) using a CNN to correct the attenuation in brain perfusion SPECT images. SPECT image datasets of 270 (44,528 slices including augmentation), 60 (5002 slices), and 30 (2558 slices) cases were used for training, validation, and testing, respectively. The acquired projection data were reconstructed in three patterns: uniform attenuation correction using Chang's method (Chang-AC), non-uniform attenuation correction using CT (CT-AC), and no attenuation correction (No-AC). The AE learned an end-to-end mapping between the No-AC and CT-AC images. The No-AC images in the test dataset were loaded into the trained AE, which generated images simulating the CT-AC images as output. The generated SPECT images were employed as attenuation-corrected images using the AE (AE-AC). The accuracy of the AE-AC images was evaluated in terms of the peak signal-to-noise ratio (PSNR) and the structural similarity metric (SSIM). The intensities of the AE-AC and CT-AC images were compared by voxel-by-voxel and region-by-region analysis. RESULTS: The PSNRs of the AE-AC and Chang-AC images, compared using CT-AC images, were 62.2, and 57.9, and their SSIM values were 0.9995 and 0.9985, respectively. The AE-AC and CT-AC images were visually and statistically in good agreement. CONCLUSIONS: The proposed AE-AC method yields highly accurate attenuation-corrected brain perfusion SPECT images.
  • Kazuhiro Kitajima; Yasuo Miyoshi; Tetsuro Sekine; Hiroyuki Takei; Kimiteru Ito; Akihiko Suto; Hayato Kaida; Kazunari Ishii; Hiromitsu Daisaki; Koichiro Yamakado
    Oncotarget 12 2 95 - 105 2021年01月 [査読有り]
     
    OBJECTIVES: This study investigated harmonized pretreatment volume-based quantitative FDG-PET/CT parameters in breast cancer patients for prognostic value. RESULTS: During a median overall follow-up period of 5.3 years, 91 patients had recurrence and 40 died. Multivariate analysis of ER-positive/HER2-negative patients showed high maximum standardized uptake value (SUVmax) (p = 0.018), high total lesion glycolysis (TLG) (p = 0.010), and clinical N-classification (p = 0.0027) as independent negative predictors of RFS, while high maximum SUVmax (p = 0.037), advanced clinical T-classification (p = 0.030), and advanced TNM stage (p = 0.0067) were independent negative predictors of OS. For recurrence and death in HER2-positive patients, high total TLG (p = 0.037, p = 0.0048, respectively) and advanced TNM stage (p = 0.048, p = 0.046, respectively) were independent prediction factors. In the triple-negative group, independent factors related to recurrence and death were high maximum SUVmax (p = 0.0014, p = 0.0003, respectively) and advanced TNM stage (p < 0.0001, p < 0.0001, respectively). MATERIALS AND METHODS: Records of 546 stage I-III invasive breast cancer patients, including 344 estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, 110 HER2-positive, and 92 triple-negative cases, treated at four institutions were reviewed retrospectively. Harmonized primary tumor and nodal maximum SUVmax, metabolic tumor volume (MTV), and TLG indicated in pretreatment FDG-PET/CT results were analyzed. Evaluations of relationships of clinicopathological factors, volume-based quantitative parameters, recurrence-free survival (RFS), and overall survival (OS) for each subtype were performed with a Cox proportional hazards model and log-rank test. CONCLUSIONS: The results indicated that potential surrogate markers for prognosis in patients with the three main subtypes of operable breast cancer include harmonized pretreatment quantitative volume-based FDG-PET/CT parameters, particularly whole-lesion SUVmax and TLG.
  • Quantitative 67Ga-citrate SPECT/CT for evaluating disease activity in patients with interstitial lung disease.
    Kazuhiro Kitajima; Naoto Azuma; Tatsuya Tsuchitani; Masao Tamura; Hisashi Komoto; Yoshie Inao; Toshiyuki Minami; Kozo Kuribayashi; Kiyoshi Matsui; Hayato Kaida; Masakatsu Tsurusaki; Yukihisa Tamaki; Koichiro Yamakado
    Hellenic journal of nuclear medicine 24 3 199 - 205 2021年 [査読有り]
  • Shota Watanabe; Kohei Hanaoka; Hayato Kaida; Tomoko Hyodo; Minoru Yamada; Masakatsu Tsurusaki; Kazunari Ishii
    Asia Oceania journal of nuclear medicine & biology 9 2 12 - 149 2021年 [査読有り]
     
    Objectives: To assess respiratory-gated (RG) positron emission tomography (PET) acquisition for patients with liver metastases during delayed PET/computed tomography (CT) scanning with fluorine-18-fluorodeoxyglucose (18F-FDG). Methods: Nineteen patients with liver metastases who had undergone early whole-body 18F-FDG PET/CT scans without the RG technique and delayed scans with the RG technique were retrospectively selected. The maximum standardized uptake value (SUVmax) of 41 liver lesions and the tumor-to-liver uptake ratios (TLRs) for these same lesions were compared among three data sets: early non-respiratory-gated (early non-RG) images, delayed non-respiratory-gated (delayed non-RG) images, and delayed respiratory-gated (delayed RG) images. In the delayed non-RG and delayed RG images, the improvements in the TLR, relative to the early non-RG images, were assessed according to lesion size. Results: For liver lesions, the SUVmax of early non-RG, delayed non-RG, and delayed RG images were 6.58±2.34, 7.69±3.08, and 9.47±3.73, respectively. There were significant differences among the three images (P<0.01). The TLR of the delayed RG images was significantly higher than those of the early non-RG and delayed non-RG images (P<0.01). In the delayed RG images, the difference in the TLR improvement for lesions ≤10 mm in size was 15% higher than that for lesions >10 mm in size; in the delayed non-RG images, the difference in the TLR improvement for the same lesion categories was 6%. Conclusion: Delayed RG imaging improves the TLR, compared with early non-RG and delayed non-RG imaging, especially for small lesions. RG PET acquisition may be a promising protocol for assessing liver metastases on delayed PET/CT scans.
  • Kazunari Ishii; Takahiro Yamada; Kohei Hanaoka; Hayato Kaida; Koichi Miyazaki; Masami Ueda; Kazushi Hanada; Kazumasa Saigoh; Julia Sauerbeck; Axel Rominger; Peter Bartenstein; Yuichi Kimura
    Annals of nuclear medicine 34 11 856 - 863 2020年11月 [査読有り]
     
    PURPOSE: It is usually easy to judge whether amyloid PET images should be interpreted as positive or negative for amyloid deposits by visual inspection or quantitative measurement standard uptake value ratio (SUVR), but the findings are equivocal in some cases. As conventional mean cortical SUVR (mcSUVR) measures accumulation in both gray matter (GM) and white matter, it may mis-estimate amyloid deposits. The purpose of the study was to develop a regional GM-dedicated SUVR measuring (GMSUVR) system for amyloid PET images with 3D-MRI, and evaluate its utility for detecting amyloid deposits in equivocal cases. METHODS: Of 126 subjects who underwent amyloid PET with 11C-PiB and 3D-MRI, the area of amyloid-positive regions and the critical regional GMSUVR thresholds were first determined in 15 amyloid-positive and 15 amyloid-negative patients, using the automatic volumetric measurement of segmented brain images system. We then tested 36 amyloid-negative, 60 amyloid-positive, and 13 equivocal subjects with this GMSUVR system and with conventional mcSUVR. RESULTS: Sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) were 100%, 92%, 97%, 95%, and 100% for the GMSUVR system; and 97%, 86%, 93%, 92% and 94%, respectively, for mcSUVR. In 24 cases in which the findings were equivocal or discordant, the sensitivity, specificity, accuracy, PPV, and NPV were all 100% for the GMSUVR system; and were 90%, 33%, 83%, 90%, and 33%, respectively, for mcSUVR. CONCLUSION: The regional GMSUVR measurement method was well able to discriminate between amyloid-positive and -negative subjects, even in cases where amyloid deposition was equivocal.
  • Takenori Kozuka; Yuko Matsukubo; Tomoya Kadoba; Teruyoshi Oda; Ayako Suzuki; Tomoko Hyodo; SungWoon Im; Hayato Kaida; Yukinobu Yagyu; Masakatsu Tsurusaki; Mitsuru Matsuki; Kazunari Ishii
    Japanese journal of radiology 38 11 1052 - 1061 2020年11月 [査読有り]
     
    PURPOSE: To evaluate the performance of a deep learning-based computer-aided diagnosis (CAD) system at detecting pulmonary nodules on CT by comparing radiologists' readings with and without CAD. MATERIALS AND METHODS: A total of 120 chest CT images were randomly selected from patients with suspected lung cancer. The gold standard of nodules ≥ 3 mm was established by a panel of three expert radiologists. Two less experienced radiologists read the images without and afterward with CAD system. Their reading times were recorded. RESULTS: The radiologists' sensitivity increased from 20.9% to 38.0% with the introduction of CAD. The positive predictive value (PPV) decreased from 70.5% to 61.8%, and the F1-score increased from 32.2% to 47.0%. The sensitivity significantly increased from 13.7% to 32.4% for small nodules (3-6 mm) and from 33.3% to 47.6% for medium nodules (6-10 mm). CAD alone showed a sensitivity of 70.3%, a PPV of 57.9%, and an F1-score of 63.5%. Reading time decreased by 11.3% with the use of CAD. CONCLUSION: CAD improved the less experienced radiologists' sensitivity in detecting pulmonary nodules of all sizes, especially including a significant improvement in the detection of clinically important-sized medium nodules (6-10 mm) as well as small nodules (3-6 mm) and reduced their reading time.
  • Yuichi Kimura; Aya Watanabe; Takahiro Yamada; Shogo Watanabe; Takashi Nagaoka; Mitsutaka Nemoto; Koichi Miyazaki; Kohei Hanaoka; Hayato Kaida; Kazunari Ishii
    Annals of nuclear medicine 34 7 512 - 515 2020年07月 [査読有り]
     
    OBJECTIVE: An artificial intelligence (AI)-based algorithm typically requires a considerable amount of training data; however, few training images are available for dementia with Lewy bodies and frontotemporal lobar degeneration. Therefore, this study aims to present the potential of cycle-consistent generative adversarial networks (CycleGAN) to obtain enough number of training images for AI-based computer-aided diagnosis (CAD) algorithms for diagnosing dementia. METHODS: We trained CycleGAN using 43 amyloid-negative and 45 positive images in slice-by-slice. RESULTS: The CycleGAN can be used to synthesize reasonable amyloid-positive images, and the continuity of slices was preserved. DISCUSSION: Our results show that CycleGAN has the potential to generate a sufficient number of training images for CAD of dementia.
  • Kazuhiro Kitajima; Hayato Kaida; Koya Nakatani; Mana Ishibashi; Takahiro Morita; Masatoyo Nakajo; Yukihisa Tamaki; Ryogo Minamimoto
    Nuclear medicine communications 41 5 443 - 451 2020年05月 [査読有り]
     
    OBJECTIVES: The aim of the study was to evaluate PET response criteria in solid tumors (PERCIST) to indicate therapeutic response to definitive chemoradiotherapy, as well as prediction of recurrence and death in patients with esophageal cancer. METHODS: Before and after recieving definitive chemoradiotherapy, 181 patients with esophageal cancer underwent fluorodeoxyglucose-PET/computed tomography (FDG-PET/CT). PERCIST, reduction rates of tumor uptake and volume of whole lesions, tumor node metastasis (TNM) staging regarding progression-free survival (PFS), and overall survival (OS) were analyzed using log-rank and Cox methods. RESULTS: Complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease (PMD) shown by PERCIST were seen in 42 (23.2%), 113 (62.4%), 14 (7.7%), and 12 (6.6%) patients, respectively. Progression developed in 137 (75.7%) patients and 101 (56.1%) patients died (median follow-up 16.9, range 3.2-124.9 months). Those who achieved CMR showed significantly longer PFS and OS as compared with patients who did not (PMR, SMD, and PMD) (both P < 0.0001). In univariate analysis, initial clinical T status (P = 0.0048), N status (P = 0.011), and TNM stage (P = 0.0006), PERCIST (P < 0.0001), and reduction rate of peak lean body mass standardized uptake value (P < 0.0001), of metabolic tumor volume (P < 0.0001), and of total lesion glycolysis (TLG) (P < 0.0001) were associated with significantly increased OS. Multivariate analysis confirmed PERCIST [hazard ratio (HR): 13.15, 95% confidence interval (CI), 4.54-55.8; P < 0.0001], and TLG reduction rate (HR: 2.21, 95% CI, 1.04-4.68; P = 0.040) as independent OS predictors. CONCLUSION: PERCIST is useful for evaluating therapeutic response to definitive chemoradiotherapy, and predicting progression and death in patients with esophageal cancer.
  • Hayato Kaida; Takahiro Kumode; Masatomo Kimura; Kazunari Ishii
    Clinical nuclear medicine 45 4 319 - 321 2020年04月 [査読有り]
     
    An 80-year-old woman experienced dyspnea. Cardiac enlargement was detected by chest radiography at a local hospital. She was admitted to our hospital, and echocardiography and CT revealed pericardial effusion and multiple tumor lesions in right atrium. F-FDG PET/CT demonstrated multiple nodular accumulations in these tumors (SUVmax, 14.5). Cytologic analysis of the pericardial fluid revealed a diffuse large B-cell lymphoma. Primary cardiac lymphoma (PCL) is rare, and there are few reports about the F-FDG PET/CT imaging features of PCLs. In high F-FDG uptake in multiple tumors in the right atrium and large pericardial effusion, a PCL should be considered.
  • Takahiro Yamada; Shogo Watanabe; Takashi Nagaoka; Mitsutaka Nemoto; Kohei Hanaoka; Hayato Kaida; Kazunari Ishii; Yuichi Kimura
    Annals of nuclear medicine 34 2 102 - 107 2020年02月 [査読有り]
     
    OBJECTIVE: This study aims to develop an algorithm named AutoRef to delineate a reference region for quantitative PET amyloid imaging. METHODS: AutoRef sets the reference region automatically using a distinguishing feature in the kinetics of reference region. This is reflected in the shapes of the tissue time activity curve. A statistical shape recognition algorithm of the gaussian mixture model is applied with considering spatial and temporal information on a reference region. We evaluate the BPND with manually set reference region and AutoRef using 86 cases (43 positive cases, 10 equivocal cases, and 33 negative cases) of dynamically scanned 11C-Pittsburgh Compound-B. RESULTS: From the Bland-Altman plot, the difference between two BPND is 0.099 ± 0.21 as standard deviation, and no significant systematic error is observed between the BPND with AutoRef and with manual definition of a reference region. Although a proportional error is detected, it is smaller than the 95% limits of agreement. Therefore, the proportional error is negligibly small. CONCLUSIONS: AutoRef presents the same performance as the manual definition of the reference region. Further, since AutoRef is more algorithmic than the ordinary manual definition of the reference region, there are few operator-oriented uncertainties in AutoRef. We thus conclude that AutoRef can be applied as an automatic delineating algorithm for the reference region in amyloid imaging.
  • Kazuhiro Kitajima; Yasuo Miyoshi; Tetsuro Sekine; Hiroyuki Takei; Kimiteru Ito; Akihiko Suto; Hayato Kaida; Hiromitsu Daisaki; Koichiro Yamakado
    Hellenic journal of nuclear medicine 23 3 272 - 289 2020年 [査読有り]
     
    Objective: The prognostic value of harmonized pretreatment volume-based quantitativefluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) parameters in metastatic breast cancer patients was investigated. Subjects and Methods: Records of 65 stage IV breast cancer patients, including 29 estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, 23 HER2-positive, and 13 triple-negative cases, from four different institutions were retrospectively reviewed. Harmonized standardized uptake value (SUVmax) of the primary tumor (pSUVmax), highest SUVmax of all malignant lesions (wSUVmax), whole-body metabolic tumor volume (WB MTV), and whole-body total lesion glycolysis (WB TLG) shown by pretreatment 18F-FDG PET/CT imaging were calculated. Cox proportional hazards model and log-rank test results were used to evaluate relationships among clinicopathological factors, volume-based quantitative 18F-FDG PET/CT parameters, progression-free survival, and overall survival (OS). Results: Disease progression occurred in 54 patients and 28 died during a median follow-up period of 52.5 months (range 2.6-133.6 months). Univariate analysis of all cases showed associations of negative ER and progesterone receptor (PR) status (P=0.0025), and high T/N stage (P=0.037/P=0.019), pSUVmax (P=0.049), WB MTV (P=0.021), and WB TLG (P=0.0010) with significantly shorter OS. Multivariate analysis confirmed negative ER and PR status (hazard ratio [HR]: 6.42, 95% confidence interval [CI]: 2.27-19.38; P=0.0054), high T stage (HR: 5.10, 95% CI:1.96-18.61, P=0.0064) and WB TLG (HR: 4.69, 95% CI:1.67-12.79, P=0.049) as independent negative OS predictors. In two groups of ER-positive/HER2-negative and triple-negative, WB TLG had a significant association with death (P= 0.021 and P=0.037, respectively) on univariate analysis. In a HER2-positive group, no independent negative OS predictors were observed. Conclusion: In metastatic breast cancer patients, harmonized pretreatment quantitative volume-based 18F-FDG PET/CT parameters, especially whole-body TLG, are potential surrogate markers for prognosis.
  • Hiroshi Matsuda; Kengo Ito; Kazunari Ishii; Eku Shimosegawa; Hidehiko Okazawa; Masahiro Mishina; Sunao Mizumura; Kenji Ishii; Kyoji Okita; Yoko Shigemoto; Takashi Kato; Akinori Takenaka; Hayato Kaida; Kohei Hanaoka; Keiko Matsunaga; Jun Hatazawa; Masamichi Ikawa; Tetsuya Tsujikawa; Miyako Morooka; Kenji Ishibashi; Masashi Kameyama; Tensho Yamao; Kenta Miwa; Masayo Ogawa; Noriko Sato
    Frontiers in neurology 11 578753 - 578753 2020年 [査読有り]
     
    Background: In clinical practice, equivocal findings are inevitable in visual interpretation of whether amyloid positron emission tomography (PET) is positive or negative. It is therefore necessary to establish a more objective quantitative evaluation method for determining the indication for disease-modifying drugs currently under development. Aims: We aimed to determine cutoffs for positivity in quantitative analysis of 18F-flutemetamol PET in patients with cognitive impairment and suspected Alzheimer's disease (AD). We also evaluated the clinical efficacy of amyloid PET in the diagnosis of AD. This study was registered in the Japan Registry of Clinical Trials (jRCTs, 031180321). Methods: Ninety-three patients suspected of having AD underwent 18F-flutemetamol PET in seven institutions. A PET image for each patient was visually assessed and dichotomously rated as either amyloid-positive or amyloid-negative by two board-certified nuclear medicine physicians. If the two readers obtained different interpretations, the visual rating was rerun until they reached consensus. The PET images were quantitatively analyzed using the standardized uptake value ratio (SUVR) and standardized Centiloid (CL) scale with the whole cerebellum as a reference area. Results: Visual interpretation obtained 61 positive and 32 negative PET scans. Receiver operating characteristic analysis determined the best agreement of quantitative assessments and visual interpretation of PET scans to have an area under curve of 0.982 at an SUVR of 1.13 and a CL of 16. Using these cutoff values, there was high agreement between the two approaches (kappa = 0.88). Five discordant cases had SUVR and CL values ranging from 1.00 to 1.22 and from 1 to 26, respectively. In these discordant cases, either diffuse or mildly focal elevation of cortical activity confused visual interpretation. The amyloid PET outcome significantly altered the diagnosis of AD (χ2 = 51.3, p < 0.0001). PET imaging elevated the proportions of the very high likelihood category from 20.4 to 46.2% and the very low likelihood category from 0 to 22.6%. Conclusion: Quantitative analysis of amyloid PET using 18F-flutemetamol can objectively evaluate amyloid positivity using the determined cutoffs for SUVR and CL. Moreover, amyloid PET may have added value over the standard diagnostic workup in dementia patients with cognitive impairment and suspected AD.
  • Diffusion-weighted MRI, 11C-choline PET/CT, and 18F-FDG PET/CT for predicting the Gleason score in prostate cancer.
    Kazuhiro Kitajima; Shingo Yamamoto; Yusuke Kawanaka; Yukako Nakanishi; Yusuke Yamada; Shuken Go; Akihiro Kanematsu; Hayato Kaida; Koichiro Yamakado
    Hell J Nucl Med 23 1 34 - 39 2020年 [査読有り]
  • Koichi Miyazaki; Kohei Hanaoka; Hayato Kaida; Yasutaka Chiba; Kazunari Ishii
    Dementia and geriatric cognitive disorders 49 3 255 - 263 2020年 [査読有り]
     
    OBJECTIVE: The aim was to examine the association between connectivity changes in the default mode network (DMN) and the progression of idiopathic normal pressure hydrocephalus (iNPH). METHODS: We retrospectively recruited cases of preclinical and clinical iNPH from 2,196 patients who had received whole-body 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) scanning. We included 31 cases with asymptomatic ventriculomegaly with features of iNPH on MRI (AVIM; reported as preclinical iNPH) and 12 with iNPH. We performed a voxel-based analysis of the brain FDG-PET images of the AVIM and iNPH groups as well as for each background-matched normal control (NC) group, using Statistical Parametric Mapping 12. Volume of interest (VOI)-based analysis was also performed. We set the VOI as the region from the precuneus to the posterior cingulate cortices (PCC), and compared the mean regional standardized uptake value ratio (SUVR) between the AVIM and iNPH group FDG-PET/CT images and each corresponding NC group. RESULTS: The voxel-based analysis showed a greater decreased FDG uptake in the PCC in the iNPH group than in the AVIM group. The VOI-based analysis revealed no significant difference in the mean SUVR of the AVIM group and the corresponding NC group, but that of the iNPH group was significantly lower than that of its corresponding NC group. CONCLUSIONS: DMN connectivity was reduced in the clinical iNPH group but not in the preclinical group. These data suggest that alterations in the functional connectivity of the DMN are related to the onset of iNPH symptoms.
  • Hayato Kaida; Koichi Azuma; Akihiko Kawahara; Shinzo Takamori; Jun Akiba; Kiminori Fujimoto; Kazunari Ishii; Masatoshi Ishibashi
    Nuclear medicine communications 41 1 48 - 57 2020年01月 [査読有り]
     
    OBJECTIVE: To investigate the relationship between the prognosis and glucose transporter-1 (Glut-1) expression or fluorine-18 fluorodeoxyglucose uptake using partial volume correction and dual-point imaging in surgically resected nonsmall cell lung cancer (NSCLC) patients. METHODS: Our patient population consisted of 108 NSCLC cases. The early maximum standardized uptake value (ESUVmax), delayed SUVmax (DSUVmax), partial volume correction SUVmax (cSUVmax) and retention index of primary lesions were calculated. Cox proportional hazard model was applied to evaluate the effects of PET parameters and Glut-1 expression. Overall survival (OS) and disease-free survival (DFS) were evaluated by Kaplan-Meier methods, and the difference in survival between subgroups was analyzed by log-rank test. RESULTS: On the Cox regression analysis, ESUVmax, DSUVmax, cSUVmax and Glut-1 were significantly related to DFS [ESUVmax, hazard ratio = 2.301, 95% confidential interval (CI) = 1.146-4.618, P = 0.019; DSUVmax, hazard ratio = 2.483, 95% CI = 1.257-4.905, P = 0.009; cSUVmax, hazard ratio = 2.205, 95% CI = 1.038-4.686, P = 0.04; Glut-1, hazard ratio = 2.095, 95% CI = 1.086-4.041, P = 0.001] and OS (ESUVmax, hazard ratio = 3.197, 95% CI = 1.339-7.633, P = 0.009; DSUVmax, hazard ratio = 3.599, 95% CI = 1.521-8.516, P = 0.004; cSUVmax, hazard ratio = 8.655, 95% CI = 2.048-36.658, P = 0.003; Glut-1, hazard ratio = 2.427, 95% CI = 5.140, P = 0.021). Retention index had no significant association with DFS or OS. On the Kaplan-Meier survival curves, the patients with high ESUVmax, DSUVmax, cSUVmax and Glut-1 showed significantly worse prognosis than those with low values (ESUVmax: DFS, P = 0.001, OS, P = 0.003; DSUVmax: DFS, P = 0.002, OS, P = 0.004; cSUVmax: DFS, P < 0.001, OS, P = 0.013; Glut-1: DFS, P = 0.012, OS, P = 0.002). CONCLUSIONS: cSUVmax, ESUVmax, DSUVmax and Glut-1 may be more useful biomarkers than retention index for predicting outcomes in NSCLC patients.
  • M. Nakajo; K. Kitajima; H. Kaida; T. Morita; R. Minamimoto; M. Ishibashi; T. Yoshiura
    Clinical Radiology 75 1 79.e9 - 79.e18 2020年01月 [査読有り]
  • Koichi Miyazaki; Kohei Hanaoka; Hayato Kaida; Yasutaka Chiba; Kazunari Ishii
    EJNMMI research 9 1 111 - 111 2019年12月 [査読有り]
     
    BACKGROUND: Decreased cerebral glucose metabolism has been reported in idiopathic normal pressure hydrocephalus (iNPH). However, the timing of appearance in the preclinical stage of iNPH remains unknown. Herein, we evaluated the changes in regional cerebral glucose metabolism with respect to the characteristic morphologic features of iNPH. METHODS: We performed a cross-sectional study in > 2000 elderly patients who received a whole body 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scanning and recruited subjects with clinical and preclinical iNPH. We included 12 subjects with iNPH, 32 subjects with asymptomatic ventriculomegaly with features of iNPH on magnetic resonance imaging (AVIM), and 33 subjects with preclinical morphologic features of DESH (PMD). We previously reported that iNPH develops in the order of PMD (asymptomatic subjects with incomplete DESH), AVIM (asymptomatic subjects with DESH), and iNPH (symptomatic subjects with DESH). We measured the median regional standardized uptake value ratio (SUVR) on 18F-fluorodeoxyglucose-positron emission tomography/computed tomography images between the three groups and compared them with background-matched normal controls in the frontal lobes, temporal lobes, medial parietal lobes, striata, and thalami. RESULTS: In the frontal and temporal lobes, the SUVR distributions of the PMD, AVIM, and PMD groups were significantly lower than for each NC (p < 0.05 for all). In the medial parietal lobes, the SUVR distributions were significantly higher in PMD and AVIM groups (p < 0.05 for all). In the thalami and striata, the SUVR distributions were significantly lower in the iNPH group (p < 0.05 for all). CONCLUSIONS: Changes in brain glucose metabolism in the cortices are observed in preclinical iNPH, while metabolic decline in the basal ganglia is only detected in clinical iNPH.
  • Koichi Miyazaki; Kazunari Ishii; Kohei Hanaoka; Hayato Kaida; Koichi Nakajima
    Neurologia medico-chirurgica 59 11 436 - 443 2019年11月 [査読有り]
     
    Disproportionately enlarged subarachnoid-space hydrocephalus (DESH) findings are often reported as characteristic radiological features of idiopathic normal pressure hydrocephalus (iNPH). However, the process of development of DESH remains unclear. The aim of the present study was to determine the dynamic deforming process and pathophysiology of iNPH. All patients >50 years of age who underwent whole body FDG-PET/CT scanning at Kindai University Hospital between May 2017 and April 2018 were included in this retrospective study, and their brain image findings and clinical information were assessed. We defined DESH-like findings, which had one or two equivocal features of the three components of DESH findings, as preclinical morphologic features of DESH (PMD). PMD were classified into six subtypes based on their component of DESH findings: PMD-T, only tight medial and high convexity subarachnoid spaces (TMC); PMD-S, only enlarged Sylvian fissures; PMD-V, only ventriculomegaly; PMD-TV, TMC and ventriculomegaly; PMD-TS, TMC and enlarged Sylvian fissures; PMD-SV, enlarged Sylvian fissures and ventriculomegaly. A total of 2196 cases (70.5 ± 9.3 years) were enrolled, with 54 cases (77.1 ± 5.9 years) with DESH findings, and 42 cases (72.9 ± 7.9 years) with PMD (five PMD-T, two PMD-V, 12 PMD-TV, 18 PMD-TS, and five PMD-SV). In each component of DESH, 35 of 42 (83.3%) cases with PMD had TMC. We suggest that the TMC is the first change on DESH findings in most iNPH cases, and may be an important part of the pathophysiology of iNPH.
  • Kazuhiro Kitajima; Shingo Yamamoto; Yukako Nakanishi; Yusuke Yamada; Takahiko Hashimoto; Toru Suzuki; Shuken Go; Akihiro Kanematsu; Michio Nojima; Masayuki Fujiwara; Hayato Kaida; Masakatsu Tsurusaki; Tomonori Kanda; Yukihisa Tamaki; Koichiro Yamakado
    Acta medica Okayama 73 4 341 - 347 2019年08月 [査読有り]
     
    We investigated the effectiveness of 11C-choline-positron emission tomography/computed tomography (PET/CT) for evaluating treatment response in patients with prostate cancer or renal cell carcinoma. We performed 34 11C-choline PET/CT scans before/after a combined total of 17 courses of treatment in 6 patients with prostate cancer and 2 with renal cell carcinoma. The 17 treatments including hormonal therapy, radiotherapy, chemotherapy, radium-223, molecular target therapy, radiofrequency ablation, transcatheter arterial embolization, and cancer immunotherapy yielded 1 (5.9%) complete metabolic response (CMR), 3 (17.6%) partial metabolic responses (PMRs), 2 (11.8%) stable metabolic diseases (SMDs), and 11 (64.7%) progressive metabolic diseases (PMDs). Target lesions were observed in bone (n=14), lymph nodes (n=5), lung (n=2), prostate (n=2), and pleura (n=1), with CMR in 4, PMR in 10, SMD in 8 and PMD in 2 lesions. SUVmax values of the target lesions before and after treatment were 7.87±2.67 and 5.29±3.98, respectively, for a mean reduction of -35.4±43.6%. The response for the 8 prostate cancer-treatment courses was PMD, which correlated well with changes in serum prostatic specific antigen (PSA) (7 of 8 cases showed increased PSA). 11C-choline-PET/CT may be an effective tool for detecting viable residual tumors and evaluating treatment response in prostate cancer and renal cell carcinoma patients.
  • Shuhei Doi; Nobuo Kashiwagi; Takao Satou; Hayato Kaida; Kazunari Ishi
    Clinical nuclear medicine 44 7 587 - 588 2019年07月 [査読有り]
     
    Previous studies have reported increased Pittsburgh compound-B (PiB) uptake in meningiomas; however, histological correlation to elucidate the underlying mechanism has not yet been done. We report a case of an 82-year-old woman with an incidental intracranial tumor that showed focal increased PiB uptake. Because of tumor growth, surgical resection was performed, yielding a histological diagnosis of meningioma. Any special and immunochemical staining for amyloid did not reveal amyloid deposition in the tumor. Our findings suggest that increased PiB uptake was not associated with amyloid in this instance.
  • Shota Watanabe; Kohei Hanaoka; Yusuke Shibata; Hayato Kaida; Kazunari Ishii
    Nuclear medicine communications 40 3 235 - 241 2019年03月 [査読有り]
     
    OBJECTIVE: The aim of this study were to estimate the influence of respiratory movement on the fluorine-18-fluorodeoxyglucose (F-FDG) PET/computed tomography (CT) imaging of patients having positive myocardial F-FDG uptake and to demonstrate an adequate respiratory-gated F-FDG PET/CT scan protocol. MATERIALS AND METHODS: An anthropomorphic chest phantom containing a cardiac ventricle phantom was filled with an fluorine-18 solution and scanned in both a nonmoving state and a moving state with respiratory gating. In the nonmoving state, PET images were acquired in static mode (static PET), whereas in the moving state, PET images were acquired in a nongated mode (nongated PET), and in a gated mode (gated PET). The gated PET images were divided into 2-10 phases. The standardized uptake value (SUV)nongated ratio and SUVgated ratio (SUVnongated ratio or SUVgated ratio=SUVmean of nongated PET or gated PET/SUVmean of static PET) were calculated. In addition, nongated PET images and gated PET images were created from 12 sets of respiratory-gated clinical F-FDG PET/CT acquisitions. The clinical 12 gated PET data were divided into 2-8 phases. We measured SUVmax of cardiac volume data at each number of phases. RESULTS: In dividing into more than three phases, the SUVgated ratio remarkably improved. In dividing into more than five phases, rate of SUVmax improvement from nongated PET showed 5% in the analysis of clinical data. CONCLUSION: For a F-FDG PET/CT scan for patients with having positive myocardial F-FDG uptake, a respiratory-gated PET protocol divided into five phases is recommended, to minimize the influence of internal motion on cardiac accumulation.
  • Hayato Kaida; Hiroki Inui; Takaaki Chikugo; Kazunari Ishii
    Case Rep Oncol 12 1 157 - 163 2019年02月 [査読有り]
  • Kazuhiro Kitajima; Koya Nakatani; Kazushige Yamaguchi; Masatoyo Nakajo; Atsushi Tani; Mana Ishibashi; Keiko Hosoya; Takahiro Morita; Takayuki Kinoshita; Hayato Kaida; Yasuo Miyoshi
    European journal of nuclear medicine and molecular imaging 45 10 1661 - 1671 2018年09月 [査読有り]
     
    PURPOSE: The purpose of this study was to evaluate therapeutic response to neoadjuvant chemotherapy (NAC) and predict breast cancer recurrence using Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST). MATERIALS AND METHODS: Fifty-nine breast cancer patients underwent fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) before and after NAC prior to planned surgical resection. Pathological complete response (pCR) of the primary tumor was evaluated using PERCIST, while effects of clinicopathological factors on progression-free survival (PFS) were examined using log-rank and Cox methods. RESULTS: Fifty-six patients and 54 primary tumors were evaluated. Complete metabolic response (CMR), partial metabolic response, stable metabolic disease, and progressive metabolic disease were seen in 45, 7, 3, and 1 patients, respectively, and 43, 7, 3, and 1 primary tumors, respectively. Eighteen (33.3%) of the 54 primary tumors showed pCR. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PERCIST to predict pCR were 100% (18/18), 30.6% (11/36), 41.9% (18/43), 100% (11/11), and 53.7% (29/54), respectively. An optimal percent decrease in peak standardized uptake value for a primary tumor corrected for lean body mass (SULpeak) of 84.3% was found to have a sensitivity of 77.8% (14/18), specificity of 77.8% (28/36), PPV of 63.6% (14/22), NPV of 87.5% (28/32), and accuracy of 77.8% (42/54). Seven (12.5%) of the 56 patients developed recurrent disease (median follow-up 28.1 months, range 11.4-96.4 months). CMR (p = 0.031), pCR (p = 0.024), and early TNM stage (p = 0.033) were significantly associated with longer PFS. CONCLUSION: PERCIST is useful for predicting pathological response and prognosis following NAC in breast cancer patients. However, FDG-PET/CT showed a tendency toward underestimation of the residual tumor, and relatively low specificity and PPV of PERCIST showed that a combination of other imaging modalities would still be needed to predict pCR.
  • Hayato Kaida; Koichi Azuma; Akihiko Kawahara; Eiji Sadashima; Satoshi Hattori; Shinzo Takamori; Jun Akiba; Kiminori Fujimoto; Axel Rominger; Takamichi Murakami; Kazunari Ishii; Masatoshi Ishibashi
    Oncotarget 9 62 31971 - 31984 2018年08月 [査読有り]
     
    Introduction: To assess the correlation among 18F-FDG uptake, Glut1, pStat1 and pStat3, and to investigate the relationship between the prognosis and 18F-FDG uptake and these molecular markers in surgically resected non-small cell lung cancer (NSCLC) patients. Results: Knockdown of Glut1 led to a significant increase in pStat1 expression. Glut1 expression positively correlated with the SUVmax, SUVmean, and TLG significantly (P<0.001). pStat3 expression negatively correlated with all PET parameters significantly (P<0.001). pStat1 had positive weak correlations with the SUVmax and SUVmean. All PET parameters and Glut1 were significantly associated with DFS (P<0.05). TLG, MTV, Glut1 and pStat1 were significantly associated with OS (P<0.05). Conclusion: pStat3 and Glut1 may be associated with 18F-FDG uptake mechanism. TLG, MTV, and Glut1 may be independent prognostic factors. Methods: The SUVmax, SUVmean, MTV and TLG of primary lesions were calculated in 140 patients. The expressions of Glut1 and Stat pathway proteins in NSCLC cell lines were examined by immune blots. Excised tumor tissue was analyzed by immunohistochemistry. OS and DFS were evaluated by the Kaplan-Meier method. The difference in survival between subgroups was analyzed by log-rank test. The prognostic significance of clinicopathological, molecular and PET parameters was assessed by Cox proportional hazard regression analysis.
  • Julia Sauerbeck; Kazunari Ishii; Chisa Hosokawa; Hayato Kaida; Franziska T Scheiwein; Kohei Hanaoka; Axel Rominger; Matthias Brendel; Peter Bartenstein; Takamichi Murakami
    Annals of nuclear medicine 32 6 398 - 403 2018年07月 [査読有り]
     
    PURPOSE: In subjects with amyloid deposition, striatal accumulation of 11C-Pittsburgh compound B (PiB) demonstrated by positron emission tomography (PET) is related to the stage of Alzheimer's disease (AD). In this study, we investigated the correlation between striatal and cortical non-displaceable binding potential (BPND). METHODS: Seventy-three subjects who complained of cognitive disturbance underwent dynamic PiB-PET studies and showed positive PiB accumulation were retrospectively selected. These subjects included 34 AD, 26 mild cognitive impairment, 2 frontotemporal lobar degeneration, 2 Parkinson's disease, 5 dementia with Lewy bodies, and 4 undefined diagnosis patients. Individual BPND images were produced from the dynamic data of the PiB-PET study, and voxel-based analyses were performed to estimate the correlations between striatal and other regional cortical BPND measures. RESULTS: There were highly significant correlations between striatal and prefrontal BPND, with the highest correlation being demonstrated in left Brodmann area 11. We found that almost all of the high cortical BPND values correlated with striatal BPND values, with the exception of the occipital cortex with low correlation. CONCLUSION: Our study demonstrated positive correlations in amyloid deposits between the striatum and other cortical areas with functional and anatomical links. The amyloid distribution in the brain is not random, but spreads following the functional and anatomical connections.
  • Kenkichi Baba; Hayato Kaida; Chikayuki Hattori; Koichiro Muraki; Tomoko Kugiyama; Hiromasa Fujita; Masatoshi Ishibashi
    Hellenic Journal of Nuclear Medicine 21 1 15 - 23 2018年01月 [査読有り]
     
    Objective: The purpose of this study was to investigate the palliative and tumoricidal effects of concurrent therapy of strontium-89 chloride (89SrCl2) and zoledronic acid (ZA) for painful bone metastases. Subjects and Methods: Fifty-one patients with painful bone metastases prostate cancer (n=17), lung cancer (n=13), breast cancer (n=12), other cancers (n=9) were treated. Bone metastases was conrmed in all patients by technetium-99m hydroxymethylene diphosphonate (99mTc-HMDP) bone scintigraphy. The numeric rating scale (NRS) and performance status (PS) were used to assess the degree of pain and patients' physical condition. The extent of bone metastases was assessed with imaging modalities including CT, MRI and/or 99mTc bone scintigraphy before treatment and 2 or 3 months after. Results: The pain relief response of 89SrCl2 with ZA for bone metastases was 94% (48/51) from 1 to 3 months after treatment. The tumoricidal effect of concurrent therapy by 89SrCl2 with ZA for painful bone metastases was 8/22 as shown by imaging modalities and the rate of non-progressive disease (non-PD) was 19/22. Pain due to bone metastases assessed with the NRS was signicantly improved (P< 0.001) in many types of primary cancer, including prostate, breast and lung cancers. Conclusion: Concurrent therapy of 89SrCl2 with ZA may offer not only pain relief, but also a tumoricidal effect for painful bone metastases.
  • Hayato Kaida; Koichi Azuma; Uhi Toh; Akihiko Kawahara; Eiji Sadashima; Satoshi Hattori; Jun Akiba; Nobuhiro Tahara; Axel Rominger; Kazunari Ishii; Takamichi Murakami; Masatoshi Ishibashi
    Hellenic Journal of Nuclear Medicine 21 1 35 - 42 2018年01月 [査読有り]
     
    Objective: To assess the correlations between dual-phase uorine-18 uorodeoxyglucose (18F-FDG) uptake and clinicopathological and immunohistochemical prognostic factors in patients with surgically resected breast cancer stage I-III. Subjects and Methods: We retrospectively analyzed the cases of 105 patients. We calculated the maximum standardized uptake value (SUVmax) at 85min (SUV1), SUVmax at 125min (SUV2) and the retention index [RI]. Spearman's rank correlation test, the Kruskal-Wallis test and receiver operating characteristic (ROC) analysis were performed to assess the association between 18F-FDG uptake and the clinicopathological and immunohistochemical factors: glucose transporter-1 (Glut-1), estrogen receptor alpha (ERα), ERβ, progesterone receptor (PR), human epidermal growth factor 2 (Her2), mammalian target of rapamycin (mTOR), and P70S6kinase (P70S6). Results: The SUV1 and SUV2 values were correlated with Glut-1, pathological tumor size, ERα negativity, and pathological stage (all P values were < 0.05), but not with mTOR, P70S6, ERβ, PR, Her2 or other factors. The SUV1 and SUV2 in the triple negative subtype were signi-cantly higher than those of the hormone receptor-positive subtype (P< 0.05). The RI was associated with pathological tumor size alone. In the ROC analysis of Glut-1, the areas under the curve for SUV1 and SUV2 were signicantly larger than for RI (SUV1, P=0.032, SUV2, P=0.022). Conclusion: Glucose transporter-1, estrogen receptor alpha negativity and nuclear grade might affect the high 18F-FDG uptake in breast cancer. The SUVmax might be more useful than the RI for predicting the Glut-1 expression and the aggressiveness of breast cancer.
  • Hayato Kaida; Kazunari Ishii; Soichiro Hanada; Yuji Tohda; Takamichi Murakami
    Clinical nuclear medicine 43 1 25 - 27 2018年01月 [査読有り]
     
    A 78-year-old man had fever, persistent wheezing, and serum C-reactive protein elevation. Malignant lymphoma was suspected because of mediastinal lymph nodes swelling on CT and soluble interleukin 2 receptor elevation. Symmetric F-FDG uptake in the tracheobronchial tree and bilateral auricles was observed on PET/CT. He was finally diagnosed as having relapsing polychondritis by auricular cartilage biopsy. F-FDG PET/CT may have crucial role in evaluating the extent of inflammation and deciding the biopsy site of relapsing polychondritis.
  • Kazuhiro Kitajima; Masatoyo Nakajo; Hayato Kaida; Ryogo Minamimoto; Kenji Hirata; Masakatsu Tsurusaki; Hiroshi Doi; Yoshiko Ueno; Keitaro Sofue; Yukihisa Tamaki; Koichiro Yamakado
    Nagoya journal of medical science 79 4 527 - 543 2017年11月 [査読有り]
     
    Positron emission tomography/computed tomography (PET/CT) integrated with 2-[18F]fluoro-2-deoxy-D-glucose (FDG) is a useful tool for acquisition of both glucose metabolism and anatomic imaging data, as only a single device and one diagnostic session is required, thus opening a new field in clinical oncologic imaging. FDG-PET/CT has been successfully used for initial staging, restaging, assessment of early treatment response, evaluation of metastatic disease response, and prognostication of intestinal cancer as well as various malignant tumors. We reviewed the current status and role of FDG-PET/CT for management of patients with esophageal cancer, gastric cancer, and colorectal cancer, with focus on both its usefulness and limitations.
  • Yuichi Wakabayashi; Kazunari Ishii; Chisa Hosokawa; Tomoko Hyodo; Hayato Kaida; Minoru Yamada; Yukinobu Yagyu; Masakatsu Tsurusaki; Takenori Kozuka; Kazuro Sugimura; Takamichi Murakami
    The Kobe journal of medical sciences 62 5 E136-E141 - E141 2017年03月 [査読有り]
     
    Using 11C-Pittsburgh compound B (PiB)-PET and MRI volume data, we investigated whether white matter (WM) PiB uptake in Alzheimer's disease (AD) brain is larger than that of cortical PiB uptake-negative (PiB-negative) brain. Forty-five subjects who underwent both PiB-PET and MRI were included in the study (32 AD patients with cortical PiB-positive and 13 cortical amyloid -negative patients). Individual areas of gray matter (GM) and WM were segmented, then regional GM and WM standard uptake value ratio (SUVR) normalized to cerebellar GM with partial volume effects correction was calculated. Three regional SUVRs except WM in the centrum semiovale in the AD group were significantly larger than those in the PiB-negative groups. Frontal WM SUVR in the AD group vs frontal WM SUVR in the PiB-negative group was 2.57 ± 0.55 vs 1.64 ± 0.22; parietal, 2.50 ± 0.52 vs 1.74 ± 0.22; posterior cingulate, 2.84 ± 0.59 vs 1.73 ± 0.22; and WM in the centrum semiovale, 2.21 ± 0.53 vs 2.42 ± 0.36, respectively. We found that PiB uptake in AD brain is significantly larger than that in PiB-negative brain in the frontal, parietal and posterior cingulate subcortical WM, except in the centrum semiovale.
  • Regional Differences in Amyloid Deposition between 11C-Pib PET Positive Patients with and without Elevated Striatal Amyloid Uptake.
    Franziska T Scheiwein; Kazunari Ishii; Chisa Hosokawa; Hayato Kaida; Tomoko Hyodo; Kohei Hanaoka; Matthias Brendel; Peter Bartenstein; Axel Rominger; Takamichi Murakami
    J Alzheimers Dis Parkinsonism 7 2 317  2017年 [査読有り]
  • Yasumitsu Hirose; Hayato Kaida
    The New England journal of medicine 375 17 1671 - 1671 2016年10月 [査読有り]
  • Hayato Kaida; Koichi Azuma; Akihiko Kawahara; Masafumi Yasunaga; Yuhei Kitasato; Satoshi Hattori; Tomoki Taira; Hiroki Ureshino; Masayoshi Kage; Kazunari Ishii; Takamichi Murakami; Masatoshi Ishibashi
    European journal of radiology 85 10 1804 - 1810 2016年10月 [査読有り]
     
    PURPOSE: We examined whether fluorine-18 fluorodeoxyglucose (FDG) uptake is related to the mammalian target of rapamycin (mTOR) signal pathway and its related proteins in pancreatic cancer patients. METHODS: We retrospectively studied 53 pancreatic cancer patients who underwent FDG positron emission tomography (PET) or FDG PET/CT, and complete curative surgical resection. The SUV max, the tumor to nontumor activity of pancreas [T/N (P)] ratio and the T/N of liver [T/N (L)] ratio were calculated. The expressions of glucose transporter-1(Glut-1) and mTOR pathway proteins in pancreas cell lines were examined by immune blots. Excised tumor tissue was analyzed by immunohistochemistry using monoclonal antibodies for Glut-1, epidermal growth factor receptor (EGFR), mTOR, p70S6kinase (p70S6) and S6 ribosomal protein (S6). RESULTS: The expressions of Glut-1, EGFR and p70S6 were significantly correlated with the SUV max, T/N (P) ratio and T/N (L) ratio. The expressions of mTOR and S6 were not correlated with all parameters. The expression of Glut-1 was positively correlated with the expressions of EGFR and p70S6, but not with mTOR or S6. S6 was positively correlated with p70S6. CONCLUSIONS: Glut-1, EGFR and p70S6 expressions are associated with the FDG uptake mechanism of pancreatic cancer. FDG uptake may predict the levels of EGFR and p70S6 expressions, and FDG uptake reflects glucose metabolism and cancer progression.
  • Yasumitsu Hirose; Hayato Kaida; Akihiko Kawahara; Satoru Matono; Toshiaki Tanaka; Seiji Kurata; Masayoshi Kage; Masatoshi Ishibashi; Toshi Abe
    Nuclear medicine communications 37 10 1053 - 61 2016年10月 [査読有り]
     
    OBJECTIVE: The aim of this study was to assess the relationship between fluorine-18 fluorodeoxyglucose (F-FDG) uptake and molecular biological markers in esophageal squamous cell carcinoma (ESCC) patients. METHODS: Our patient population included 51 patients who underwent F-FDG PET/computed tomography before surgery. Excised tumor tissue was analyzed immunohistochemically using monoclonal antibodies for glucose transporter-1 (GLUT-1), GLUT-3, CD34 [microvessel density (MVD) marker], CD68 (macrophage marker), and CD163 (tumor-associated macrophage marker). The relationships among pathological factors [pathological T stage (p-T stage), pathological lymph node status (p-N status), pathological stage (p-stage), and pathological tumor length], the maximum standardized uptake value (SUVmax), and these molecular biological markers were evaluated using Spearman's rank test and the Kruskal-Wallis test. RESULTS: GLUT-1, GLUT-3, CD34, and CD163 significantly correlated with SUVmax (r=0.547, P<0.001 for GLUT-1; r=0.569, P<0.001 for GLUT-3; r=0.463, P=0.001 for CD34, r=0.455, P=0.001 for CD163), whereas SUVmax, GLUT-1, GLUT-3, CD34, and CD163 significantly correlated with p-T stage (r=0.552, P<0.001 for SUVmax, r=0.307, P=0.03 for GLUT-1, r=0.349, P=0.013 for GLUT-3, r=0.313, P=0.027 for CD34, r=0.526 for CD163, P<0.001), but not with p-N status. CD68 levels showed no significant correlation with SUVmax, p-T stage, p-stage, or p-N status. CONCLUSION: SUVmax, GLUT-1 expression, GLUT-3 expression, MVD, and TAMs show a relationship with the tumor stage and extent of ESCC. GLUT-1, GLUT-3, MVD, and TAMs are associated with the mechanism of F-FDG uptake in ESCC.
  • Akihiro Honda; Nobuhiro Tahara; Yoshikazu Nitta; Atsuko Tahara; Sachiyo Igata; Munehisa Bekki; Tomohisa Nakamura; Yoichi Sugiyama; Hayato Kaida; Seiji Kurata; Kiminori Fujimoto; Toshi Abe; Mika Enomoto; Hisashi Adachi; Jagat Narula; Sho-Ichi Yamagishi; Yoshihiro Fukumoto
    Arteriosclerosis, thrombosis, and vascular biology 36 9 1980 - 8 2016年09月 [査読有り]
     
    OBJECTIVE: Endothelial dysfunction is an initial step in atherosclerotic cardiovascular disease. However, involvement of vascular inflammation in endothelial dysfunction is not fully investigated in humans because of the lack of diagnostic modality to noninvasively evaluate vascular inflammation. We assessed the relationship between endothelial function and vascular inflammation evaluated by [(18)F]-fluorodeoxyglucose-positron emission tomography/computed tomographic imaging. APPROACH AND RESULTS: We examined endothelial function and vascular inflammation by flow-mediated dilation (FMD) of the brachial artery and [(18)F]-fluorodeoxyglucose-positron emission tomography/computed tomographic imaging of carotid arteries, respectively, in 145 subjects (95 men and 50 women; mean age, 61.8±9.5 years) who underwent a risk-screening test for cardiovascular disease in Kurume University Hospital. Vascular inflammation was measured by blood-normalized standardized uptake value, known as a target:background ratio (TBR). We investigated whether absolute changes from baseline of %FMD after antihypertensive treatment for 6 months (Δ%FMD) were correlated with those of TBR in 33 drug-naive patients with essential hypertension. Multiple logistic regression analysis revealed that age (odds ratio, 1.767 for 10-year increase), male sex (odds ratio, 0.434), low-density lipoprotein-cholesterol (odds ratio, 1.630 for 26-mg/dL increase), and TBR values (odds ratio, 1.759 for 0.2 increase) were independently associated with %FMD in 145 patients. There was an inverse correlation between Δ%FMD and ΔTBR; ΔTBR was a sole independent associate of Δ%FMD in hypertensive patients (r=-0.558; P<0.001). CONCLUSIONS: The present study showed that vascular inflammation in the carotid arteries evaluated by [(18)F]-fluorodeoxyglucose-positron emission tomography/computed tomography was one of the independent correlates of decreased %FMD, thus suggesting the association of vascular inflammation with endothelial dysfunction in humans.
  • Nobuhiro Tahara; Saki Hirakata; Kota Okabe; Atsuko Tahara; Akihiro Honda; Sachiyo Igata; Hayato Kaida; Toshi Abe; Hidetoshi Akashi; Hiroyuki Tanaka; Yoshihiro Fukumoto
    European heart journal 37 24 1933 - 1933 2016年06月 [査読有り]
  • Kazuhiro Kitajima; Hiroshi Doi; Tomonori Kanda; Tomohiko Yamane; Tetsuya Tsujikawa; Hayato Kaida; Yukihisa Tamaki; Kozo Kuribayashi
    Japanese journal of radiology 34 6 387 - 399 2016年06月 
    Integrated positron emission tomography/computed tomography (PET/CT) using 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) has emerged as a powerful tool for combined metabolic and anatomic evaluation in clinical oncologic imaging. This review discusses the utility of (18)F-FDG PET/CT as a tool for managing patients with lung cancer. We discuss different patient management stages, including diagnosis, initial staging, therapy planning, early treatment response assessment, re-staging, and prognosis.
  • Kotaro Kuwaki; Keiichi Mitsuyama; Hayato Kaida; Hidetoshi Takedatsu; Shinichiro Yoshioka; Hiroshi Yamasaki; Ryosuke Yamauchi; Shuhei Fukunaga; Toshi Abe; Osamu Tsuruta; Takuji Torimura
    Cytotherapy 18 2 291 - 9 2016年02月 [査読有り]
     
    BACKGROUND AIMS: Endoscopy is the gold standard for the diagnosis and follow-up of patients with Crohn disease (CD). However, a less invasive approach is now being sought for the management of these patients. The objective of this study was to examine whether (18)F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) might be relevant for monitoring the disease activity in CD patients undergoing granulocyte/monocyte apheresis (GMA). METHODS: This study was conducted in 12 patients with CD who were receiving treatment with 10 once-a-week GMA sessions with the Adacolumn. The response to treatment was monitored by measuring standard laboratory variables, Crohn's Disease Activity Index (CDAI) score, International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) score, and regional and global bowel uptakes on FDG-PET. RESULTS: In 6 of the 12 patients, significant improvement of the CDAI was observed after the final session of GMA. The patients who showed clinical response to GMA had a decrease in the regional and global bowel uptakes on FDG-PET, whereas those who did not respond showed no change. In the patients who responded to the GMA, the decrease in regional bowel uptake on FDG-PET in each disease area of the same patient varied in parallel. There was a significant correlation between decrease in the global bowel uptake on FDG-PET and improvement of the CDAI and IOIBD scores. CONCLUSIONS: The longitudinal changes in FDG-PET uptakes are of potential clinical interest for assessing the regional and global bowel disease activity in CD patients undergoing GMA therapy.
  • Shinichiro Nagamitsu; Rieko Sakurai; Michiko Matsuoka; Hiromi Chiba; Shuichi Ozono; Hitoshi Tanigawa; Yushiro Yamashita; Hayato Kaida; Masatoshi Ishibashi; Tatsuki Kakuma; Paul E Croarkin; Toyojiro Matsuishi
    Frontiers in psychiatry 7 16 - 16 2016年 [査読有り]
     
    Several lines of evidence suggest that anxiety plays a key role in the development and maintenance of anorexia nervosa (AN) in children. The purpose of this study was to examine cortical GABA(A)-benzodiazepine receptor binding before and after treatment in children beginning intensive AN treatment. Brain single-photon emission computed tomography (SPECT) measurements using (123)I-iomazenil, which binds to GABA(A)-benzodiazepine receptors, was performed in 26 participants with AN who were enrolled in a multimodal treatment program. Sixteen of the 26 participants underwent a repeat SPECT scan immediately before discharge at conclusion of the intensive treatment program. Eating behavior and mood disturbances were assessed using Eating Attitudes Test with 26 items (EAT-26) and the short form of the Profile of Mood States (POMS). Clinical outcome scores were evaluated after a 1-year period. We examined association between relative iomazenil-binding activity in cortical regions of interest and psychometric profiles and determined which psychometric profiles show interaction effects with brain regions. Further, we determined if binding activity could predict clinical outcome and treatment changes. Higher EAT-26 scores were significantly associated with lower iomazenil-binding activity in the anterior and posterior cingulate cortex. Higher POMS subscale scores were significantly associated with lower iomazenil-binding activity in the left frontal, parietal cortex, and posterior cingulate cortex (PCC). "Depression-Dejection" and "Confusion" POMS subscale scores, and total POMS score showed interaction effects with brain regions in iomazenil-binding activity. Decreased binding in the anterior cingulate cortex and left parietal cortex was associated with poor clinical outcomes. Relative binding increases throughout the PCC and occipital gyrus were observed after weight gain in children with AN. These findings suggest that cortical GABAergic receptor binding is altered in children with AN. This may be a state-related change, which could be used to monitor and guide the treatment of eating disorders.
  • Yasumitus Hirose; Hayato Kaida; Akihiko Kawahara; Seiji Kurata; Masatoshi Ishibashi; Toshi Abe
    Hellenic journal of nuclear medicine 18 3 257 - 260 2015年09月 [査読有り]
     
    In a 49 years old woman a large abdominal tumor was diagnosed by abdominal ultrasound. Dynamic contrast-enhanced computed tomography (CECT) showed a large tumor with minute calcification and poor contrast enhancement in the left abdominal cavity. The fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG PET/CT) scan showed low F-18-FDG uptake in the tumor. The SUV max (early image) was 1.90, and that of the delayed image was 2.86. A gastrointestinal stromal tumor (GIST) was suspected.Tumor resection revealed that it was a leiomyoma originating in the major curvature of the stomach.In conclusion, the findings of low F-18-FDG uptake on F-18-FDG PET and poor contrast enhancement on CECT in a gastric submucosal tumor suggested of a gastric leiomyoma rather than GIST.
  • Onishi R; Noguchi M; Kaida H; Moriya F; ChikuiK; Kurata S; Kawahara A; Kage M; Ishibashi M; Matsuoka K
    Oncology letters 10 2 822 - 828 2015年08月 [査読有り]
     
    The present study aimed to examine the association between 18F-fluorodeoxyglucose (18F-FDG) uptake and cell proliferation markers; in addition, the correlation between 18F-FDG uptake and biological characteristic in patients with renal cell carcinoma (RCC) was investigated using dual-phase 18F-FDG-positron emission tomography/computed tomography (PET/CT). Dual-phase 18F-FDG PET/CT was performed on 31 RCC patients and the maximum standardized uptake values at 1 h (SUV1) and 2 h (SUV2) as well as the retention index (RI; %) in the primary tumors were calculated. Monoclonal antibodies for Ki-67, minichromosome maintenance 2 (MCM2) and topoisomerase II α (topo II α) were used to assess the expression levels of their respective proteins in excised tumor tissue using immunohistochemistry. The results demonstrated that RI and SUV2 in patients with Stage I/II + grade 1 (G1) RCC were significantly decreased compared with all patients with other stages/grades (RI, P=0.0065; SUV2, P=0.043); in addition, significantly increased uptake and RI were detected in patients with metastases compared with patients without metastases (SUV1, P=0.029; SUV2, P=0.0003; RI, P<0.001). All proliferation markers significantly correlated with RI (Ki-67, r=0.501, P=0.004; MCM2, r=0.359, P=0.047; topo II α, r=0.402, P=0.024), while SUV1 and SUV2 correlated with Ki-67 only. In conclusion, the results of the present study demonstrated that dual-phase 18F-FDG-PET/CT was more useful for predicting cell proliferation in RCC compared with single-phase imaging alone. However, follow-ups are required in order to determine whether dual-phase 18F-FDG-PET/CT provides independent prognostic information.
  • Seiji Kurata; Kimio Ushijima; Akihiko Kawahara; Hayato Kaida; Kouichirou Kawano; Yasumitsu Hirose; Masayoshi Kage; Toshiharu Kamura; Masatoshi Ishibashi; Toshi Abe
    Annals of nuclear medicine 29 7 643 - 9 2015年08月 [査読有り]
     
    OBJECTIVE: Multidrug resistance (MDR) has been suggested to be a major cause of failure of chemotherapy treatment for cancer. It is associated with the expression of MDR-related and apoptosis-related proteins. Recently, technetium-99m hexakis 2-methoxyisobutylisonitrile ((99m)Tc-MIBI) has been suggested as a tumor-seeking agent for the detection of MDR. The aim of this study was to evaluate (99m)Tc-MIBI single-photon emission computed tomography (SPECT)(/CT) for functional imaging of MDR-related and apoptosis-related proteins in patients with ovarian cancer. METHODS: Eleven women (mean age 63 years, range 53-76) with a clinical suspicion of ovarian cancer were prospectively studied. All patients were examined with (99m)Tc-MIBI imaging before surgery. After intravenous injection of 740 MBq (99m)Tc-MIBI, SPECT(/CT) imaging at 10 min and 2 h was performed. Based on the semiquantitative analysis of (99m)Tc-MIBI SPECT(/CT), both early and delayed tumor uptake ratios and washout rate % were calculated. The expression of MDR-related and apoptosis-related proteins was assessed in surgically excised tumors. Immunohistochemical staining was performed to quantify the expression levels of multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein1 (MRP1), MRP3, lung resistance protein (LRP), breast cancer resistance protein (BCRP), Y-box-binding protein-1 (YB-1), Bcl-2, Bax and glutathione-S-transferase. (99m)Tc-MIBI imaging results and immunohistochemical results were compared. RESULTS: Laparotomy was performed in all patients. Six ovarian cancers were proven by histopathological examination. Five of the six ovarian cancers were positive for (99m)Tc-MIBI uptake on both early and delayed images with (99m)Tc-MIBI SPECT(/CT). MDR-related and apoptosis-related proteins were found to be expressed in all tumors. For the five positive (99m)Tc-MIBI uptake cases, the washout rate % of (99m)Tc-MIBI uptake showed a significant positive correlation with the expression of YB-1 (r = 0.988, P = 0.0015), and the early tumor uptake ratio showed a significant positive correlation with the expression of Bax (r = 0.882, P = 0.047). CONCLUSIONS: Our results suggested that (99m)Tc-MIBI SPECT(/CT) might be a valuable diagnostic imaging technique to evaluate MDR-associated YB-1 and Bax-mediated apoptosis in patients with ovarian cancer.
  • Igata S; Tahara N; Tahara A; Honda A; Nitta Y; Kusaba K; Niiyama H; Kaida H; Abe T; Yoshiyama H; Fukumoto Y
    European heart journal 36 25 1629 - 1629 2015年07月 [査読有り]
  • Nobuhiro Tahara; Sho-Ichi Yamagishi; Norihiro Kodama; Atsuko Tahara; Akihiro Honda; Yoshikazu Nitta; Sachiyo Igata; Takanori Matsui; Masayoshi Takeuchi; Hayato Kaida; Seiji Kurata; Toshi Abe; Yoshihiro Fukumoto
    The Journal of clinical endocrinology and metabolism 100 5 E739-47 - E747 2015年05月 [査読有り]
     
    CONTEXT: Body fat distribution and inflammation may play a role in metabolic derangements and cardiovascular disease in obesity. OBJECTIVE: The aim of this study is to investigate clinical and biochemical factors associated with area and metabolic activity in the visceral and subcutaneous adipose tissues (VAT and SAT). PARTICIPANTS: (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography imaging was performed in 251 consecutive subjects (62.6 ± 9.3 y) for risk screening. MAIN OUTCOME MEASURES: We examined which clinical, anthropometric, metabolic, and inflammatory variables including advanced glycation end products (AGEs) and pigment epithelium-derived factor (PEDF) were independently associated with area and metabolic activity in VAT and SAT. Adipose tissue area was determined with computed tomography, whereas metabolic activity was assessed by (18)F-fluorodeoxyglucose uptake expressed as a target to background ratio (TBR) of blood-normalized standardized uptake. RESULTS: Serum levels of AGEs and PEDF were 9.81 ± 3.21 U/mL and 14.0 (range 10.8-17.7) μg/mL, respectively. Although the area in VAT and SAT was associated with waist circumference and sex, each adipose tissue area and TBR had different metabolic risk profiles. The TBR value in VAT was higher than that in SAT. In a multiple stepwise regression analysis, AGEs and medication for hypertension were independently associated with VAT TBR (R(2) = 0.102), whereas medication for diabetes, mean intima-media thickness, AGEs, and PEDF were the independent correlates of SAT TBR (R(2) = 0.132). CONCLUSIONS: The present study demonstrated that area and metabolic activity in VAT and SAT could be differently regulated, suggesting the involvement of AGEs and PEDF in adipose tissue inflammation.
  • Kenji Suda; Nobuhiro Tahara; Akihiro Honda; Motofumi Iemura; Hironaga Yoshimoto; Yoshiyuki Kudo; Hayato Kaida; Toshi Abe; Kentaro Sawada; Hidetoshi Akashi; Hiroyuki Tanaka; Yoshihiro Fukumoto
    International journal of cardiology 180 88 - 90 2015年02月
  • Suda K; Tahara N; Honda A; Yoshimoto H; Kishimoto S; Kudo Y; Kaida H; Abe T; Ueno T; Fukumoto Y
    International journal of cardiology 179 61 - 62 2015年01月
  • Shinichiro Nagamitsu; Yushiro Yamashita; Hitoshi Tanigawa; Hiromi Chiba; Hayato Kaida; Masatoshi Ishibashi; Tatsuyuki Kakuma; Paul E Croarkin; Toyojiro Matsuishi
    Frontiers in psychiatry 6 84 - 84 2015年 [査読有り]
     
    The child behavior checklist-dysregulation profile (CBCL-DP) refers to a pattern of elevated scores on the attention problems, aggression, and anxiety/depression subscales of the child behavior checklist. The aim of the present study was to investigate the potential role of GABA inhibitory neurons in children with attention deficit/hyperactivity disorder (ADHD) and dysregulation assessed with a dimensional measure. Brain single photon emission computed tomography (SPECT) was performed in 35 children with ADHD using 123I-iomazenil, which binds with high affinity to benzodiazepine receptors. Iomazenil binding activities were assessed with respect to the presence or absence of a threshold CBCL-DP (a score ≥210 for the sum of the three subscales: Attention Problems, Aggression, and Anxiety/Depression). We then attempted to identify which CBCL-DP subscale explained the most variance with respect to SPECT data, using "age," "sex," and "history of maltreatment" as covariates. Significantly higher iomazenil binding activity was seen in the posterior cingulate cortex (PCC) of ADHD children with a significant CBCL-DP. The Anxiety/Depression subscale on the CBCL had significant effects on higher iomazenil binding activity in the left superior frontal, middle frontal, and temporal regions, as well as in the PCC. The present brain SPECT findings suggest that GABAergic inhibitory neurons may play an important role in the neurobiology of the CBCL-DP, in children with ADHD.
  • Hayato Kaida; Nobuhiro Tahara; Atsuko Tahara; Akihiro Honda; Yoshikazu Nitta; Sachiyo Igata; Masatoshi Ishibashi; Sho-ichi Yamagishi; Yoshihiro Fukumoto
    Atherosclerosis 237 2 404 - 9 2014年12月 [査読有り]
     
    OBJECTIVE: The purpose of this study was to investigate the relationship between serum levels of malondialdehyde-modified low-density lipoprotein cholesterol (MDA-LDL) and vascular inflammation evaluated by fluorine-18 fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT). METHODS/RESULTS: The study involved 106 consecutive patients (75 males and 31 female, mean age 62.5 ± 7.7 years) who visited our hospital for cardiovascular risk screening and underwent carotid ultrasonography, (18)F-FDG PET/CT, complete history, physical examinations, and determination of blood chemistry including high-sensitivity C-reactive protein (hsCRP), asymmetric dimethylarginine (ADMA), and MDA-LDL. Vascular inflammation, was measured as blood-normalized standardized (18)F-FDG uptake value, known as the target-to-background ratio (TBR) of carotid arteries. Univariate and multiple stepwise regression analyses were performed for determining independent correlates of carotid TBR values. Median MDA-LDL, mean carotid TBR values and carotid intima-media thickness (IMT) were 127.5 (IQR 92.0-147.8) U/l, 1.55 ± 0.22, and 0.72 ± 0.15 mm, respectively. Univariate analysis revealed that carotid TBR values positively correlated with MDA-LDL (p = 0.043) and carotid IMT (p = 0.049). Multiple stepwise regression analysis demonstrated that MDA-LDL (p = 0.043) and carotid IMT (p = 0.038) were independently associated with carotid TBR values. CONCLUSION: The present study reveals that serum levels of MDA-LDL are independently associated with vascular inflammation evaluated by (18)F-FDG PET/CT. Circulating MDA-LDL may be a more useful clinical biomarker for vascular inflammation within the atherosclerotic plaques than hsCRP or ADMA.
  • Yuhei Kitasato; Masafumi Yasunaga; Koji Okuda; Hisafumi Kinoshita; Hiroyuki Tanaka; Yoshinobu Okabe; Akihiko Kawahara; Masayoshi Kage; Hayato Kaida; Masatoshi Ishibashi
    Pancreas 43 7 1060 - 5 2014年10月 [査読有り]
     
    OBJECTIVES: The purpose of this study was to assess the correlations among the maximum standardized uptake value (SUVmax) on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography (FDG-PET/CT); the expressions of glucose transporter 1 (GLUT-1), glucose transporter 3, and epidermal growth factor receptor (EGFR); as well as prognosis in patients with invasive ductal carcinoma of the pancreas. METHODS: A total of 41 patients with surgically resected and histologically proven invasive ductal carcinoma of the pancreas who underwent preoperative FDG-PET/CT were assessed. The SUVmax at the primary tumor site was measured by FDG-PET/CT, and immunohistochemical staining of tumor sections was performed for GLUT-1, glucose transporter 3, and EGFR. RESULTS: Higher FDG uptake (SUVmax, >3.40) and GLUT-1 expression were significantly associated with shorter overall survival (P < 0.05). The SUVmax was not found to be significantly correlated with clinicopathological characteristics such as TNM classification, lymph node metastasis, and tumor differentiation. The EGFR expression was significantly correlated with the SUVmax (P = 0.024). CONCLUSIONS: Higher FDG uptake and GLUT-1 expression in invasive ductal carcinoma of the pancreas seems to be an important prognostic factor. In addition, the EGFR expression was significantly correlated with the SUVmax.
  • Ohya T; Yamashita Y; Shibuya I; Hara M; Nagamitsu S; Kaida H; Kurata S; Ishibashi M; Matsuishi T
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 18 4 536 - 9 2014年07月 [査読有り]
     
    We describe a 15-year-old girl with subacute sclerosing panencephalitis (SSPE) in stage II who was treated with isoprinosine, intraventricular interferon alpha (IFN-α), and ribavirin for 3 years. She is alive at three years from onset and studies at school with the assistance of a special educational teacher. To assess residual brain function, serial (18)FDG-positron emission tomography (PET) was performed three times to measure cortical metabolism: at onset, a year later, and three years later. At onset, PET study revealed preserved glucose metabolism of the cerebral cortex. In serial PET study, glucose metabolism of the cerebral cortex was also preserved even after three years. Although SSPE is a progressive disease of the neuronal system, and typically leads to death in approximately 2-3 years, the neurological prognosis of our case was good. We consider that combination therapy in the very early stage without hypometabolism in the cerebral cortex may be effective for SSPE.
  • Hayato Kaida; Seiji Kurata; Yasumitsu Hirose; Takashi Okamura; Koichi Oshima; Masatoshi Ishibashi
    Hellenic journal of nuclear medicine 17 2 145 - 147 2014年05月 [査読有り]
     
    A 69 years old woman with adult T-cell leukemia (ATL) (chronic type) was referred for a fluorine-18 fluorodeoxyglucose positron emission and computed tomography (F-18-FDG PET/CT). Multiple hypermetabolic pulmonary and bone lesions were evident. The patient underwent chemotherapy, but did not respond, and she died approximately 8 months from the onset of symptoms. Autopsy showed ATL cells infiltrating the lung parenchyma and the pulmonary hilum. In conclusion, we present a case of hypermetabolic pulmonary lesions associated with thoracic CT findings on a F-18-FDG PET/CT scan in a patient with a chronic adult T-cell leukemia.
  • Yasumitsu Hirose; Hiroaki Suefuji; Hayato Kaida; Masanobu Hayakawa; Satoshi Hattori; Seiji Kurata; Yuko Watanabe; Yukiko Kunou; Akihiko Kawahara; Takashi Okamura; Koichi Ohshima; Masayoshi Kage; Masatoshi Ishibashi; Naofumi Hayabuchi
    Leukemia & lymphoma 55 3 520 - 5 2014年03月 [査読有り]
     
    The aim of this study was to investigate correlations between the standardized uptake value of the biopsy site (BSUVmax) and levels of glucose transporter (GLUT)-1, GLUT-3 and hexokinase-II (HK-II), between BSUVmax and the Ki-67 proliferation index (MIB-1), and between BSUVmax and clinicopathological factors. Sixty-eight patients with diffuse large B-cell lymphoma (DLBCL) were included in this study. BSUVmax was significantly correlated with GLUT-1, GLUT-3 and the International Prognostic Index (IPI) (GLUT-1: r = 0.584, IPI: r = 0.363, p < 0.001; GLUT-3: r = 0.369, p = 0.009; IPI: r = 0.363, p = 0.004), but not with MIB-1 and HK-II. A statistically significant correlation was observed between GLUT-3 expression and each of IPI and gene expression profiling (GEP) (IPI: p = 0.0186; GEP: p = 0.0179). 2-Deoxy-2-[(18)F]-fluoro-d-glucose (FDG) uptake was significantly correlated with the levels of GLUT-1 and GLUT-3 and with IPI. The results indicated that GLUT-3 expression is related to GEP and IPI, and that BSUVmax and GLUT-3 may have a relationship with the prognosis of DLBCL.
  • Hayato Kaida; Akihiko Kawahara; Masanobu Hayakawa; Satoshi Hattori; Seiji Kurata; Kiminori Fujimoto; Koichi Azuma; Yasumitsu Hirose; Shinzo Takamori; Yuji Hiromatsu; Tadashi Nakashima; Hiromasa Fujita; Masayoshi Kage; Naofumi Hayabuchi; Masatoshi Ishibashi
    Nuclear medicine communications 35 1 36 - 43 2014年01月 [査読有り]
     
    OBJECTIVES: The aim of this study was to reveal the differences in clinicopathological factors affecting maximum standardized uptake value (SUVmax) between esophageal squamous cell carcinoma (ESCC), non-small-cell lung cancer (NSCLC), and papillary thyroid cancer (PTC). METHODS: This study consisted of 119 patients with ESCC (n=43), PTC (n=40), or NSCLC (n=36). We investigated the correlations between SUVmax and clinicopathological factors by using Spearman's correlation coefficient and the Kruskal-Wallis test. Multiple regression analysis was used to investigate which clinicopathological factors significantly affected SUVmax in each cancer type. RESULTS: The SUVmax correlated with glucose transporter-1 (GLUT-1) expression in NSCLC (r=0.536, P=0.007) and ESCC (r=0.597, P<0.001) but not in PTC. The SUVmax correlated with Ki-67 expression in NSCLC (r=0.381, P=0.022) and PTC (r=0.374, P=0.017) but not in ESCC. A high SUVmax was correlated with a higher pathological T stage (p-T stage) in NSCLC (r=0.536) and ESCC (r=0.597, both P<0.001) but not in PTC. An elevated SUVmax was significantly associated with pathological lymph node status (p-N) in NSCLC, but not in ESCC and PTC. In multiple regression analysis, p-T stage and GLUT-1 expression were statistically significant factors in ESCC, and p-T stage was a statistically significant factor in NSCLC. In PTC, Ki-67 showed a statistically significant association with SUVmax. CONCLUSION: SUVmax in NSCLC depended on the tumor invasion area; SUVmax in ESCC depended on tumor depth and GLUT-1 expression; and SUVmax in PTC might be associated with cell proliferation. The biological factors affecting SUVmax differ according to tumor type.
  • Norihiro Kodama; Nobuhiro Tahara; Atsuko Tahara; Akihiro Honda; Yoshikazu Nitta; Minori Mizoguchi; Hayato Kaida; Masatoshi Ishibashi; Toshi Abe; Hisao Ikeda; Jagat Narula; Yoshihiro Fukumoto; Sho-ichi Yamagishi; Tsutomu Imaizumi
    The Journal of clinical endocrinology and metabolism 98 11 4438 - 45 2013年11月 [査読有り]
     
    CONTEXT: Excess visceral fat is associated with chronic systemic inflammation and cardiovascular complications. Pioglitazone has been reported to variably influence visceral fat volume; however, its effect on metabolic activity of the visceral fat remains uncharacterized. OBJECTIVE: The aim of this study was to assess the effects of pioglitazone on glucose metabolism of fat tissue by using (18)F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography imaging. DESIGN, SETTING, AND PARTICIPANTS: FDG-PET and computed tomography imaging were performed in 56 patients with impaired glucose tolerance or type 2 diabetes mellitus; lipid and glycemic profiles and inflammatory biomarkers were obtained in all patients. These patients were randomized to treatment with either pioglitazone or glimepiride for 16 weeks. MAIN OUTCOME MEASURES: The metabolic activity of the visceral fat tissues as assessed by FDG uptake was expressed as a target-to-background ratio (TBR) of blood-normalized standardized uptake value. RESULTS: The study was completed in 32 pioglitazone-treated and 21 glimepiride-treated patients (40 men and 13 women; mean age, 67.7 ± 8.1 y; body mass index, 25.0 ± 3.6 kg/m(2); glycated hemoglobin, 6.78 ± 0.70%). Both treatments were well-tolerated and comparably improved glycemic control. At baseline, visceral fat exhibited a higher TBR value than subcutaneous fat (0.55 ± 0.14 vs 0.30 ± 0.07, P < .001). Pioglitazone, but not glimepiride, significantly decreased the visceral fat volume (130.5 ± 53.0 to 122.1 ± 51.0 cm(2), P = .013) and TBR values (0.57 ± 0.16 to 0.50 ± 0.11, P = .007). Neither pioglitazone nor glimepiride treatment showed any effect on the volume or TBR values of subcutaneous fat. After 16 weeks of treatment with pioglitazone, reduction in visceral fat TBR was correlated to the increase in high-density lipoprotein cholesterol levels. CONCLUSIONS: Our study indicated that pioglitazone decreased the visceral fat volume and its metabolic activity in patients with impaired glucose tolerance or type 2 diabetes mellitus. The beneficial effects of pioglitazone on visceral fat may be independent of its glucose-lowering effect.
  • Yoshikazu Nitta; Nobuhiro Tahara; Atsuko Tahara; Akihiro Honda; Norihiro Kodama; Minori Mizoguchi; Hayato Kaida; Masatoshi Ishibashi; Naofumi Hayabuchi; Hisao Ikeda; Sho-ichi Yamagishi; Tsutomu Imaizumi
    JACC. Cardiovascular imaging 6 11 1172 - 82 2013年11月 [査読有り]
     
    OBJECTIVES: The aim of this study was to compare the effect of pioglitazone with glimepiride on coronary arterial inflammation with serial (18)F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) combined with computed tomography (CT) angiography. BACKGROUND: Recent studies have shown that FDG-PET combined with CT is a reliable tool to visualize and quantify vascular inflammation. Although pioglitazone significantly prevented the progression of coronary atherosclerosis and reduced the recurrence of myocardial infarction in patients with type 2 diabetes mellitus (DM), it remains unclear whether pioglitazone could attenuate coronary artery inflammation. METHODS: Fifty atherosclerotic patients with impaired glucose tolerance or type 2 DM underwent determination of blood chemistries, anthropometric and inflammatory variables, and FDG-PET/CT angiography, and then were randomized to receive either pioglitazone or glimepiride for 16 weeks. Effects of the treatments on vascular inflammation of the left main trunk were evaluated by FDG-PET/CT angiography at baseline and end of the study. Vascular inflammation of the left main trunk was measured by blood-normalized standardized uptake value, known as a target-to-background ratio. RESULTS: Three patients dropped out of the study during the assessment or treatment. Finally, 25 pioglitazone-treated patients and 22 glimepiride-treated patients (37 men; mean age: 68.1 ± 8.3 years; glycosylated hemoglobin: 6.72 ± 0.70%) completed the study. After 16-week treatments, fasting plasma glucose and glycosylated hemoglobin values were comparably reduced in both groups. Changes in target-to-background ratio values from baseline were significantly greater in the pioglitazone group than in the glimepiride group (-0.12 ± 0.06 vs. 0.09 ± 0.07, p = 0.032), as well as changes in high-sensitivity C-reactive protein (pioglitazone vs. glimepiride group: median: -0.24 [interquartile range (IQR): -1.58 to -0.04] mg/l vs. 0.08 [IQR: -0.07 to 0.79] mg/l, p = 0.031). CONCLUSIONS: Our study indicated that pioglitazone attenuated left main trunk inflammation in patients with impaired glucose tolerance or DM in a glucose-lowering independent manner, suggesting that pioglitazone may protect against cardiac events in patients with impaired glucose tolerance or DM by suppressing coronary inflammation. (Anti-Inflammatory Effects of Pioglitazone; NCT00722631).
  • Kurata S; Tateishi U; Shizukuishi K; Yoneyama T; Hino A; Kaida H; Fujimoto K; Ishibashi M; Inoue T
    Annals of nuclear medicine 27 5 481 - 6 2013年06月 [査読有り]
     
    OBJECTIVES: The purpose of this study was to evaluate the prevalence, distribution, and relationship of (18)F-fluoride uptake and arterial calcification in oncologic patients using (18)F-fluoride PET/CT. METHODS: Image data obtained from 29 oncologic patients undergoing whole-body (18)F-fluoride PET/CT were evaluated retrospectively. Arterial wall (18)F-fluoride uptake and calcification were analyzed both quantitatively and semiquantitatively in 8 patients with arterial (18)F-fluoride uptake. RESULTS: Arterial (18)F-fluoride uptake was observed at 35 lesions in 8 (28 %) of the 29 patients, and calcification was observed at 345 lesions in the same patients. Five of the 8 patients had prostate cancer, and the remaining patients had hepatocellular carcinoma or malignant melanoma. In these 8 patients, the prevalence of both (18)F-fluoride uptake and calcification was highest in the abdominal aorta, followed by the descending thoracic aorta and the aortic arch. Colocalization of radiotracer accumulation and calcification could be observed in the 32 lesions (91 %) with arterial (18)F-fluoride uptake, and only the 3 lesions (9 %) with arterial (18)F-fluoride uptake were not colocalized with arterial calcification. The presence of both arterial radiotracer uptake and calcification was significantly associated with advancing age (P < 0.01). CONCLUSION: Our results suggest that (18)F-fluoride PET/CT might be a useful modality for detecting active mineral deposition sites of atherosclerosis in oncologic patients.
  • Hayato Kaida; Uhi Toh; Masanobu Hayakawa; Satoshi Hattori; Teruhiko Fujii; Seiji Kurata; Akihiko Kawahara; Yasumitsu Hirose; Masayoshi Kage; Masatoshi Ishibashi
    Nuclear medicine communications 34 6 562 - 70 2013年06月 [査読有り]
     
    OBJECTIVES: This study was conducted to evaluate the relationship between fluorine-18 fluorodeoxyglucose metabolic parameters [maximum standardized uptake value (SUV(max)), metabolic tumor volume (MTV), and total lesion glycolysis (TLG)] and clinicopathological factors of breast cancer. METHODS: The study comprised 93 patients. A volumetric region of interest was drawn over the abnormal focal uptake of breast cancer. Spearman's rank correlation, the Kruskal-Wallis test, and receiver operating characteristic analysis were used to investigate the relationship between clinicopathological factors and metabolic parameters and determine which metabolic parameters were most highly associated with clinicopathological factors. RESULTS: All parameters had a statistically significant relationship with pathological T stage (p-T stage), pathological N status (p-N status), pathological stage (p-stage), and triple-negative type (TN) (all P values were <0.05). There were statistically significant differences between SUV(max) and TLG in relation to lymphatic invasion, estrogen receptor, and nuclear grade (P<0.05). High MTV showed a tendency toward association with estrogen receptor negativity, but the relation did not reach the level of statistical significance (P=0.056). No statistically significant relationship was observed between MTV and lymphatic invasion or nuclear grade. In the receiver operating characteristic analysis of p-T stage and p-stage, the AUC for TLG was significantly larger than that for SUV(max) (P=0.0003 and 0.048, respectively). There were marginally significant differences between TLG and MTV in relation to p-stage (P=0.058). CONCLUSION: TLG may reflect tumor metabolism for clinicopathological factors of breast cancer better than SUV(max) or MTV.
  • Yuko Watanabe; Hiroaki Suefuji; Yasumitsu Hirose; Hayato Kaida; Gen Suzuki; Jun Uozumi; Etsuyo Ogo; Mayumi Miura; Konomi Takasu; Kanoko Miyazaki; Keita Nakahara; Masatoshi Ishibashi; Takashi Okamura; Koichi Ohshima; Naofumi Hayabuchi
    International journal of hematology 97 1 43 - 9 2013年01月 [査読有り]
     
    Positron emission tomography (PET) is used for staging and response evaluation in primary gastric lymphoma (PGL). However, the implications of [(18)F]-2-fluoro-2-deoxy-D-glucose ((18)F-FDG) uptake in PGL at first diagnosis have not been reported. The relationship between (18)F-FDG uptake and the expression of facilitative glucose transporters (GLUTs), hexokinase II (HK II), and Ki67, as well as malignant potential in PGL, was assessed in this study. We analyzed 23 patients with PGL [nine with diffuse large B-cell lymphoma (DLBCL); seven with high-grade mucosa-associated lymphoid tissue (MALT) lymphoma; and seven with low-grade MALT lymphoma]. The expression levels of GLUT1, GLUT3, HK II, and Ki67 were evaluated according to the percentage of positive area determined by immunohistochemistry. Standardized uptake values correlated significantly with pathological malignant potentials (low-grade/high-grade MALT lymphoma and DLBCL: p = 0.001-0.002), Ki67 (p < 0.001), and GLUT1 expression (p = 0.02). We determined that (18)F-FDG uptake is related to GLUT1 expression and tumor histological grade as well as Ki67 in PGL.
  • Yoshiaki Zaizen; Koichi Azuma; Seiji Kurata; Eiji Sadashima; Satoshi Hattori; Tetsuro Sasada; Yohei Imamura; Hayato Kaida; Akihiko Kawahara; Takashi Kinoshita; Masatoshi Ishibashi; Tomoaki Hoshino
    European journal of radiology 81 12 4179 - 84 2012年12月 [査読有り]
     
    BACKGROUND: [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET) imaging has been employed as a non-invasive diagnostic tool for malignant tumors. Total lesion glycolysis (TLG) on FDG-PET is calculated by multiplying the mean standardized uptake value (SUVmean) by the tumor volume. Unlike the maximum standardized uptake value (SUVmax), which represents the point of greatest metabolic activity within tumors, TLG has been suggested to reflect global metabolic activity in whole tumors. METHODS: We retrospectively examined whether or not FDG-PET measurements, including SUVmean, SUVmax, and TLG, could predict progression-free survival (PFS) or overall survival (OS) in patients with non-small cell lung cancer (NSCLC) receiving chemotherapy. RESULTS: This study involved 81 consecutive patients with NSCLC who received chemotherapy. All of the patients underwent FDG-PET examination before treatment. SUVmean, SUVmax, and TLG on FDG-PET were significantly associated with gender, smoking status, and tumor histology. With adjustment for several other variables, Cox regression analysis showed that TLG was significantly prognostic for both PFS [hazard ratio=2.34; 95% confidence interval, 1.18-4.64; P=0.015] and OS (hazard ratio=2.80; 95% confidence interval, 1.12-6.96; P=0.003), whereas SUVmean and SUVmax had no significant association with PFS (P=0.693 and P=0.322, respectively) or OS (P=0.587 and P=0.214, respectively). CONCLUSIONS: Our findings suggest that TLG may be more useful than SUVmean and SUVmax for predicting PFS and OS in NSCLC patients receiving chemotherapy. The TLG measurement on FDG-PET imaging could be routinely recommended to advanced NSCLC patients.
  • Nobuhiro Tahara; Sho-ichi Yamagishi; Masayoshi Takeuchi; Akihiro Honda; Atsuko Tahara; Yoshikazu Nitta; Norihiro Kodama; Minori Mizoguchi; Hayato Kaida; Masatoshi Ishibashi; Naofumi Hayabuchi; Takanori Matsui; Tsutomu Imaizumi
    Diabetes care 35 12 2618 - 25 2012年12月 [査読有り]
     
    OBJECTIVE: Advanced glycation end products (AGEs) evoke inflammatory reactions, contributing to the development and progression of atherosclerosis. We investigated the relationship between serum AGE level and vascular inflammation. RESEARCH DESIGN AND METHODS: The study involved 275 outpatients at Kurume University, Japan (189 males and 86 females; mean age 61.2 ± 8.8 years) who underwent complete history and physical examinations and determinations of blood chemistry and anthropometric variables, including AGEs. Serum AGE level was examined by enzyme-linked immunosorbent assay. Vascular [(18)F]fluorodeoxyglucose (FDG) uptake, an index of vascular inflammation, was measured as blood-normalized standardized uptake value, known as the target-to-background ratio (TBR), by FDG-positron emission tomography (FDG-PET). Furthermore, we examined whether the changes in serum AGE level after treatment with oral hypoglycemia agents (OHAs) were correlated with those of TBR in another 18 subjects whose AGE value was >14.2 units/mL (mean ± 2 SD). RESULTS: Mean serum AGE level and carotid TBR values were 9.15 ± 2.53 and 1.43 ± 0.22 units/mL, respectively. Multiple stepwise regression analysis revealed that TBR was independently correlated with AGEs (P < 0.001), carotid intima-media thickness (P < 0.01), and BMI (P < 0.02). When age- and sex-adjusted AGE values stratified by TBR tertiles were compared using ANCOVA, a significant trend was observed (P < 0.01). In addition, the changes in AGEs after OHA treatment were positively (r = 0.50, P < 0.05) correlated with those in TBR value. CONCLUSIONS: The current study reveals that serum AGE level is independently associated with vascular inflammation evaluated by FDG-PET, suggesting that circulating AGE value may be a biomarker that could reflect vascular inflammation within an area of atherosclerosis.
  • Yasumitsu Hirose; Hayato Kaida; Seiji Kurata; Yoshinobu Okabe; Masayoshi Kage; Masatoshi Ishibashi
    Hellenic journal of nuclear medicine 15 3 247 - 250 2012年09月 [査読有り]
     
    A 60 years old asymptomatic male underwent fluorine-18 fluorodeoxyglucose positron emission tomography (F-18-FDG PET) for his medical check-up, and abnormal F-18-FDG uptake was observed in the retroperitoneum. The maximum standardized uptake value (SUVmax) was 5.2. Based on CT, MRI and F-18-FDG PET findings, the differential diagnosis included specific or non-specific inflammatory change, malignant lymphoma, trauma, gastrointestinal stromal tumor and soft-tissue sarcoma. Tumor resection was performed, and the histopathological finding was an inflammatory pseudotumor (IPT) originating at the mesentery in the retropetoneum. After two years and eight months from his initial operation, recurrent IPT was detected by F-18-FDG PET for follow up, although he was asymptomatic. The IPT could be of traumatic origin since the patient suffered a severe abdominal trauma 6 months before. A mesenteric IPT is very rare, and to our knowledge, this is the first case report of F-18-FDG PET detecting a mesenteric IPT. In conclusion, when abnormal high F-18-FDG uptake is observed in the mesentery incidentally in clinical routine examination, IPT should be included as one of the differential diagnoses. F-18-FDG may be useful in detecting local recurrence and follow-up after operation. Hell J Nucl Med 2012; 15(3): 247-250 Epub ahead of print: 26-10-2012 Published on line: 2 December 2012
  • Hayato Kaida; Seiji Kurata; Akihiko Kawahara; Yuji Hiromatsu; Masayoshi Kage; Masatoshi Ishibashi
    Hellenic journal of nuclear medicine 15 3 261 - 261 2012年09月 [査読有り]
  • Shunji Arikawa; Masafumi Uchida; Yukiko Kunou; Hayato Kaida; Jun Uozumi; Naofumi Hayabuchi; Yoshinobu Okabe; Kenta Murotani
    Pancreas 41 4 535 - 540 2012年05月 [査読有り]
     
    OBJECTIVE: We aimed to compare perfusion computed tomography (CTP) characteristics of the normal pancreas with those of chronic pancreatitis (CP) and to examine the possibility of evaluating pancreatic exocrine function with CTP. METHODS: Thirty-two patients (control group, n = 18; CP group, n = 14) who completed the whole pancreas CT perfusion examination with 256-slice CT were studied. Four parameters, including perfusion (PF), peak enhancement intensity (PEI), time-to-peak (TTP), and blood volume (BV), were measured and compared between the control and CP groups, and between patients with and without exocrine pancreatic insufficiency (EPI) in the CP group. Pancreatic exocrine function was determined via serum trypsinogen. RESULTS: There was no significant difference between the distribution of PF, PEI, and BV in different pancreas regions, namely, the head, body, and tail (P > 0.05). PF, PEI, and BV of the CP group were significantly decreased, and TTP was significantly increased compared with the control group (P < 0.05). A significant decrease of PF, PEI, and BV and increase of TTP were observed in patients with EPI than in patients without EPI (P < 0.05). CONCLUSIONS: Perfusion CT is an appropriate imaging technique to diagnose CP and may be useful as a screening test to rule out early EPI.
  • Maiko Kobayashi; Hayato Kaida; Akihiko Kawahara; Satoshi Hattori; Seiji Kurata; Masanobu Hayakawa; Yasumitsu Hirose; Masafumi Uchida; Masayoshi Kage; Hiromasa Fujita; Naofumi Hayabuchi; Masatoshi Ishibashi
    Clinical nuclear medicine 37 5 447 - 52 2012年05月 [査読有り]
     
    PURPOSE: To examine the relationship between glucose transporter-1 (GLUT-1) and vascular endothelial growth factor (VEGF) expression and (18)F-FDG uptake in esophageal squamous cell cancer patients. MATERIALS AND METHODS: Fifty-seven patients (52 male and 5 female) were included in this study. (18)F-FDG PET/CT was performed prior to the surgery. Immunohistochemistry was performed using postoperative histopathological specimens. The estimation of immunohistochemistry was conducted using scoring analysis. We investigated the correlations between maximum standardized uptake value (SUV(max)) and GLUT-1/VEGF expressions/pathologic tumor length (p-tumor length), and the relationships between pathologic T (p-T) stage and GLUT-1/VEGF expressions/SUV(max) and between lymph node metastasis (p-N) stage and GLUT-1/VEGF expressions/SUV(max). RESULTS: SUV(max) significantly correlated with GLUT-1 expressions and p-tumor length (GLUT-1: r = 0.475, P < 0.001; p-tumor length: r = 0.475, P < 0.001). SUV(max) of the primary tumor had a significant relationship with p-T stage, p-N stage, and VEGF expression (p-T stage: P < 0.001; p-N stage: P = 0.037; VEGF expression: P = 0.009). There was a statistically significant difference between GLUT-1 expression and p-T stage/VEGF expression, but not p-N stage (p-T stage: P = 0.012; VEGF expression: P = 0.01; p-N stage: P = 0.572). VEGF expression had a significant relationship with p-T stage, but not with p-N stage (p-T stage: P = 0.032; p-N stage: P = 0.763). CONCLUSION: (18)F-FDG uptake can be determined by GLUT-1 and VEGF. SUV(max) would have a connection with the tumor progression and lymph node metastasis.
  • Yasumitsu Hirose; Hayato Kaida; Masatoshi Ishibashi; Jun Uozumi; Shunji Arikawa; Seiji Kurata; Naofumi Hayabuchi; Keita Nakahara; Koichi Ohshima
    Clinical nuclear medicine 37 2 152 - 7 2012年02月 [査読有り]
     
    PURPOSE: The aim of this study was to compare endoscopic macroscopic classification with fluorine-18 fluorodeoxyglucose (F-18 FDG) uptake in gastric mucosa-associated lymphoid tissue (MALT) lymphoma and to investigate the usefulness of F-18 FDG positron emission tomography (PET) for diagnosing gastric MALT lymphoma. MATERIALS AND METHODS: Sixteen patients with gastric MALT lymphoma who underwent F-18 FDG PET and gastrointestinal imaging modalities were included in this study. Sixteen healthy asymptomatic participants undergoing both F-18 FDG PET and endoscopy for cancer screening were in the control group. We investigated the difference of F-18 FDG uptake between the gastric MALT lymphoma and the control group and compared the uptake pattern in gastric MALT lymphoma with our macroscopic classification. RESULTS: The endoscopic findings of 16 gastric MALT lymphoma patients were classified macroscopically as chronic gastritis-like tumors (n = 6), depressed tumors (n = 5), and protruding tumors (n = 5). Abnormal gastric F-18 FDG uptake was observed in 63% of tumors in the gastric MALT lymphoma group and 50% of cases in the control group. The median maximum standardized uptake values for gastric MALT lymphoma patients and control group were 4.0 and 2.6, respectively, the difference of which was statistically significant (P = 0.003). F-18 FDG uptake results were positive for all protruding tumors but only 50% for chronic gastritis-like tumors and 40% for depressed-type tumors. CONCLUSIONS: F-18 FDG PET may be a useful method for evaluating protrusion-type gastric MALT lymphoma. When strong focal or diffuse F-18 FDG uptake is detected in the stomach, endoscopic biopsy should be performed, even if the endoscopic finding is chronic gastritis.
  • Kenji Suda; Nobuhiro Tahara; Yoshiyuki Kudo; Hironaga Yoshimoto; Motofumi Iemura; Takafumi Ueno; Hayato Kaida; Masatoshi Ishibashi; Tsutomu Imaizumi
    International journal of cardiology 154 2 193 - 4 2012年01月 [査読有り]
  • Kenkichi Baba; Masatoshi Ishibashi; Hayato Kaida; Teruhiko Fujii; Yuji Hiromatsu; Akihiko Kawahara; Masayoshi Kage; Naofumi Hayabuchi
    Japanese journal of radiology 29 8 533 - 9 2011年10月 [査読有り]
     
    PURPOSE: The aim of this study was to investigate the relation between (99m)Tc-tetrofosmin uptake and extracellular signal-regulated kinase mitogen-activated protein kinase (ERK MAPK) expression in papillary thyroid cancer patients. MATERIALS AND METHODS: Our study population consisted of 14 patients. The histopathological findings for all patients were confirmed by surgery. Patients were administ 740 MBq of (99m)Tc-tetrofosmin. The tumor/background (T/B) ratios in regions of interest (ROIs) were measured at 10 min, 1 h, and 3 h to determine the uptake by papillary cancer. Immunohistopathological staining was performed, and the expression of phospho-ERK MAPK in papillary cancer was investigated. The relation between the expression of phospho-ERK MAPK and the T/B ratio was examined using the Mann-Whitney U-test. RESULTS: (99m)Tc-tetrofosmin uptake was positive in all patients. There was a statistically significant relation between the T/B ratio (at 3 h) and the expression of phospho-ERK MAPK but not with the T/B ratio at 10 min or 1 h: T/B ratio at 10 min (P = 0.32), at 1 h (P = 0.62), and at 3 h (P = 0.0072). CONCLUSION: Our results suggest that the relation between (99m)Tc-tetrofosmin uptake (3 h T/B ratio) may lead us to assume cell proliferation of papillary cancer.
  • Minori Mizoguchi; Nobuhiro Tahara; Atsuko Tahara; Yoshikazu Nitta; Norihiro Kodama; Toyoharu Oba; Kazutoshi Mawatari; Hideo Yasukawa; Hayato Kaida; Masatoshi Ishibashi; Naofumi Hayabuchi; Haruhito Harada; Hisao Ikeda; Sho-Ichi Yamagishi; Tsutomu Imaizumi
    JACC. Cardiovascular imaging 4 10 1110 - 8 2011年10月 [査読有り]
     
    OBJECTIVES: The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging. BACKGROUND: Atherosclerosis is intrinsically an inflammatory disease. Although hyperglycemia is associated with an increased risk of atherosclerotic cardiovascular disease, there are no clinical data to show the preference of any specific oral hypoglycemic agents to prevent atherosclerotic plaque inflammation. METHODS: A total of 56 impaired glucose tolerant or diabetic patients with carotid atherosclerosis underwent a complete history, determinations of blood chemistries, anthropometric variables, and FDG-PET. They were randomly assigned to receive either pioglitazone (15 to 30 mg) or glimepiride (0.5 to 4.0 mg) for 4 months with titration to optimal dosage. Effects of the drugs on atherosclerotic plaque inflammation were evaluated by FDG-PET at study completion. Plaque inflammation was measured by blood-normalized standardized uptake value, known as a target-to-background ratio. RESULTS: The study was completed in 31 pioglitazone-treated patients and 21 glimepiride-treated patients. Although both treatments reduced fasting plasma glucose and hemoglobin A1c values comparably, pioglitazone, but not glimepiride, decreased atherosclerotic plaque inflammation. Compared with glimepiride, pioglitazone significantly increased high-density lipoprotein cholesterol level. High-sensitivity C-reactive protein was decreased by pioglitazone, whereas it was increased by glimepiride. Multiple stepwise regression analysis revealed that the increase in high-density lipoprotein cholesterol level was independently associated with the attenuation of plaque inflammation. CONCLUSIONS: Our present study suggests that pioglitazone could attenuate atherosclerotic plaque inflammation in patients with impaired glucose tolerance or in diabetic patients independent of glucose lowering effect. Pioglitazone may be a promising strategy for the treatment of atherosclerotic plaque inflammation in impaired glucose tolerance or diabetic patients. (Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT; NCT00722631).
  • Hayato Kaida; Yuji Hiromatsu; Seiji Kurata; Akihiko Kawahara; Satoshi Hattori; Tomoki Taira; Maiko Kobayashi; Masafumi Uchida; Kentaro Yamada; Hiroyuki Mihashi; Hirohito Umeno; Masayoshi Kage; Tadashi Nakashima; Naofumi Hayabuchi; Masatoshi Ishibashi
    Nuclear medicine communications 32 8 690 - 8 2011年08月 [査読有り]
     
    OBJECTIVE: To examine the relationship between clinicopathological factors and fluorine-18-fluorodeoxyglucose (F-FDG) uptake in patients with papillary thyroid cancer (PTC). MATERIALS AND METHODS: Fifty-four patients were included in this study.F-FDG positron emission tomography was performed before surgery. Immunohistochemistry of glucose transporter (GLUT) was performed using postoperative histopathological specimens. We investigated the relationship between maximum standardized uptake value (SUVmax) and GLUT-1, GLUT-3, and GLUT-4 expression/SUVmax and prognostic risk factors {tumor size, age, sex, extrathyroidal extension, and lymph node metastasis [ly (+)]}. RESULTS: GLUT-3 and GLUT-4 expressions significantly correlated with SUVmax (GLUT-3: r=0.38, P=0.008; GLUT-4: r=0.46, P=0.001), but GLUT-1 did not (r=0.21, P=0.147). The tumor size correlated with SUVmax (r=0.5, P<0.001), but GLUT-1, GLUT-3, and GLUT-4 did not (GLUT-1: r=0.006, P=0.681; GLUT-3: r=0.05, P=0.705; GLUT-4: r=-0.17, P=0.217). Both SUVmax and GLUT-4 expressions were statistically significant with ly (+) (SUVmax: P=0.012; GLUT-4: P=0.018), but GLUT-1 and GLUT-3 expressions were not (GLUT-1: P=0.165; GLUT-3: P=0.499). There was no significant difference between other clinicopathological factors and SUVmax or any GLUT expressions. CONCLUSION: F-FDG uptake in PTC may be determined by GLUT-3 and GLUT-4 expressions and may be related to tumor size and lymph node metastasis of PTC. F-FDG uptake may reflect tumor progression of PTC.
  • Yasumitsu Hirose; Hayato Kaida; Masatoshi Ishibashi; Akihiko Kawahara; Maiko Kobayashi; Naofumi Hayabuchi
    Japanese journal of radiology 29 3 217 - 21 2011年04月 [査読有り]
     
    A 40-year-old woman discovered through palpation a tumor in the upper lateral quadrant of the left mammary gland. Mammography, ultrasonography (US), and magnetic resonance imaging (MRI) showed a 10 mm diameter tumor. Fluorine-18 fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) showed abnormal accumulation in the detected tumor, and the maximum standardized uptake value was 2.2. The patient underwent tumor resection. The postoperative histopathological finding was intraductal papilloma. The intraductal papilloma showed strong expression of glucose transporter (GLUT)-4 on membrane and/or cytoplasm, and weak expression of GLUT-1 and GLUT-3 by immunohistochemistry. This case suggests that other glucose transporters (e.g., GLUT-4), other pathological factors, and cytokines may have a close relation with (18)F-FDG accumulation in intraductal papilloma more than GLUT-1 or GLUT-3 expression.
  • Yohei Imamura; Koichi Azuma; Seiji Kurata; Satoshi Hattori; Tetsuro Sasada; Takashi Kinoshita; Masaki Okamoto; Tomotaka Kawayama; Hayato Kaida; Masatoshi Ishibashi; Hisamichi Aizawa
    Lung cancer (Amsterdam, Netherlands) 71 1 49 - 54 2011年01月 [査読有り]
     
    [(18)F]Fluorodeoxyglucose (FDG) uptake has been shown to correlate well with tumor proliferation rates. In patients with non-small cell lung cancer (NSCLC) receiving chemotherapy, we analyzed the relationships between the maximum standardized uptake value (SUVmax) obtained by FDG positron emission tomography (FDG-PET) and other clinical factors, and examined whether or not SUVmax could predict progression-free survival (PFS) and/or overall survival (OS). This retrospective study involved 62 consecutive NSCLC patients (35 male and 27 female: median age, 65 years). All patients underwent FDG-PET examination before treatment. As the first-line treatment, the patients received chemotherapy with (n=15) or without (n=47) radiotherapy. Survival curves were obtained by the Kaplan-Meier method, and differences in survival between subgroups were analyzed by the log-rank test and the Cox proportional hazards model. Significant correlations were observed between SUVmax and gender (P=0.006), histology (P<0.001), smoking status (P=0.049), stage (P=0.015), and treatment modality (P=0.008), but not other factors, including age (P=0.402) and performance status (P=0.421). The median SUVmax was 5.1 (25-75th percentile: 3.45-7.0) in patients with adenocarcinoma and 8.3 (25-75th percentile: 6.9-9.9) in those with other types of NSCLC. Adenocarcinomas showed significantly lower SUVmax than the other tumor types (P<0.001). Cox analysis adjusting for possible confounding factors, including gender, smoking status, histology and stage, demonstrated that the hazard ratios increased as the SUVmax increased in terms of both PFS (P=0.008) and OS (P=0.045), indicating that SUVmax predicts outcome independently of other clinical factors, such as histology and stage. Our findings indicate that FDG-PET examination can provide information useful for prognostication in NSCLC.
  • Shunji Arikawa; Masafumi Uchida; Jun Uozumi; Jun Sakoda; Hayato Kaida; Yukiko Kunou; Yasumitsu Hirose; Toshi Abe; Naofumi Hayabuchi; Yoshiki Naito; Yoshinobu Okabe; Hideya Suga; Hisafumi Kinoshita
    The Kurume medical journal 57 4 91 - 100 2011年 [査読有り]
     
    This study aimed to compare the usefulness of multidetector row CT (MDCT), MR cholangiopancreatography (MRCP), and endoscopic ultrasonography (EUS) in diagnosing branch duct intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Imaging and pathological findings were retrospectively evaluated for 25 patients with branch duct IPMNs of the pancreas who underwent surgical resection (13 adenomas, 4 borderline lesions, and 8 carcinomas). MDCT and MRCP were performed on all 25 patients, whereas EUS was performed on 22 patients. MDCT and MRCP were used to identify features predictive of malignancy, including carcinoma, borderline lesions, and the presence of thickened irregular walls/septa or a solid mass. EUS was used to identify the presence of intramural nodules or a solid mass. Correlations between histopathology and maximum diameter of the main pancreatic duct (MPD) or cyst size detected by MDCT and MRCP were also examined. Presence of a solid mass was highly correlated with malignancy with all imaging methods (MDCT; P=0.001, MRCP; P=0.008, EUS; P<0.001, respectively). Presence of thickened irregular walls/septa on MDCT correlated well with malignancy (P=0.019). In contrast, presence of thickened irregular walls/septa on MRCP and intramural nodules on EUS did not correlate with malignancy. No significant correlation was found between malignancy and average maximum MPD diameter or cyst size (P>0.05), though values tended to be larger in malignant tumors. Our results suggest that the presence of thickened irregular walls/septa or a solid mass on MDCT are highly correlated with malignancy, and that MDCT is useful for diagnosis of branch duct IPMNs of the pancreas.
  • Nobuhiro Tahara; Atsuko Tahara; Yoshikazu Nitta; Norihiro Kodama; Minori Mizoguchi; Hayato Kaida; Kenkichi Baba; Masatoshi Ishibashi; Naofumi Hayabuchi; Jagat Narula; Tsutomu Imaizumi
    JACC. Cardiovascular imaging 3 12 1219 - 28 2010年12月 [査読有り]
     
    OBJECTIVES: This study evaluated the usefulness of fasting (18)F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in the diagnosis and management of cardiac sarcoidosis (CS) and compared it with FDG uptake in dilated cardiomyopathy (DCM). BACKGROUND: Cardiac sarcoidosis may clinically present as DCM but is amenable to systemic corticosteroid therapy if disease activity is high. Although alterations of FDG uptake have been reported in CS, limited information is available on the quantitative estimates of FDG uptake. METHODS: Fasting FDG-PET was performed in 24 systemic sarcoidosis patients and was compared with 8 age-matched DCM patients. FDG-PET was also performed in 15 age-matched healthy control subjects. Twelve of the 24 sarcoidosis patients had cardiac involvement based on criteria established by the Japanese Ministry of Health and Welfare; the remaining 12 of 24 patients revealed no evidence of cardiac involvement. The myocardial FDG uptake was quantified by measuring the standardized uptake value in 17 myocardial segments in each subject. Coefficient of variation (COV), which equals the standard deviation of uptake divided by the average uptake of 17 segments, was calculated as an index of heterogeneity in the heart. RESULTS: The FDG uptake was distinctly heterogeneous in CS patients. The COV value was significantly greater in CS patients (0.25 ± 0.05) than control subjects (0.14 ± 0.03, p < 0.01), sarcoidosis patients without cardiac involvement (0.14 ± 0.03, p < 0.01), or DCM patients (0.15 ± 0.02, p < 0.01). The COV value in DCM patients was similar to control subjects or sarcoidosis patients without cardiac involvement. The cutoff COV value for the diagnosis of CS was 0.18 (sensitivity: 100%; specificity: 97%). After corticosteroid therapy in CS patients, the COV value was decreased to 0.14 ± 0.06 (p < 0.05) and became essentially similar to the other groups. CONCLUSIONS: Heterogeneous myocardial FDG uptake may be a useful diagnostic marker of disease activity for CS.
  • Seiji Kurata; Masatoshi Ishibashi; Koichi Azuma; Hayato Kaida; Shinzo Takamori; Kiminori Fujimoto; Maiko Kobayashi; Yasumitsu Hirose; Hisamichi Aizawa; Naofumi Hayabuchi
    Japanese journal of radiology 28 6 446 - 52 2010年07月 [査読有り]
     
    The aim of this study was to compare the results of semiquantitative analysis by(18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) with plasma osteopontin levels in the same asbestos-related pleural disease population. A total of 17 patients with asbestos-related pleural disease were prospectively recruited. They underwent PET/CT, and plasma osteopontin levels were measured. The maximum standardized uptake value (SUVmax) was determined from the most active pleural lesion in each patient. Malignant pleural mesothelioma (MPM) was histologically proven in 6 patients, and 11 patients had proven benign asbestos-related pleural diseases (7 pleural plaques, 4 asbestos pleurisy). Significant differences in SUVmax were found between patients with MPM and those with asbestos pleurisy (P = 0.031) and between patients with MPM and those with pleural plaques (P = 0.012). A significant difference was found in the plasma osteopontin levels between patients with asbestos pleurisy and patients with pleural plaques (Bonferroni correction, P = 0.024). The SUVmax in patients with benign asbestos-related diseases was statistically positively correlated with plasma osteopontin in the same group (Spearman's r = 0.75, P < 0.05). PET/CT might be more helpful than plasma osteopontin for distinguishing benign asbestos-related pleural diseases from MPM, and the SUVmax in benign asbestos-related pleural diseases may reflect changes in pleural inflammation.
  • Hayato Kaida; Masatoshi Ishibashi; Miya Yuzuriha; Seiji Kurata; Syunji Arikawa; Akihiko Kawahara; Jun Uozumi; Masafumi Uchida; Maiko Kobayashi; Yasumitsu Hirose; Hiromasa Fujita; Masayoshi Kage; Naofumi Hayabuchi
    Clinical nuclear medicine 35 7 505 - 9 2010年07月 [査読有り]
     
    A 74-year-old woman had dysphagia and underwent esophagogastroduodenoscopy. A giant submucosal tumor was seen from the middle to the lower esophagus. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG-PET/CT) was performed and F-18 FDG was found to accumulate in the submucosal tumor. The maximum standardized uptake value of the early phase was 4.93 and that of the delayed phase was 6.48. Gastrointestinal stromal tumor (GIST) was confirmed by both fine needle aspiration under endoscopic ultrasound and postoperative histopathologic findings. We stained the postoperative histopathologic specimen to investigate glucose transporter (GLUT) expression using immunohistochemistry, which revealed that GLUT-1 had a weak expression on membranes and GLUT-4 had a strong expression on membranes or in cytoplasm. GLUT-3 had no expression on membranes or in cytoplasm. Esophageal GIST is rare and the relationship between GLUT expression and F-18 FDG accumulation in GIST is probably rare.
  • Hiroko Kaibara; Hayato Kaida; Masatoshi Ishibashi; Seiji Kurata; Korenori Otsubo; Kiminori Fujimoto; Masafumi Uchida; Toshi Abe; Maiko Kobayashi; Ryousuke Doi; Yukiko Kunou; Takashi Okamura; Koichi Oshima; Naofumi Hayabuchi
    Annals of nuclear medicine 23 9 807 - 11 2009年11月 [査読有り]
     
    A 61-year-old woman presented with pancytopenia and underwent a bone marrow biopsy. The patient was diagnosed with nonsecretory myeloma (plasmablastic type) based on both the bone marrow biopsy findings and her laboratory data. Fluorine-18 fluorodeoxyglucose-positron emission tomography ((18)F-FDG-PET) was performed prior to chemotherapy showing diffuse bone marrow uptake, splenic uptake, and focal uptake of the right anterior chest wall. The patient underwent an (18)F-FDG-PET examination to evaluate the curative effects after three cycles of chemotherapy, and no abnormal uptake on (18)F-FDG-PET was found. Bone marrow biopsy to evaluate the curative effect showed no viable tumor cells. We present a rare case of nonsecretory plasmablastic myeloma detected by (18)F-FDG-PET.
  • Rin Yamaguchi; Yasuhiko Futamata; Fumihiro Yoshimura; Naotaka Murakami; Kikuo Koufuji; Rumiko Kutami; Kazuyuki Kojima; Shino Ohki; Seiji Kurata; Hayato Kaida; Masatoshi Ishibashi; Hirohisa Yano
    Japanese journal of radiology 27 7 280 - 4 2009年08月 [査読有り]
     
    Positron emission tomography (PET) with (18)F-fluorodeoxyglucose (FDG) has been shown to be an effective and accurate diagnostic technique for breast cancer. However, benign breast lesions have also been reported to show a false-positive FDG uptake on PET. We present two cases of benign tumors that revealed FDG uptake on PET and were difficult to distinguish from breast cancer. A 46-year-old premenopausal woman noticed a mass in her right breast. Ultrasonography showed a hypoechoic mass with the size of 7.7 x 3.9 mm and an irregular shape in the right breast. PET demonstrated a focal accumulation of FDG with a maximum standardized uptake value (SUVmax) of 2.1. Excisional biopsy was performed, and ductal adenoma was diagnosed. In the second case, a 36-year-old premenopausal woman was pointed out as showing an abnormality in the left breast on screening mammography. Ultrasonography showed a hypoechoic mass of 1.5 x 1.2 cm in size in the left breast. The lesion was depicted as a mass with prominent enhancement on dynamic CT and a focal accumulation of FDG with SUV max of 3.5 on PET. It was diagnosed as fibroadenoma of mastopathic type histopathologically by excisional biopsy. The readers should be aware that these benign tumors may cause false-positive results on PET.
  • 有川 俊二; 内田 政史; 魚住 淳; 服部 睦行; 鈴木 弦; 甲斐田 勇人; 淡河 恵津世; 早渕 尚文
    臨床放射線 54 7 883 - 887 金原出版(株) 2009年07月 
    58歳女。頸部食道扁平上皮癌に対し5-fluorouracil/cisplatin併用化学療法を施行し、partial responseで放射線科転科となった。経口摂取不十分であったため経皮内視鏡的胃瘻造設術を行い、放射線治療は4MVX線1.8Gy/day、総線量61.0Gyの予定で開始し、化学療法はCDDP 7mg/body、5-FU 350mg/bodyの併用療法を施行した。放射線治療36Gy時の胸部CTでは頸部食道癌、腫大していた頸部・上縦隔リンパ節の著明な縮小を認め、更に左鎖骨上窩や縦隔に遊離ガス像を認めた。腹部単純X線では上行結腸から横行結腸にかけて腸管壁に沿った線状影、肝下極や右腎周囲に遊離ガス像を認め、腹部CTでは回腸から横行結腸にかけての広範囲に腸管気腫症と後腹膜気腫、腹腔内遊離ガスを認めた。腹腔内遊離ガスと縦隔気腫を合併した腸管気腫症と診断したが、消化管穿孔を示唆する腹膜刺激症状の所見はなく、保存的加療を行うこととなった。中心静脈栄養管理を開始し、その後の全消化管造影検査で明らかな消化管穿孔は認めなかった。約2週間後のX線で縦隔気腫、後腹膜や腸管壁のガス像は消失しており、腹部膨満感を認めず、経口摂取を開始した。更に2週間後に食道癌の治療も完遂し、CRで退院となった。
  • Shiroh Miura; Hiroko Nakagawara; Hayato Kaida; Minoru Sugita; Kazuhito Noda; Kyoko Motomura; Yasumasa Ohyagi; Mitsuyoshi Ayabe; Hisamichi Aizawa; Masatoshi Ishibashi; Takayuki Taniwaki
    Clinical neurology and neurosurgery 111 2 211 - 5 2009年02月 [査読有り]
     
    Two cases of spinocerebellar ataxia type 14 (SCA14) with a G128D mutation in the protein kinase C gamma gene (PRKCG) without a definite family history have been reported previously. Here, we describe the first familial cases of SCA14 with a G128D mutation in PRKCG. Among three family members, the chief complaints varied and included ataxic gait, cervical dystonia, and positional vertigo. Moreover, retinal degeneration and facial muscle weakness were observed, although these are not expected to be present in SCA14. Cerebral blood flow evaluation using single photon emission computed tomography (SPECT) also differed among family members. It is possible that patients with the G128D mutation suffering from SCA14 may sometimes be classified as unaffected due to the varying clinical signs among family members.
  • H. Kaida; M. Ishibashi; S. Kurata; Y. Uchiyama; N. Tanaka; T. Abe; M. Kobayashi; H. Kaibara; M. Uchida; T. Nakashima; H. Fujita; N. Hayabuchi
    NUKLEARMEDIZIN-NUCLEAR MEDICINE 48 5 179 - 184 2009年 [査読有り]
     
    Aim: To examine the utility of 2'-[(18)F]-fluoro-2'-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting multiple primary cancers (MPC) in patients with hypopharyngeal cancer (HPC), Patients, methods: Seventy patients with HPC underwent FDG-PET to determine the staging. Routine clinical examinations were carried out, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound (US), and oesophagealgastroduodenoscopy (EGDS). The detection rate of synchronous and metachronous cancer was calculated based on FDG-PET alone or FDG-PET combined with clinical routine examination. Sensitivity, specificity, positive predictive values (PPV), negative predictive values (NPV), and accuracy were used to diagnose oesophageal cancer using FDG-PET Results: Of the 70 patients, 12 (17.1%) had 15 synchronous tumours, and 2 of the 58 remaining patients (3.4%) had metachronous tumours. Oesophageal cancer was discovered most frequently: superficial type (n = 6), advanced type (n = 4). On a per-patient basis, 11 of 12 patients (91.6%) were diagnosed with synchronous tumours, and on a per-lesion basis, 12 of 15 lesions (80.0%) were detected by FDG-PET. The sensitivity specificity, accuracy, PPV, and NPV of FDG-PET regarding oesophageal cancer were 70%, 100%, 95.7%, 100%, and 95.2% respectively. Three of the six superficial types were positive on FDG-PET. Both of the metachronous tumour lesions were detected by FDG-PET. Conclusion: FDG-PET is useful for estimating the MPC in HPC patients, Since 3 of 10 synchronous oesophageal cancer were missed with PET alone, a combination with EGDS should be considered to exclude synchronous oesophageal cancer.
  • Hayato Kaida; Masatoshi Ishibashi; Teruhiko Fuji; Seiji Kurata; Masafumi Uchida; Kenkichi Baba; Teruo Miyagawa; Hiroko Kaibara; Seiji Kawamura; Etsuyo Ogo; Naofumi Hayabuchi
    Nuclear medicine communications 29 10 885 - 93 2008年10月 [査読有り]
     
    OBJECTIVE: To prospectively evaluate the breast cancer detection of prone breast positron emission tomography (PET) images in comparison with supine whole-body PET images. MATERIAL AND METHODS: One hundred and eighteen female patients (age range 28-91 years) with 122 lesions suspected of having breast cancer underwent fluorine-18 fluorodeoxyglucose PET for preoperative staging. After the whole-body image was acquired, prone breast PET imaging was performed. The findings from both images were compared with the histopathologic results. Sensitivity, specificity, positive predictive value, negative predictive value (NPV), and accuracy were used to compare the diagnostic accuracy of prone breast PET images with that of whole-body PET images. RESULTS: Sensitivity, specificity, positive predictive value, NPV, and accuracy of whole-body PET images were 83, 50, 97, 17, and 80%, and of prone breast PET images they were 95, 50, 96, 43, and 93%. Ten of 114 breast cancerous lesions (8.8%) were detected on prone breast PET images alone. Statistical difference was found between the sensitivity, accuracy, and NPV of prone breast PET images and those of whole-body PET images (P<0.0001 for sensitivity and accuracy and P<0.0009 for NPV). CONCLUSION: Our data about the 122 lesions, suspected of breast cancer, with regard to the usefulness of prone breast PET imaging indicate that prone breast PET images are effective in detecting breast cancer.
  • Fumika Takata; Hayato Kaida; Masatoshi Ishibashi; Seiji Kurata; Jun Uozumi; Masafumi Uchida; Takashi Okamura; Shinji Uchida; Kouichi Oshima; Shgeki Ban; Shigenobu Meno; Naofumi Hayabuchi
    Clinical nuclear medicine 33 3 204 - 7 2008年03月 [査読有り]
     
    F-18 FDG uptake of splenic involvement by malignant lymphoma has frequently been seen, but reports of F-18 FDG PET related to primary splenic lymphoma (PSL) are very rare. We describe herein a case of PSL detected by F-18 FDG PET. A 66-year-old woman was referred for further examination due to indications of a solitary splenic tumor. F-18 FDG PET revealed the abnormal focal uptake of the spleen. Laparoscopic splenorectomy was performed to acquire the histopathological findings. The histopathological findings of splenic tumor were diffuse large B-cell lymphoma.
  • Hayato Kaida; Masatoshi Ishibashi; Teruhiko Fujii; Seiji Kurata; Etsuyo Ogo; Maki Tanaka; Naofumi Hayabuchi
    Annals of nuclear medicine 22 2 95 - 101 2008年02月 [査読有り]
     
    OBJECTIVE: The aim of this study was to investigate the detection rate of breast cancer by positron emission tomography cancer screening using a breast positioning device. METHODS: Between January 2004 and January 2006, 1,498 healthy asymptomatic individuals underwent cancer screening by fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) at our institution; 660 of 1498 asymptomatic healthy women underwent breast PET imaging in the prone position using the breast positioning device to examine the mammary glands in addition to whole-body PET imaging. All subjects that showed abnormal (18)F-FDG uptake in the mammary glands were referred for further examination or surgery at our institution or a local hospital. Our data were compared with the histopathological findings or findings of other imaging modalities in our institution and replies from the doctors at another hospital. RESULTS: Of the 660 participants, 7 (1.06%) were found to have breast cancers at a curable stage. All the seven cancers were detected by breast PET imaging, but only five of these were detected by whole-body PET imaging; the other two were detected by breast PET imaging using the breast positioning device. CONCLUSIONS: In cancer screening, prone breast imaging using a positioning device may help to improve the detection rate of breast cancer. However, overall cancer including mammography and ultrasonography screening should be performed to investigate the false-negative cases and reduce false-positive cases. The effectiveness of prone breast PET imaging in cancer screening should be investigated using a much larger number of cases in the near future.
  • Nobuhiro Tahara; Hisashi Kai; Hiroyuki Nakaura; Minori Mizoguchi; Masatoshi Ishibashi; Hayato Kaida; Kenkichi Baba; Naofumi Hayabuchi; Tsutomu Imaizumi
    European heart journal 28 18 2243 - 8 2007年09月 [査読有り]
     
    AIMS: There is increasing evidence that (18)F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging can be useful for non-invasive measurement of atherosclerotic plaque inflammation in humans. However, it is unknown how often atherosclerosis has inflammation in humans. Thus, we examined the prevalence of inflammation in documented carotid atherosclerosis using FDG-PET imaging. METHODS AND RESULTS: FDG-PET imaging was performed in 100 consecutive patients who underwent carotid artery ultrasonography (CA-US) for screening of carotid atherosclerosis. Carotid atherosclerosis was considered when patients had the plaque score >or=5 and/or the focal thickening of the maximum intima-media complex >or=2 mm (localized plaque) by CA-US. The inflammation of carotid atherosclerosis was quantified by measuring the standardized uptake value (SUV) of FDG of the carotid artery. Inflammation was defined as present if the SUV score was >or=1.60 (>or=1 x standard deviation above the average). FDG-PET imaging revealed inflammation in 12 of 41 (29%) patients having carotid atherosclerosis, whereas in 6 of 59 (10%) patients not having carotid atherosclerosis (P < 0.01). In patients with documented atherosclerosis by CA-US, body mass index, waist circumference, and the number of localized plaques were greater in a subset with inflammation than in a subset without. CONCLUSION: Inflammation was visualized by FDG-PET imaging in approximately 30% of patients with documented carotid atherosclerosis.
  • Seiji Kurata; Masatoshi Ishibashi; Yuji Hiromatsu; Hayato Kaida; Ikuyo Miyake; Masafumi Uchida; Naofumi Hayabuchi
    Annals of nuclear medicine 21 6 325 - 30 2007年08月 [査読有り]
     
    OBJECTIVE: To investigate and evaluate the prevalence of incidental thyroid diffuse and diffuse-plus-focal fluorine-18 fluorodeoxyglucose (FDG) uptake in healthy subjects who underwent cancer screening on positron emission tomography (PET) scan, and also to evaluate the prevalence of thyroid cancer and Hashimoto's thyroiditis. METHODS: We carried out a retrospective review of 1626 subjects who underwent PET scanning at our institution. Diffuse uptake was defined as FDG uptake in the whole thyroid gland, whereas diffuse-plus-focal uptake was defined as a thyroid lesion with both diffuse uptake and focal FDG uptake. The maximum standardized uptake value of the thyroid lesions was recorded and reviewed. In each selected subject with positive thyroid FDG uptake, serum thyroid-stimulating hormone, thyroid hormone, and thyroid antibodies were measured. Fine needle aspiration cytology was performed on patients with a definite nodule using ultrasonography. RESULTS: Twenty-nine subjects (1.78%) were identified as having either diffuse FDG uptake (n = 25, 1.53%) or diffuse-plus-focal FDG uptake (n = 4, 0.24%). All subjects with diffuse FDG uptake were diagnosed as having Hashimoto's thyroiditis. In 1 of the 25 subjects with diffuse FDG uptake and two of the four with diffuse-plus-focal FDG uptake, histopathologic diagnosis showed papillary thyroid carcinoma associated with Hashimoto's thyroiditis. However, PET scan did not detect papillary carcinoma associated with Hashimoto's thyroiditis in one of the three subjects. CONCLUSIONS: Our results suggest that although diffuse FDG uptake usually indicates Hashimoto's thyroiditis, the risk of thyroid cancer must be recognized in both diffuse FDG uptake and diffuse-plus-focal FDG uptake on PET scan.
  • Hayato Kaida; Masatoshi Ishibashi; Seiji Kurata; Masafumi Uchida; Naofumi Hayabuchi
    Annals of nuclear medicine 21 3 185 - 8 2007年06月 [査読有り]
     
    We present a case of inferior vena cava (IVC) tumor thrombus detected by fluorine- 18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET). A man underwent operations for the treatment of sigmoid colon cancer at the age of 63. Because tumor markers [carcinoembryonic antigen (CEA) and CA19-9] were increased at the age of 67, abdominal contrast-enhanced computed tomography (CT) was performed. CT revealed IVC dilatation, including a low-attenuation area. 18F-FDG-PET was performed to make the differential diagnosis between tumor thrombus and clot. 18F-FDG-PET showed that 18F-FDG had accumulated in the IVC region. We considered the IVC tumor thrombus because of the 18F-FDG uptake in the IVC region and the patient's clinical course. To our knowledge, there are a few reports concerning 18F-FDG-PET and IVC tumor thrombus. 18F-FDG-PET may be useful in diagnosing tumor thrombus.
  • Nobuhiro Tahara; Hisashi Kai; Sho-ichi Yamagishi; Minori Mizoguchi; Hiroyuki Nakaura; Masatoshi Ishibashi; Hayato Kaida; Kenkichi Baba; Naofumi Hayabuchi; Tsutomu Imaizumi
    Journal of the American College of Cardiology 49 14 1533 - 9 2007年04月 [査読有り]
     
    OBJECTIVES: We investigated factors for carotid artery inflammation by [(18)F]-fluorodeoxyglucose (FDG) positron emission tomography (PET). BACKGROUND: Inflammation is present in some atherosclerotic plaques. The FDG-PET is capable of identifying and quantifying vascular inflammation within atherosclerotic plaques. METHODS: The FDG-PET imaging was performed in 216 consecutive patients (63 +/- 9 years, men:women 147:69) for cancer screening. Vascular inflammation in carotid atherosclerosis was quantified by measuring the standardized uptake value (SUV) of FDG into the artery. RESULTS: Multiple stepwise regression analysis revealed significant relationships between SUV and waist circumference (p < 0.001), hypertensive medication (p < 0.001), carotid intima-media thickness (p < 0.001), high-density lipoprotein cholesterol (p < 0.01, inversely), homeostasis model assessment of insulin resistance (p < 0.05), or high sensitivity C-reactive protein (p < 0.05). Age- and gender-adjusted SUV of FDG was significantly higher (p < 0.0001) in proportion to the accumulation of the number of the components of the metabolic syndrome. Thus, the metabolic syndrome was associated with increased FDG uptake in carotid atherosclerosis. CONCLUSIONS: Our present study may suggest that the metabolic syndrome is associated with inflammation in carotid atherosclerosis. (Detection of Plaque Inflammation by Positron Emission Tomography (PET); http://www.clinicaltrials.gov/ct/show/NCT00114504; NCT00114504).
  • Nobuhiro Tahara; Hisashi Kai; Masatoshi Ishibashi; Hiroyuki Nakaura; Hayato Kaida; Kenkichi Baba; Naofumi Hayabuchi; Tsutomu Imaizumi
    Journal of the American College of Cardiology 48 9 1825 - 31 2006年11月 [査読有り]
     
    OBJECTIVES: We investigated whether simvastatin attenuates plaque inflammation by using 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) co-registered with computerized tomography. BACKGROUND: Inflammation plays a key role in progression and destabilization of atherosclerotic plaque. 18F-fluorodeoxyglucose PET is a promising tool for visualizing inflammation of atherosclerotic plaque. Antiinflammatory action is one of the pleiotropic effects of statins. METHODS: Forty-three consecutive subjects, who underwent 18FDG-PET for cancer screening and had 18FDG uptakes in the thoracic aorta and/or the carotid arteries, were randomized to either statin group receiving simvastatin (n = 21) or diet group receiving dietary management only (n = 22). The maximum standardized uptake values (SUVs) were measured in individual plaques, and were averaged for analysis of the subjectwise results. The responses were assessed after 3-month treatments. RESULTS: Positron emission tomography revealed 117 and 123 18FDG-positive plaques in the statin and diet groups, respectively. Simvastatin, but not diet alone, attenuated plaque (18)FDG uptakes and decreased the SUVs (p < 0.01). Simvastatin reduced low-density lipoprotein cholesterol (LDL-C) by 30% (p < 0.01) and increased high-density lipoprotein cholesterol (HDL-C) by 15% (p < 0.01), whereas LDL-C and HDL-C levels were not changed in the diet group. In the statin group, the decrease in the SUV was well correlated with the HDL-C elevation (p < 0.01) but not with the LDL-C reduction. CONCLUSIONS: 18F-fluorodeoxyglucose PET visualized plaque inflammation and simvastatin attenuated it. The LDL-C-independent effects of simvastatin may participate in the beneficial effect. 18F-fluorodeoxyglucose PET has a potential for visually monitoring plaque inflammation and the therapeutic effectiveness of statins.
  • Sakae Nagaoka; Satoshi Itano; Masatoshi Ishibashi; Takuji Torimura; Kenkichi Baba; Junji Akiyoshi; Junichi Kurogi; Satoru Matsugaki; Kinya Inoue; Nobuyoshi Tajiri; Akio Takada; Eiji Ando; Ryoko Kuromatsu; Hayato Kaida; Mina Kurogi; Hironori Koga; Ryukichi Kumashiro; Naofumi Hayabuchi; Masamichi Kojiro; Michio Sata
    Liver international : official journal of the International Association for the Study of the Liver 26 7 781 - 8 2006年09月 [査読有り]
     
    BACKGROUND/AIMS: This study aimed to evaluate the usefulness of (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (PET) and PET plus computed tomography (CT) fusion images for the detection of extrahepatic metastases of hepatocellular carcinoma (HCC) and combined hepatocellular and cholangiocarcinoma (combined HCC/CC). METHODS: Twenty-one patients with HCC and combined HCC/CC were enrolled in the study from December 2004 to February 2005. In all patients, PET and CT of the chest to pelvis region were performed. The sensitivity of PET plus CT fusion images was compared with the sensitivity of PET, CT, and bone scintigraphy. RESULTS: In 14 patients, a total of 58 extrahepatic metastases were diagnosed. The detection rate of PET plus CT fusion images, PET, CT, and bone scintigraphy was 98.2% (57 of 58 metastases), 89.6% (52 of 58 metastases), 91.2% (52 of 57 metastases), and 68.7% (11 of 16 bone metastases), respectively. No extrahepatic metastases were detected in the other seven patients. The detection rate of PET was 10/18 (55.6%) for intrahepatic lesions of HCC and combined HCC/CC. CONCLUSIONS: The fusion of PET plus CT images is useful in detecting extrahepatic metastases in HCC and combined HCC/CC patients.
  • Hayato Kaida; Masatoshi Ishibashi; Maiko Nakamura; Kenkichi Baba; Nobuhiro Tahara; Jun Uozumi; Naofumi Tomita; Syunji Arikawa; Naofumi Hayabuchi
    Annals of nuclear medicine 20 4 317 - 20 2006年05月 [査読有り]
     
    We report a case of early gastric cancer and early colon cancer detected by positron emission tomography (PET) cancer screening. A 64-year-old male patient with an unremarkable past history except for hypertension and cerebrovascular disease underwent 18F-FDG PET for cancer screening. Images revealed increased uptake in the gastric antrum and sigmoid colon. Both areas appeared suspicious for neoplasm on subsequent fluoroscopy and endoscopy, and biopsies were positive for neoplasia at both sites. The gastric lesion was treated by distal gastrectomy and D2 lymphadenectomy and the colon cancer by endoscopic mucosal resection (EMR). Both surgical specimens were positive for cancer.
  • Hayato Kaida; Masatoshi Ishibashi; Hidemi Nishida; Kenkichi Baba; Naofumi Hayabuchi
    Clinical nuclear medicine 30 8 569 - 70 2005年08月 [査読有り]
     
    A 41-year-old man experienced continuous convulsions, unconsciousness, and a high temperature. His laboratory findings revealed an increase in serum creatine phosphokinase, serum myoglobulin, and urinary myoglobulin levels. He had taken many psychotropic drugs as treatment for schizophrenia and was very dehydrated. Because a diagnosis of rhabdomyolysis was suspected, Tc-99m HMDP bone scintigraphy was performed. It showed diffusely increased soft tissue uptake in his shoulder girdles, vertebral area, psoas iliac muscles, and gluteofemoral muscles, leading to a diagnosis of rhabdomyolysis. Bone scintigraphy is useful in making an early diagnosis and evaluating the location and degree of muscle injury in rhabdomyolysis.
  • Hayato Kaida; Masatoshi Ishibashi; Hidemi Nishida; Kenkichi Baba; Yuji Hiromatsu; Seiya Okuda; Naofumi Hayabuchi
    Annals of nuclear medicine 19 5 367 - 72 2005年07月 [査読有り]
     
    OBJECTIVE: The semi-quantitative method of bone scintigraphy [bone to soft tissue (B/ST) ratio] has been used in diagnosing and evaluating systemic metabolic bone diseases. The aim of this study is to evaluate of the therapeutic effect of secondary hyperparathyroidism (SHP). METHODS: The subjects were ten hemodialysis patients with SHP. Seven patients underwent parathyroidectomy (PTX), and 22-Oxacalcitoriol (derivative of 1,25-dihydroxyvitamin D3) (OCT) was given to three patients. Bone scintigraphy and blood tests [intact parathyroid hormone (PTH), alkaline phosphatase (ALP), calcium (Ca), phosphorus (P), bone alkaline phosphatase (BALP), and deoxypridinoline (DPYD)] were performed before and after treatment. Regions of interest were drown around cranium, lumbar vertebrae, femoral neck and soft tissue of left medial thigh to calculate the B/ST ratio. RESULT: The B/ST ratios of cranium, lumbar vertebrae, and femoral neck were reduced significantly after PTX (cranium, p = 0.0079, lumbar vertebrae, p = 0.0282, femoral neck, p = 0.0252). Intact PTH, ALP, Ca, P, BALP and DPYD levels were reduced significantly after PTX (intact PTH, p = 0.003, Ca, p = 0.0005, P, p = 0.0393, ALP, p = 0.0051, DPYD, p = 0.0232, BALP, p = 0.0324). After OCT administration, the B/ST ratio of each bony region showed tendency to diminish, although not significantly. Intact PTH levels were reduced significantly, although ALP, BALP, and DPYD levels were not. Ca and P levels were increased significantly because of the medicinal action of OCT. CONCLUSION: The B/ST ratio of cranium may be non-invasive method and have potential in evaluating the therapeutic effect of SHP.
  • Hidemi Nishida; Hayato Kaida; Masatoshi Ishibashi; Kenkichi Baba; Keisuke Kouno; Seiya Okuda
    Annals of nuclear medicine 19 4 325 - 9 2005年06月 [査読有り]
     
    We present a case of a thirty-eight-year-old man who had exercise-induced acute renal failure (exercise-induced ARF). He experienced oliguria, general fatigue, and vague discomfort in the lower abdomen after he exercised. As he had suffered from hypouricemia before, he was diagnosed as having exercise-induced ARF associated with hypouricemia. Enhanced computed tomography (CT) images showed patchy wedge-shaped contrast enhancement on his bilateral kidneys, consistent with characteristic observations for exercise-induced ARF. Tc-99m diethylene triamine pentaacetic acid (DPTA) renography revealed decreases in both the renal blood flow (RBF) and glomerular filtration rate (GFR), and revealed parenchymal dysfunction of the bilateral kidneys. Renogram revealed a hypofunctional pattern on the bilateral kidneys. CT images and Tc-99m DTPA renography also had improved when the symptoms of exercised-induced ARF indicated improvement. It has been hypothesized that one cause of exercise-induced ARF may be renal vasocontraction. Although CT images are useful in evaluating exercise-induced ARF, Tc-99m DTPA renography can more easily and safely evaluate renal function. We also show that Tc-99m DTPA renography is useful in precisely evaluating the degree of improvement of exercise-induced ARF.
  • Hayato Kaida; Masatoshi Ishibashi; Hidemi Nishida; Kenkichi Baba; Yuji Hiromatsu; Seiya Okuda; Naofumi Hayabuchi
    Annals of nuclear medicine 19 3 179 - 84 2005年05月 [査読有り]
     
    OBJECTIVE: Intact parathyroid hormone (PTH) assay has recently been reported to be effective in evaluating both 1-84 PTH (whole PTH) and inactive 7-84 PTH. Inactive 7-84 PTH is considered to be increased in hemodialysis patients and to prevent the effects of 1-84 PTH, and intact PTH is considered to overestimate the PTH activity in these patients. As such, a whole PTH assay has recently been developed. The purpose of this study was to examine the usefulness of a whole PTH assay using the bone to soft tissue (B/ST) ratio on bone scintigraphy. METHOD: Twenty-five hemodialysis patients were included in our study. In all patients, bone scintigraphy and a blood test [whole PTH, intact PTH, alkaline phosphatase (ALP), calcium (Ca), and phosphorus (P)] were performed. Regions of interest (ROIs) were drawn around the cranium, lumbar vertebrae, left femoral neck, and soft tissue of the medial left thigh to obtain the B/ST ratio. RESULTS: The B/ST ratio of the cranium and left femoral neck correlated with whole PTH and intact PTH. In particular, the B/ST ratio of the cranium correlated most significantly with the value of whole PTH. Whole PTH levels correlated with intact PTH levels (r = 0.891, p < 0.0001). CONCLUSION: Our data indicate that a whole PTH assay may be useful in evaluating PTH activity using the B/ST ratio. The B/ST ratio of the cranium may reflect the bone metabolism of hemodialysis patients.
  • Hidemi Nishida; Masatoshi Ishibashi; Yuji Hiromatsu; Hayato Kaida; Kenkichi Baba; Ikuyo Miyake; Hirofumi Ikedo; Seiya Kato; Kei Fukami; Shuji Iida; Seiya Okuda
    Endocrine journal 52 2 223 - 8 2005年04月 [査読有り]
     
    To determine the usefulness of parathyroid scintigraphy in histological estimation for secondary hyperparathyroidism (2HPT) using Tc-99m sestamibi or Tc-99m tetrofosmin. Tc-99m sestamibi (MIBI) and Tc-99m tetrofosmin (Tetro) parathyroid imaging following double-phase study, magnetic resonance imaging (MRI), and ultrasound were performed on 14 patients with 2HPT. All patients underwent parathyroidectomy. The uptake of two tracers in parathyroid areas was compared with the histopathologic findings. Forty-nine parathyroid glands were surgically explored and histologically proven to be hyperplastic. Of these, 42 were diagnosed with nodular type (N-type) hyperplasia, and 7 with diffuse type (D-type) hyperplasia. MIBI and Tetro parathyroid imagings detected 34 and 35 parathyroid glands, respectively. The sensitivity of MIBI was determined to be 76.2% (32/42) for N-type, and 28.6% (2/7) for D-type. The sensitivity of Tetro was determined to be 78.6% (33/42) for N-type and 28.6% (2/7) for D-type. The sensitivity of both MIBI and Tetro was significantly higher for N-type than for D-type, 76.2% (32/42) vs. 28.6% (2/7) in MIBI, P = 0.022; 78.6% (33/42) vs. 28.6% (2/7) in Tetro, P = 0.015. The sensitivity of MRI was determined to be 76.2% (32/42) for N-type and 42.9% (3/7) for D-type, and the sensitivity of ultrasound was 71.4% (30/42) for N-type and 71.4% (5/7) for D-type. There was no significant difference in the sensitivity of MRI or ultrasound between N-type and D-type. The uptake ratios of MIBI and Tetro were also greater for N-type than for D-type. The detectability of both MIBI and Tetro was greater for N-type than for D-type. Tc-99m MIBI or Tc-99m Tetro parathyroid scintigraphy therefore may be used clinically to distinguish N-type from D-type parathyroid gland hyperplasia.
  • Hidemi Nishida; Hayato Kaida; Masatoshi Ishibashi; Yuji Hiromatsu; Kenkichi Baba; Shuji Iida; Seiya Okuda
    Annals of nuclear medicine 19 2 91 - 4 2005年04月 [査読有り]
     
    OBJECTIVE: It is important to estimate the bone metabolism in patients with renal osteodystrophy. The methods of estimation must be noninvasive, accurate, and able to measure repeatedly. METHODS: The regions of interest on bone scintigraphy were drawn over the radius in 22 hemodialysis patients (10 males, 12 females). The bone/soft tissue ratio (B/ST ratio) was calculated for all patients. The bone soft tissue ratio of both skull (S) and radius (R) was obtained from the resultant count ratios. We investigated the correlation between intact parathyroid hormone (PTH), alkaline phosphatase (ALP) and the uptake ratios S and R. RESULTS: Intact PTH had a significantly linear correlation with R (r = 0.745, p < 0.0001) and S (r = 0.702, p = 0.0001). ALP also had a significantly linear correlation with R (r = 0.537, p = 0.009) and S (r = 0.772, p < 0.0001). CONCLUSION: The measurement of the bone soft tissue ratio of radius on bone scintigraphy was crucial for estimating renal osteodystrophy.
  • H Kaida; M Ishibashi; K Baba; H Nishida; K Matsuoka; N Hayabuchi
    BRITISH JOURNAL OF RADIOLOGY 77 922 869 - 870 2004年10月 [査読有り]
  • Yuji Hiromatsu; Masatoshi Ishibashi; Hidemi Nishida; Seiji Kawamura; Hiroo Kaku; Kenkichi Baba; Hayato Kaida; Ikuyo Miyake
    Endocrine journal 50 3 239 - 44 2003年06月 [査読有り]
     
    To determine if subacute thyroiditis (SAT) is associated with changes in the regional perfusion of the thyroid gland, we performed Tc-99 m sestamibi scans on eleven patients with SAT who had painful goiter and clinical thyrotoxicosis. Eleven patients had Tc-99 m pertechnetate and Tc-99 m sestamibi scintigraphy during the acute stage of SAT. The thyroid uptake ratio of sestamibi was compared with the laboratory data and color Doppler ultrasonography. Tc-99 m pertechnetate scintigraphy in the thyroid was markedly reduced during the acute stage of SAT. Conversely, Tc-99 m sestamibi showed diffuse increased uptake in the thyroid region, suggesting increased perfusion. On the other hand, there was near absence of vascularization in the acute phase and slight increase in the recovery phase by color Doppler ultrasonography. The clearance rate of Tc-99 m sestamibi during the early phase (from 10 min to 1 h) was decreased in the acute stage of SAT. The sestamibi uptake ratio correlated with serum immunosuppressive acidic protein (IAP) in the acute stage of SAT and the sestamibi uptake ratio in the recovery stage of SAT was correlated with serum thyrotropin levels. Tc-99 m sestamibi uptake in the early phase in the acute stage of SAT may reflect the inflammatory process associated with SAT.

書籍

  • 胸部画像診断の勘ドコロNEO
    甲斐田勇人; 花岡宏平; 石井一成 (担当:分担執筆範囲:胸部病変とPET)株式会社メジカルビュー 2023年01月
  • プリンシプル消化器疾患の臨床3 ここまできた肝臓病診療
    甲斐田勇人; 石井一成; 村上卓道 (担当:共著範囲:核医学検査)株式会社中山書店 2017年 146-149
  • 心・血管病の分子イメージング
    甲斐田勇人; 倉田精二; 石橋正敏 (担当:共著範囲:癌)永井書店 2010年 35-41

講演・口頭発表等

  • An initial prospective clinical study of tumor hypoxia evaluated with 18F-fluromisonidazole PET/CT in esophageal cancer patients undergoing neoadjuvant chemotherapy.  [通常講演]
    Hayato Kaida; Osamu Shiraishi; Hiroaki Kato; Kohei Hanaoka; Akihiko Kawahara; Satoshi Hattori; Makoto Hosono; Akihiko Ito; Takushi Yasuda; Kazunari Ishii
    第83回日本医学放射線学会総会 2024年04月 口頭発表（一般）
  • CT and MR features of soft tissue angiosarcoma.  [通常講演]
    Nobuo Kashiwagi; Mio Sakai; Atsushi Kawata; Katsuyuki Nakanishi; Yu Tanaka; Hayato Kaida; Kazunari Ishii; Hiroto Takahashi; Noriyuki Tomiyama
    European Congress of Radiology (ECR2024) 2024年02月 ポスター発表
  • Epipericardial fat necrosisの1例  [通常講演]
    辻田有志; 浜川岳文; 藤谷哲也; 平川真由美; 逢坂友也; 浦瀬篤史; 上月瞭平; 鈴木絢子; 小路田泰之; 平山 歩; 松久保祐子; 山田 穣; 任 誠雲; 小塚健倫; 甲斐田勇人; 鶴﨑正勝; 石井一成
    第336回日本医学放射線学会関西地方会 2024年02月 口頭発表（一般）
  • 【教育講演】日常臨床のFDG-PET/CT診断：腫瘍  [招待講演]
    甲斐田勇人
    第63回日本核医学会学術総会 2023年11月 口頭発表（招待・特別）
  • AIで生成したアミロイド画像におけるスライス間の連続性の評価  [通常講演]
    渡邉 綾; 山田誉大; 永岡 隆; 根本充貴; 渡部 浩; 茨木正信; 松原佳亮; 花岡宏平; 甲斐田勇人; 石井一成; 木村裕一
    第63回日本核医学会総会 2023年11月 口頭発表（一般）
  • 予備的な腫瘍部位の指定が不要な深層生成技術を用いたFDG-PET/CT像上の肺野内局所異常検知  [通常講演]
    瀬川 新; 根本充貴; 甲斐田勇人; 木村裕一; 永岡 隆; 山田誉大; 花岡宏平; 北島一宏; 槌谷達也; 石井一成
    第63回日本核医学会総会 2023年11月 口頭発表（一般）
  • 青色ゴムまり様母斑症候群の1例  [通常講演]
    河野 淳; 浜川岳文; 藤谷哲也; 平川真由美; 逢坂友也; 浦瀬篤史; 上月瞭平; 鈴木絢子; 小寺 卓; 小路田泰之; 辻田有志; 平山 歩; 松久保祐子; 山田 穣; 任 誠雲; 小塚健倫; 甲斐田勇人; 鶴﨑正勝; 石井一成; 川中雄介; 林 秀敏
    第335回日本医学放射線学会関西地方会 2023年10月 口頭発表（一般）
  • 頭部専用PETの臨床と展望  [招待講演]
    甲斐田勇人
    第3回神経疾患を考える会 2023年09月 口頭発表（招待・特別）
  • Development of a specialized image reconstruction technique for dedicated breast positron emission tomography.  [通常講演]
    Hanaoka K; Watanabe S; Ishikawa-Morimoto D; Yamakawa Y; Kobayashi T; Ohtani A; Kumakawa S; Ito T; Komoike Y; Kaida H; Ishii K
    European Association of Nuclear Medicine (EANM'23) 2023年09月 ポスター発表
  • 教師無し深層画像生成を用いたFDG-PET/CT像上の肺病変検出  [通常講演]
    瀬川 新; 根本充貴; 甲斐田勇人; 木村裕一; 永岡 隆; 三上勝大; 山田誉大; 花岡宏平; 北島一宏; 槌谷達也; 石井一成
    生体医工学シンポジウム2023 口頭発表（一般）
  • 腫瘍核医学における機器・ソフトの進歩  [招待講演]
    甲斐田勇人
    SAMI2023 (第8回Advance Medical Imaging研究会) 2023年07月 口頭発表（招待・特別）
  • 乳房PET検査のための再構成手法  [通常講演]
    花岡宏平; 石川大介; 山川善之; 小林哲哉; 大谷 篤; 熊川志帆; 位藤俊一; 菰池佳史; 山田誉大; 甲斐田勇人; 石井一成
    第5回日本核医学会近畿支部会 2023年07月 口頭発表（一般）
  • 生成系AIを用いた読影医によるアノテーション不要なFDG-PET/CT像の肺病変強調手法  [通常講演]
    大谷和暉; 根本充貴; 甲斐田勇人; 瀬川 新; 木村裕一; 永岡 隆; 三上勝大; 山田誉大; 花岡宏平; 槌谷達也; 北島一宏; 石井一成
    第5回日本核医学会近畿支部会 2023年07月 口頭発表（一般）
  • アミロイドPET撮像判断のための生成系AIによるFDG画像からのアミロイド画像合成の検討  [通常講演]
    本田実沙; 山田誉大; 永岡 隆; 三上勝大; 根本充貴; 花岡宏平; 甲斐田勇人; 石井一成; 木村裕一
    第5回日本核医学会近畿支部会 2023年07月 口頭発表（一般）
  • Validation of a Glucose Metabolism to Tau Deposition Ratio Image in the Alzheimer’s Continuum.  [通常講演]
    Kazunari Ishii; Takahiro Yamada; Kohei Hanaoka; Hayato Kaida; Kenji Ishii; Takashi Kato; Akinori Nakamura; for BATON; Study Group
    Society of Nuclear Medicine & Molecular Imaging (SNMMI 2023 Annual Meeting） 2023年06月 ポスター発表
  • 心サルコイドーシスFDG PET/CT検査における呼吸同期・心電図同期収集の効果  [通常講演]
    花岡宏平; 渡邊翔太; 石川大介; 甲斐田勇人; 安田昌和; 岩永善高; 中澤 学; 石井一成
    第33回日本心臓核医学会総会・学術大会 2023年06月 口頭発表（一般）
  • Initial study of an algorithm for estimating the presence of amyloid accumulation from 18F-FDG PET images using machine learning  [通常講演]
    Takahiro Yamada; Kohei Hanaoka; Hayato Kaida; Kazunari Ishii
    Brain & BrainPET 2023 2023年06月 ポスター発表
  • 検診を契機に発見された子宮腺肉腫の一例  [通常講演]
    鈴木絢子; 鶴﨑正勝; 上月瞭平; 浦瀬篤史; 小寺 卓; 平山 歩; 任 誠雲; 山田 穣; 甲斐田勇人; 小塚健倫; 石井一成; 黄 彩実; 松村謙臣; 榎木英介; 前西 修
    第36回日本腹部放射線学会 2023年06月 口頭発表（一般）
  • Pix2Pix画像スタイル変換を用いた 教師無し異常検知による FDG-PET/CT像上肺病変強  [通常講演]
    大谷和暉; 根本充貴; 甲斐田勇人; 瀬川新; 中前有香子; 村中皓紀; 吉田昂平; 木村裕一; 永岡隆; 山田誉大; 花岡宏平; 槌谷達也; 北島一宏; 石井一成
    第62回日本生体医工学大会 2023年05月 ポスター発表
  • Clinical role of FDG-PET/CT for the diagnosis of Esophageal cancer  [通常講演]
    Hayato Kaida; Minoru Yamada; Yuko Matsukubo; Hiroaki Kato; Sung-Woon Im; Osamu Shiraishi; Takenori Kozuka; Makoto Hosono; Takushi Yasuda; Kazunari Ishii
    第82回日本医学放射線学会総会 2023年04月 ポスター発表
  • 母斑基底細胞癌症候群(Gorlin症候群)の1例  [通常講演]
    福田隼己; 関 紳一郎; 浦瀬篤史; 上月瞭平; 小寺 卓; 鈴木絢子; 浜川岳文; 藤谷哲也; 石田 愛; 平山 歩; 若林雄一; 松久保祐子; 山田 穣; 兵頭朋子; 任 誠雲; 甲斐田勇人; 小塚健倫; 鶴崎正勝; 石井一成
    第333回日本医学放射線学会関西地方会 2023年02月 口頭発表（一般）
  • Acceleration Motion Compensation Diffusion-weighted Imaging For Aortitis: Phantom and Clinical Studies.  [通常講演]
    Hyodo T; Nozaki Y; Kaida H; Morimoto-Ishikawa D; Ueda Y; Ito M; Yasuda N; Fukushima H; Yamamoto A; Ishii K
    The RSNA 108th Scientific Assembly and Annual Meeting 2022年11月 ポスター発表
  • Fibrolamellar Hepatocellular Carcinomaの一例  [通常講演]
    山田 穣; 浜川岳文; 藤谷哲也; 浦瀬篤史; 上月瞭平; 小寺 卓; 鈴木絢子; 平山 歩; 石田 愛; 若林雄一; 関 紳一郎; 山田誉大; 松久保祐子; 任 誠雲; 兵頭朋子; 甲斐田勇人; 小塚健倫; 鶴崎正勝; 石井一成
    第332回日本医学放射線学会関西地方会 2022年10月 口頭発表（一般）
  • Detection of Bone Metastasis on FDG-PET/CT Images using Multi-step Anomaly Voxel Detection and Local Patch analysis with Unsupervised Deep Features and Image Textures.  [通常講演]
    Haruno Yamaguchi; Mitsutaka Nemoto; Hayato Kaida; Yuichi Kimura; Takashi Nagaoka; Takahiro Yamada; Kohei Hanaoka; Kazuhiro Kitajima; Tatsuya Tsuchitani; Kazunari Ishii
    The13th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB2022) 2022年09月 ポスター発表
  • Predicting the prognosis in tongue cancer patients using harmonized 18F-FDG PETCT parameters. A multicenter study.  [通常講演]
    Hayato Kaida; Kazuhiro Kitajima; Testsuro Sekine; Kimiteru Ito; Hiromitsu Daisaki; Takayuki Kimura; Akifumi Enomoto; Naoki Otsuki; Kazunari Ishii
    The13th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB2022) 2022年09月 ポスター発表
  • Detection of Bone Metastasis on FDG-PET/CT Images using Multi-step Anomaly Voxel Detection and Local Patch analysis with Unsupervised Deep Features and Image Textures  [通常講演]
    Haruno Yamaguchi; Mitsutaka Nemoto; Hayato Kaida; Yuichi Kimura; Takashi Nagaoka; Takahiro Yamada; Kohei Hanaoka; Kazuhiro Kitajima; Tatsuya Tsuchitani; Kazunari Ishii
    The13th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB2022) 2022年09月 ポスター発表
  • Study for detecting pulmonary nodules on FDG-PET/CT images with training small dataset  [通常講演]
    Arata Segawa; Mitsutaka Nemoto; Hayato Kaida; Yuichi Kimura; Takashi Nagaoka; Haruno Yamaguti; Yukako Nakamae; Takahiro Yamada; Kohei Hanaoka; Kazuhiro Kitajima; Tatsuya Tsuchitani; Kazunari Ishii
    The13th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB2022) 2022年09月 ポスター発表
  • FDG-PET/CTで集積を認めた膵臓アミロイドーシスの一例  [通常講演]
    甲斐田勇人; 山田 穣; 関 紳一郎; 松久保祐子; 任 誠雲; 花岡宏平; 山田誉大; 兵頭朋子; 鶴崎正勝; 細野 眞; 石井一成
    第4回日本核医学会近畿支部会 2022年07月 口頭発表（一般）
  • Comparison of lesion detectability of dedicated breast PET and whole-body PET/CT.  [通常講演]
    Hanaoka K; Watanabe S; Morimoto-Ishikawa D; Ueno N; Ohtani A; Yamakawa Y; Minagawa S; Mizuta T; Kaida H; Itoh T; Komoike Y; Ishii K
    Society of Nuclear Medicine & Molecular Imaging (SNMMI 2022 Annual Meeting） 2022年06月 ポスター発表
  • Comparison between the μ-maps of different PET tracers: 18F-FDG and 18F-flutemetamol, generated by the attenuation correction method without external radiation source.  [通常講演]
    Takahiro Yamada; Kohei Hanaoka; Yoshiyuki Yamakawa; Suzuka Minagawa; Atsushi Ohtani; Tetsuro Mizuta; Hayato Kaida; Kazunari Ishii
    Society of Nuclear Medicine & Molecular Imaging (SNMMI 2022 Annual Meeting） 2022年06月 口頭発表（一般）
  • Acceleration Motion Compensation Diffusion-weighted Imaging for Large Vessel Vasculitis: Phantom Model and Initial Clinical Experience.  [通常講演]
    Hyodo T; Morimoto-Ishikawa D; Kaida H; Ueda Y; Tomita D; Yamamoto A; Itoh M; Yasuda N; Fukushima H; Nozaki Y; Matsumura I; Ishii K
    The Joint Annual Meeting ISMRM-ESMRMB & ISMRT 31st Annual Meeting. 2022年05月 口頭発表（一般）
  • 乳房専用PET装置で明瞭に描出することができた非浸潤性乳管癌症例  [通常講演]
    上野尚美; 花岡宏平; 渡邊翔太; 石川大介; 甲斐田勇人; 位藤俊一; 菰池佳史; 石井一成
    第31回乳癌画像研究会（Web） 2022年02月 口頭発表（一般）
  • 大型血管炎診断におけるMR拡散強調像の動き補正技術  [通常講演]
    若菜みゆき; 兵頭朋子; 甲斐田勇人; 石井一成; 石川大介; 伊藤 洵; 安田奈央; 福島弘之; 冨田大介; 山本敦弘; 野﨑祐史; 松村 到
    第330回日本医学放射線学会関西地方会（Web） 2022年02月 口頭発表（一般）
  • 2種類の異常検知を用いたFDG-PET/CT像上のがん骨転移病変自動検出  [通常講演]
    山口明乃; 根本充貴; 甲斐田勇人; 木村裕一; 永岡 隆; 山田誉大; 花岡宏平; 北島一宏; 槌谷達也; 石井一成
    第61回日本核医学会学術総会 2021年11月 口頭発表（一般）
  • 頭部・乳房用TOF-PET装置による腋窩領域の追加撮像  [通常講演]
    花岡宏平; 渡邊翔太; 石川大介; 甲斐田勇人; 菰池佳史; 石井一成; 竹ノ内志帆; 山川善之; 大谷 篤; 水田哲郎
    第61回日本核医学会学術総会 2021年11月 口頭発表（一般）
  • 敵対的生成ネットワークで合成したPET画像における定量性の検討
    渡邉 綾; 木村裕一; 山田誉大; 渡辺翔吾; 永岡 隆; 根本充貴; 宮崎晃一; 花岡宏平; 甲斐田勇人; 石井一成
    第61回日本核医学会学術総会 2021年11月 口頭発表（一般）
  • 頭部と乳房のPET検査に特化したTOF-PET装置の開発  [通常講演]
    竹ノ内志帆; 水田哲郎; 大谷 篤; 山川義之; 石井一成; 甲斐田勇人; 菰池佳史; 花岡宏平; 渡邊翔太; 石川大介
    第61回日本核医学会学術総会 2021年11月 口頭発表（一般）
  • 食道癌の化学放射線療法に対するDeauville scoreでの予後検討  [通常講演]
    甲斐田勇人; 山田 穣; 松久保祐子; 任 誠雲; 石井一成; 稲田正浩; 細野 眞; 西村恭昌; 山田誉大; 花岡宏平
    第61回日本核医学会学術総会 2021年11月 口頭発表（一般）
  • 肺転移の診断が困難であった乳房外パジェット病（アポクリン腺癌）の一例
    任 誠雲; 若菜みゆき; 鈴木絢子; 石田 愛; 関 紳一郎; 松久保祐子; 山田穣; 小塚健倫; 兵頭朋子; 甲斐田勇人; 鶴﨑正勝; 石井一成
    第329回日本医学放射線学会関西地方会 2021年10月 口頭発表（一般）
  • 片側性にFDG高集積を呈した亜急性甲状腺炎の一例  [通常講演]
    若菜みゆき; 甲斐田勇人; 任 誠雲; 山田 穣; 関 紳一郎; 松久保祐子; 兵頭朋子; 鶴崎正勝; 石井一成
    第57回日本医学放射線学会秋季臨床大会（Web） 2021年09月 ポスター発表
  • 11C-methonine PET/CTで高集積を認めた傍鞍部炎症性肉芽腫の一例  [通常講演]
    甲斐田勇人; 奥田武司; 山田 穣; 関 紳一郎; 松久保祐子; 任 誠雲; 花岡宏平; 山田誉大; 兵頭朋子; 鶴﨑正勝; 細野 眞; 石井一成
    第3回日本核医学会近畿支部会（Web） 2021年07月 口頭発表（一般）
  • ソマトスタチン受容体シンチグラフィによる神経内分泌腫瘍の画像診断  [招待講演]
    甲斐田勇人
    NET Academy in South Osaka 2021年06月 公開講演，セミナー，チュートリアル，講習，講義等
  • 再発肺がんの診断：FDG-PET / CTの臨床的役割  [招待講演]
    甲斐田勇人
    第80回日本医学放射線学会総会 2021年04月 口頭発表（招待・特別）
  • 有DESH所見患者の脳ドパミントランスポーターシンチグラフィ所見  [通常講演]
    宮﨑晃一; 山田誉大; 花岡宏平; 甲斐田勇人; 石井一成
    第22回日本正常圧水頭症学会 2021年02月 口頭発表（一般）
  • ソマトスタチン受容体シンチグラフィによる神経内分泌腫瘍の診断  [招待講演]
    甲斐田勇人
    第23回大阪神戸腹部画像・IVR医学研究会 2020年12月 公開講演，セミナー，チュートリアル，講習，講義等
  • 認知症自動診断AIアルゴリズム学習のための深層学習により加増したアミロイド画像の検証  [通常講演]
    渡邉 綾; 木村裕一; 山田誉大; 渡辺翔吾; 永岡 隆; 根本充貴; 宮崎晃一; 花岡宏平; 甲斐田勇人; 石井一成
    第60回日本核医学会学術総会 2020年11月 口頭発表（一般）
  • One-class SVMを用いた異常検知によるPET/CT上の骨転移病変自動検出  [通常講演]
    田中敦子; 根本充貴; 甲斐田勇人; 木村裕一; 永岡 隆; 牛房和之; 山田誉大; 花岡宏平; 北島一宏; 槌谷達也; 石井一成
    第60回日本核医学会学術総会 2020年11月 口頭発表（一般）
  • 食道癌の術前化学療法に対するFDG-PET/CTの有用性の検討－多施設共同研究  [通常講演]
    甲斐田勇人; 石井一成; 安田卓司; 北島一宏; 中條正豊; 石橋 愛; 南本亮吾; 平田健司; 中谷航也; Ao Hung; 服部 聡
    第60回日本核医学会学術総会 2020年11月 口頭発表（一般）
  • The 11C-methioine PET/CT findings of brain tumor.  [通常講演]
    Hayato Kaida; Takeshi Okuda; Kohei Hanaoka; Minoru Yamada; Yuko Matsukubo; SungWoon Im; Yukinobu Yagyu; Amami Kato; Kazunari Ishii
    第79回日本医学放射線学会総会 2020年05月 ポスター発表
  • pleural appendage（胸膜脂肪垂）の画像診断.  [通常講演]
    松久保祐子; 松木 充; 若菜みゆき; 鈴木絢子; 浜川岳文; 沼本勲男; 小田晃義; 門場智也; 藤谷哲也; 任 誠雲; 兵頭朋子; 甲斐田勇人; 柳生行伸; 小塚健倫; 鶴﨑正勝; 石井一成
    第324回日本医学放射線学会関西地方会 2020年02月 口頭発表（一般）
  • 卵巣顆粒膜細胞腫の再発・転移の画像診断.  [通常講演]
    浜川岳文; 松木 充; 若菜みゆき; 鈴木絢子; 沼本勲男; 小田晃義; 門場智也; 藤谷哲也; 松久保祐子; 任 誠雲; 兵頭朋子; 甲斐田勇人; 柳生行伸; 鶴﨑正勝; 小塚健倫; 石井一成; 松村謙臣; 大谷知之
    第324回日本医学放射線学会関西地方会 2020年02月 口頭発表（一般）
  • MRCPで検出される胃底腺ポリープの検討  [通常講演]
    沼本勲男; 松木 充; 若菜みゆき; 鈴木絢子; 浜川岳文; 小田晃義; 門場智也; 松久保祐子; 藤谷哲也; 山田 穣; 兵頭朋子; 任 誠雲; 甲斐田勇人; 柳生行伸; 柏木伸夫; 小塚健倫; 鶴﨑正勝; 石井一成; 大谷知之
    第323回日本医学放射線学会関西地方会 2019年11月
  • 術後再発に特異な画像所見を示した卵巣low grade serous carcinomaの1例  [通常講演]
    鈴木絢子; 松木 充; 若菜みゆき; 浜川岳文; 沼本勲男; 小田晃義; 門場智也; 松久保祐子; 藤谷哲也; 山田 穣; 兵頭朋子; 任 誠雲; 甲斐田勇人; 柳生行伸; 柏木伸夫; 小塚健倫; 鶴﨑正勝; 石井一成; 八幡 環; 小谷泰史; 松村謙臣; 大谷知之
    第323回日本医学放射線学会関西地方会 2019年11月
  • AI異常検知に基づくPET/CT上の頸胸部病変の自動認識  [通常講演]
    田中敦子; 根本充貴; 甲斐田勇人; 木村祐一; 山田誉大; 牛房和之; 花岡宏平; 北島一宏; 槌谷達也; 石井一成
    第59回日本核医学会学術総会 2019年11月 口頭発表（一般）
  • 認知症自動診断AIアルゴリズム学習のための深層学習によるアミロイド画像の加増手法の検討  [通常講演]
    渡邉 綾; 山田誉大; 永岡 隆; 根本充貴; 花岡宏平; 甲斐田勇人; 石井一成; 木村裕一
    第59回日本核医学会学術総会 2019年11月
  • FDG PET/CTによる食道癌術前化学療法の治療効果判定に関する検討  [通常講演]
    甲斐田勇人; 白石 治; 岩間 密; 加藤寛章; 木村 豊; 花岡宏平; 山田 穣; 北島一宏; 安田卓司; 石井一成
    第59回日本核医学会学術総会 2019年11月
  • Impact of respiratory and ECG gated 18F-FDG PET/CT for cardiac sarcoidosis  [通常講演]
    Hanaoka K; Watanabe S; Shibata Y; Kaida H; Ishii K. Ishii
    EANM2019 2019年10月
  • The evaluation of tumor response to neoadjuvant chemotherapy for esophageal cancer using PERCIST 1.0-multicenter study  [通常講演]
    Kaida H; Kitajima K; Nakajo M; Ishibashi M; Minamimoto R; Hirata K; Nakatani K; Yasuda T; Ishii K
    EANM2019 2019年10月
  • Radiation Exposure of Nurses Including Eye Lens in PET Facility in Association with Performance Status of Patients  [通常講演]
    Hosono M; Takahara N; Yakushiji Y; Sakaguchi K; Yamada Y; Kaida H; Ishii K; Nishimura Y
    EANM2019 2019年10月
  • Altered regional cerebral glucose metabolism in preclinical stages of iNPH  [通常講演]
    Miyazaki K; Hanaoka K; Kaida H; Ishii K
    Hydrocephalus 2019 2019年09月 ポスター発表
  • Clustering-Based Data Reduction Algorithm with Simplified Reference Tissue Model to Generate Parametric Images in Amyloid Imaging  [通常講演]
    Yamada T; Kimura Y; Sakata M; Nagaoka T; Nemoto M; Hanaoka K; Kaida H; Ishii K
    Brain&Brain PET2019 2019年07月
  • FDG-PET/CTで集積を認めた心臓原発悪性リンパ腫の一例  [通常講演]
    甲斐田勇人; 山田 穣; 松久保祐子; 花岡宏平; 任 誠雲; 柳生行伸; 細野 眞; 石井一成
    第52回日本核医学会近畿地方会 2019年06月
  • 虫垂粘液腫が肝臓に穿破したと思われた1例  [通常講演]
    沼本勲男; 松木 充; 土居秀平; 鈴木絢子; 小田晃義; 門場智也; 藤谷哲也; 松久保祐子; 山田 穣; 兵頭朋子; 任 誠雲; 甲斐田勇人; 柳生行伸; 小塚健倫; 柏木伸夫; 鶴﨑正勝; 細野 眞; 田北雅弘; 家根由典
    第33回日本腹部放射線学会 2019年06月
  • Optimization of respiratory gated 18F-FDG PET/CT scan protocol for cardiac sarcoidosis  [通常講演]
    Kohei Hanaoka; Shota Watanabe; Yusuke Shibata; Hayato Kaida; Makoto Hosono; Kazunari Ishii
    SNMMI 2019 Annual Meeting 2019年06月 ポスター発表
  • Comparison among 18F-FDG uptake parameters for assessing the prognosis of esophageal squamous cell carcinoma  [通常講演]
    Hayato Kaida; Osamu Shiraishi; Mitsuru Iwama; Hiroaki Kato; Yutaka Kimura; Kohei Hanaoka; Kazuhiro Kitajima; Makoto Hosono; Takushi Yasuda; Kazunari Ishii
    SNMMI 2019 Annual Meeting 2019年06月 ポスター発表
  • Nuclear protein in testis (NUT) midline carcinomaの一例  [通常講演]
    山田 穣; 柏木伸夫; 土居秀平; 沼本勲男; 門場智也; 松久保祐子; 兵頭朋子; 甲斐田勇人; 任 誠雲; 柳生行伸; 小塚健倫; 岡野意浩; 坂田尚己; 松木 充; 石井一成
    第55回日本小児放射線学会学術集会 2019年06月
  • 拡散強調像にて拡散制限を伴ったpolypoid endometriosisの1例  [通常講演]
    若菜みゆき; 松木 充; 沼本勲男; 鈴木絢子; 浜川岳文; 藤谷哲也; 小田晃義; 門場智也; 松久保祐子; 山田 穣; 兵頭朋子; 任 誠雲; 甲斐田勇人; 柳生行伸; 柏木伸夫; 小塚健倫; 鶴﨑正勝; 石井一成; 松村謙臣; 大谷知之
    第322回日本医学放射線学会関西地方会 2019年06月
  • FDG-PET/CT の統計的異常検知処理による転移を考慮した頸胸部病変の自動検出  [通常講演]
    田中敦子; 根本 充貴; 甲斐田勇人; 木村裕一; 永岡 隆; 山田誉大; 花岡宏平; 石井一成
    第58回日本生体医工学大会 2019年06月 口頭発表（一般）
  • 大型血管炎の診断に対する18F-FDG PET/CTの有用性  [通常講演]
    Hayato Kaida; Nobuhiro Tahara; Kohei Hanaoka; Minoru Yamada; Yuko Matsukubo; SungWoon Im; Yukinobu Yagyu; Takenori Kozuka; Makoto Hosono; Kazunari Ishii
    第78回日本医学放射線学会総会 2019年04月 ポスター発表
  • 空間分解能を温存したノイズ低減アルゴリズムを用いたアミロイドイメージング動態撮像の短時間化  [通常講演]
    山田誉大; 木村裕一; 北西 巧; 永岡 隆; 根本充貴; 花岡宏平; 甲斐田勇人; 石井一成
    第8回核医学画像解析研究会 2018年12月 口頭発表（一般）
  • FDG PET/CTによる食道癌術前化学療法の予後解析  [通常講演]
    甲斐田勇人; 白石 治; 岩間 密; 加藤寛章; 木村 豊; 花岡宏平; 山田 穣; 北島一宏; 細野 眞; 安田卓司; 石井一成
    第58回日本核医学会学術総会 2018年11月 ポスター発表
  • AI異常検知を用いたFDG-PET/CT上の頸胸部原発性・転移性病変の検出  [通常講演]
    根本充貴; 甲斐田勇人; 田中敦子; 牛房和之; 山田誉大; 木村裕一; 花岡宏平; 石井一成
    第58回日本核医学会学術総会 2018年11月
  • SRTM法を用いたアミロイドイメージングに対する空間分解能を損なわないノイズ低減アルゴリズムの検討  [通常講演]
    山田誉大; 木村裕一; 根本充貴; 坂田宗之; 永岡 隆; 花岡宏平; 甲斐田勇人; 石井一成
    第58回日本核医学会学術総会 2018年11月
  • The risk factors for occult lymph node metastasis and recurrence by F-18 FDG uptake in clinical N0 esophageal squamous cell carcinoma patients.  [通常講演]
    Kaida H; Shiraishi O; Iwama M; Kato H; Kimura Y; Kitajima K; Hosono M; Yasuda T; Ishii K
    European Association of Nuclear Medicine(EANM) 2018 2018年10月 ポスター発表
  • 頭頚部扁平上皮癌からの骨転移  [通常講演]
    鈴木絢子; 柏木伸夫; 沼本勲男; 小田晃義; 門場智也; 兵頭朋子; 山田 穣; 甲斐田勇人; 柳生行伸; 任 誠雲; 鶴﨑正勝; 小塚健倫; 松木 充; 石井一成; 中西克之
    第54回日本医学放射線学会秋季臨床大会 2018年10月
  • FDG-PETによる血管病のイメージング  [通常講演]
    甲斐田勇人
    第8回大阪放射線医学研究会 2018年07月
  • PERCISTによる乳癌術前化学療法の治療効果判定～国内多施設共同研究～  [通常講演]
    北島一宏; 南本亮吾; 平田健司; 山根登茂彦; 甲斐田勇人; 中條正豊; 森田敬裕; 中谷航也; 石橋 愛
    第51回日本核医学会近畿地方会（Web開催） 2018年07月
  • FDG-PET/CTで集積を認めた後腹膜由来の骨外性Ewing肉腫の一例  [通常講演]
    甲斐田勇人; 山田 穣; 細野 眞; 花岡宏平; 筑後孝章; 石井一成
    第51回日本核医学会近畿地方会（Web開催） 2018年07月
  • PETアミロイドイメージングのための空間分解能を損なわないノイズ低減アルゴリズムの臨床画像による評価  [通常講演]
    木村裕一; 山田誉大; 藤井康介; 渡辺翔吾; 永岡 隆; 根本充貴; 花岡宏平; 甲斐田勇人; 石井一成
    第57回日本生体医工学会大会 2018年06月
  • 横行結腸に生じたバンドによる絞扼性イレウスの一例 横行結腸軸捻転との比較  [通常講演]
    沼本勲男; 松木 充; 土居秀平; 鈴木絢子; 小田晃義; 門場智也; 藤谷哲也; 松久保祐子; 兵頭朋子; 山田 穣; 任 誠雲; 甲斐田勇人; 柳生行伸; 柏木伸夫; 小塚健倫; 鶴﨑正勝; 細野 眞; 石井一成
    第319回日本医学放射線学会関西地方会 2018年06月 口頭発表（一般）
  • The prognostic values of 18F-FDG uptake and molecular markers in resected non-small cell lung cancer patients.  [通常講演]
    Hayato Kaida
    19th Workshop of the German-Japanese Radiological Affiliation 2018年05月 口頭発表（一般）
  • Static and moving phantom studies for radiation treatment planning in a 4-dimentional PET/CT  [通常講演]
    Kohei Hanaoka; Masahiko Okumura; Yasumasa Nishimura; Shota Watanabe; Yusuke Shibata; Hayato Kaida; Makoto Hosono; Kazunari Ishii; Takamichi Murakami
    12th World Congress of the World Federation of Nuclear Medicine and Biology 2018年04月 ポスター発表
  • Algorithm for Amyloid Imaging to Preserve the Contrast Between Gray and White Matter Using Simplified Reference Tissue Model.  [通常講演]
    Takahiro Yamada; Yuichi Kimura; Kosuke Fujii; Shogo Watanabe; Takashi Nagaoka; Mitsutaka Nemoto; Kohei Hanaoka; Hayato Kaida; Chisa Hosokawa; Kazunari Ishii
    12th World Congress of the World Federation of Nuclear Medicine and Biology 2018年04月 ポスター発表
  • Predicting the prognosis after surgical resection by 18F-FDG PET/CT imaging in esophageal cancer patients  [通常講演]
    Hayato Kaida; Chisa Hosokawa; Osamu Shiraishi; Mitsuru Iwama; Hiroaki Kato; Yutaka Kimura; Kazuhiro Kitajima; Makoto Hosono; Takushi Yasuda; Takamichi Murakami; Kazunari Ishii
    12th World Congress of the World Federation of Nuclear Medicine and Biology 2018年04月 ポスター発表
  • 核医学イメージングを用いての前立腺癌の再発や転移診断  [通常講演]
    甲斐田勇人; 石井一成; 細川知紗; 山田 穣; 細野 眞; Axel Rominger; Peter Bartenstein; 村上卓道
    第77回日本医学放射線学会総会 2018年04月 ポスター発表
  • Noise Reduction Algorithm for Amyloid Image Preserving Image Resolution. — Quantitative Evaluation Using Clinical Images —  [通常講演]
    Takahiro Yamada; Yuichi Kimura; Kosuke Fuji; Shogo Watanabe; Mitsutaka Nemoto; Kohei Hanaoka; Hayato Kaida; Chisa Hosokawa; Kazunari Ishii
    Human Amyloid Imaging 2018 2018年01月 ポスター発表
  • 後腹膜発生動静脈奇形の一例  [通常講演]
    土居秀平; 松木 充; 鈴木絢子; 沼本勲男; 小田晃義; 藤谷哲也; 兵頭朋子; 山田 穣; 任 誠雲; 甲斐田勇人; 柳生行伸; 柏木伸夫; 細川知紗; 小塚健倫; 鶴﨑正勝; 今岡いずみ; 細野 眞; 石井一成; 村上卓道
    第317回日本医学放射線学会関西地方会 2017年11月
  • 皮質病変を認めた非アルコール性ウェルニッケ脳症の一例  [通常講演]
    鈴木絢子; 松木 充; 土居秀平; 沼本勲男; 小田晃義; 藤谷哲也; 兵頭朋子; 山田 穣; 任 誠雲; 甲斐田勇人; 柳生行伸; 柏木伸夫; 細川知紗; 小塚健倫; 鶴﨑正勝; 今岡いずみ; 細野 眞; 石井一成; 村上卓道
    第317回日本医学放射線学会関西地方会 2017年11月
  • Prognostic assessment of 18F-FDG uptake using dual point imaging and partial volume correction in resected non-small cell lung cancer patients  [通常講演]
    Hayato Kaida; Koichi Azuma; Akihiko Kawahara; Shizo Takamori; Masayoshi Kage; Kiminori Fujimoto; Rominger Axel; Kazunai Ishii; Takamichi Murakami; Masatoshi Ishibashi
    European Association of Nuclear Medicine(EANM) 2017 2017年10月 ポスター発表 Vienna, Austria
  • Volumetric parameterを用いた食道癌切除患者の予後因子の検討  [通常講演]
    甲斐田勇人; 石井一成; 細川知紗; 柳生行伸; 任 誠雲; 兵頭朋子; 山田 穣; 細野 眞; 村上卓道; 安田卓司
    第57回日本核医学会学術総会 2017年10月 口頭発表（一般） 横浜
  • 前立腺癌転移・再発に対する核医学診断の有用性  [招待講演]
    甲斐田勇人
    南大阪CRPC放射線内用療法セミナー 2017年09月 公開講演，セミナー，チュートリアル，講習，講義等 堺
  • PET検診の現状と効果  [招待講演]
    甲斐田勇人
    近畿大学校友会尼崎支部総会 2017年07月 公開講演，セミナー，チュートリアル，講習，講義等 尼崎
  • FDG-PET/CTで集積を認めた異所性甲状腺癌の一例  [通常講演]
    甲斐田勇人; 石井一成; 細川知紗; 仁 誠雲; 細野 眞; 村上卓道; 花岡宏平; 乾 浩己
    第50回日本核医学会近畿地方会 2017年07月 口頭発表（一般）
  • TAFRO症候群の1例  [通常講演]
    鈴木絢子; 沼本勲男; 松木 充; 小田晃義; 山田 穣; 兵頭朋子; 任 誠雲; 甲斐田勇人; 柳生行伸; 細川知紗; 小塚健倫; 柏木伸夫; 鶴﨑正勝; 今岡いずみ; 石井一成; 榎木英介; 村上卓道
    第31回日本腹部放射線学会 2017年06月 口頭発表（一般）
  • Prognostic impact of 18F-FDG PET parameters and molecular markers expression in resected non-small cell lung cancer patients  [通常講演]
    Kaida H; Azuma K; Kawahara A; Sadashima E; Hattori S; Akiba J; Rominger A; Takamori S; Fujimoto K; Hosono M; Ishii K; Murakami T; Ishibashi M
    SNMMI 2017 Annual Meeting 2017年06月 ポスター発表
  • 食道癌切除患者におけるFDG集積の予後検討  [通常講演]
    甲斐田勇人; 石井一成; 細川知紗; 柳生行伸; 任 誠雲; 兵頭朋子; 山田 穣; 細野 眞; 安田卓司; 村上卓道
    第76回日本医学放射線学会総会 2017年04月
  • PET検査のススメ～癌から認知症まで～  [招待講演]
    甲斐田勇人
    平成28年度近畿大学校友会沖縄支部講演会 2017年03月 その他
  • 転移性耳下腺腫瘍のCT MRI所見  [通常講演]
    柏木伸夫; 任 誠雲; 甲斐田勇人; 柳生行伸; 小塚建倫; 細川知紗; 松木 充; 鶴﨑正勝; 今岡いずみ; 細野 眞; 石井一成; 村上卓道
    第315回日本医学放射線学会関西地方会 2017年02月 口頭発表（一般）
  • 認知症患者における線条体アミロイド沈着の検討  [通常講演]
    細川知紗; 石井一成; Sauerbeck J; Scheiwein F; 甲斐田勇人; 兵頭朋子; 山田 穣; 細野 眞; 花岡宏平; 村上卓道
    第56回日本核医学会学術総会 2016年11月
  • 非小細胞肺癌のFDG集積とGlut-1, pStat1, pStat3での予後因子の検 討  [通常講演]
    甲斐田勇人; 石井一成; 村上卓道; 藤本公則; 東 公一; 河原明彦; 高森信三; 服部 聡; 石橋正敏
    第56回日本核医学会学術総会 2016年11月 口頭発表（一般）
  • FDG-PET/CTを契機に発見された再発性多発軟骨炎の一例  [通常講演]
    甲斐田勇人; 石井一成; 細川知紗; 細野 眞; 村上卓道
    PETサマーセミナーin熊本 2016年08月 公開講演，セミナー，チュートリアル，講習，講義等
  • 11C-PiB PET陽性認知症の線条体集積の有無の検討  [通常講演]
    細川知紗; 石井一成; Julia Sauerbeck; Franziska Scheiwein; 甲斐田勇人; 兵頭朋子; 山田 穣; 細野 眞; 花岡宏平; 村上卓道
    第49回日本核医学会近畿地方会 2016年07月 口頭発表（一般）
  • Cerebral glucose metabolic reduction patterns of PiB accumulation positive and negative cognitive disordered subjects  [通常講演]
    Hosokawa C; Ishii K; Kimura Y; Kaida H; Wakabayashi Y; Hyodo T; Hosono M; Murakami T
    Society of Nuclear Medicine (SNM) 2016 Annual Meeting 2016年06月 口頭発表（一般）
  • Japan-German Exchange Program  [通常講演]
    Kaida H; Sauerbeck J; Scheiwein F
    Japanese-German Bi-Annual Meeting 2016 Preliminary schedule of the scientific meeting. 2016年06月 口頭発表（一般）
  • Increased Pittsburgh Compound-B Accumulation in the Subcortical White Matter of Alzheimer's Disease Brain  [通常講演]
    Yuichi Wakabayashi; Kazunari Ishii; Chisa Hosokawa; Tomoko Hyodo; Hayato Kaida; Minoru Yamada; Yukinobu Yagyu; Masakatsu Tsurusaki; Takenori Kozuka; Kazuro Sugimura; Takamichi Murakami
    第11回日本分子イメージング学会 2016年05月 口頭発表（一般）
  • PET研修セミナー医師・歯科医師コース 臨床編6 腹部・婦人科領域  [招待講演]
    甲斐田勇人
    第16回日本核医学会春季大会 2016年04月 公開講演，セミナー，チュートリアル，講習，講義等
  • The possible correlation of striatal uptake of 11C-PiB PET with regional cerebral hypometabolism in cognitive impairment patients  [通常講演]
    Chisa Hosokawa; KazunarinIshii; Yuichi Kimura; Hayato Kaida; Yuichi Wakabayashi; Tomoko Hyodo; Yuzuru Yamada; Takenori Kozuka; Makoto Hosono; Takamichi Murakami
    The 75th Annual Meeting of the Japan Radiological Sciety. 2016年04月 ポスター発表
  • Vascular Inflammation Evaluated by 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography is Associated with Endothelial Dysfunction ―Effect of Anti-hypertensive Treatment―  [通常講演]
    Akihiro Honda; Nobuhiro Tahara; Yoshikazu Nitta; Atsuko Tahara; Sachiyo Igata; Munehisa Bekki; Tomohisa Nakamura; Youichi Sugiyama; Hayato Kaida; Masatoshi Ishibashi; Shoichi Yamagishi; Yoshihiro Fukumoto
    第80回日本循環器学会学術集会 2016年03月 ポスター発表
  • Myocardial Glucose Metabolism Evaluated by Fasting 18Fluorodeoxyglucose-Positron Emission Tomography in Pulmonary Hypertension  [通常講演]
    Tomohisa Nakamura; Nobuhiro Tahara; Youichi Sugiyama; Munehisa Bekki; Atsuko Tahara; Akihiro Honda; Hayato Kaida; Eita Kumagai; Sachiyo Igata; Yoshihiro Fukumoto
    第80回日本循環器学会学術集会 2016年03月 口頭発表（一般）
  • 上顎洞術後変化としての眼窩下管拡大  [通常講演]
    福井秀行; 柏木伸夫; 任 誠雲; 甲斐田勇人; 柳生行伸; 小塚健倫; 細川知紗; 熊野正士; 鶴﨑正勝; 松木 充; 今岡いずみ; 細野 眞; 石井一成; 村上卓道
    第35回日本画像医学会 2016年02月 口頭発表（一般）
  • 神経核内封入体病の1例  [通常講演]
    沼本勲男; 松木 充; 福井秀行; 若林雄一; 日高正二朗; 渡口真史; 藤谷哲也; 山川美帆; 兵頭朋子; 山田 穣; 任 誠雲; 甲斐田勇人; 柳生行伸; 柏木伸夫; 細川知紗; 小塚健倫; 鶴﨑正勝; 今岡いずみ; 細野 眞; 石井一成; 村上卓道
    第312回日本医学放射線学会関西地方会 2016年02月 口頭発表（一般）
  • PiB陰性例の18F-FDG PETによる脳代謝分布の検討  [通常講演]
    細川知紗; 石井一成; 若林雄一; 兵頭朋子; 花田一志; 甲斐田勇人; 細野 眞; 木村裕一; 村上卓道
    第55回日本核医学会学術総会 2015年11月 口頭発表（一般）
  • 膵癌のFDG集積とmTOR関連マーカーとの相関性に関する分子病理学的検討  [通常講演]
    甲斐田勇人; 東 公一; 河原明彦; 安永昌史; 服部 聡; 倉田精二; 廣瀬靖光; 鹿毛政義; 石井一成; 村上卓道; 石橋正敏
    第55回日本核医学会学術総会 2015年11月 口頭発表（一般）
  • 上顎洞術後変化としての眼窩下管拡大  [通常講演]
    福井秀行; 柏木伸夫; 任 誠雲; 甲斐田勇人; 柳生行伸; 小塚健倫; 細川知紗; 熊野正士; 鶴﨑正勝; 松木 充; 今岡いずみ; 石井一成; 細野 眞; 村上卓道
    第311回公益社団法人日本医学放射線学会関西地方会 2015年10月 口頭発表（一般）
  • FDG-PETによる動脈硬化イメージング  [通常講演]
    甲斐田勇人
    第15回近畿放射線医学フォーラム 2015年10月 公開講演，セミナー，チュートリアル，講習，講義等
  • Introducing the glucose metabolism to amyloid deposition ratio image.  [通常講演]
    Kazunari Ishii; Ruichi Takahashi; Yuichi Wakabayashi; Chisa Hosokawa; Hayato Kaida; Takamichi Murakami
    The European Association of Nuclear Medicine（EANM2015) 2015年10月 ポスター発表
  • The correlation between 18F-FDG uptake and Glut-1, p-Stat1 and p-Stat3 in non-small cell lung cancer patients.  [通常講演]
    Hayato Kaida; Koichi Azuma; Akihiko Kawahara; Satoshi Hattorri; Shinzo Takamori; Eiji Sadashima; Kiminori Fujimoto; Masayoshi Kage; Yasumitsu Hirose; Seiji Kurata; Kazunari Ishii; Takamichi Murakami; Masatoshi Ishibashi
    The European Association of Nuclear Medicine（EANM2015) 2015年10月 ポスター発表
  • ビギナーズコース4〔腹部、リンパ腫、検診〕腹部骨盤領域の悪性腫瘍診断におけるPET検査の有用性と位置づけ  [通常講演]
    甲斐田勇人
    PETサマーセミナー2015in東京ベイ 2015年09月 公開講演，セミナー，チュートリアル，講習，講義等
  • PET検診で発見されたFDG集積を伴う解離性大動脈瘤の一例.  [通常講演]
    甲斐田勇人; 石井一成; 村上卓道; 田原宣広; 本多亮博; 福本義弘; 石橋正敏
    第48回日本核医学会近畿地方会 2015年07月 口頭発表（一般）
  • 膀胱子宮内膜症の経過を追った2例.  [通常講演]
    沼本勲男; 今岡いずみ; 若林雄一; 藤谷哲也; 山川美帆; 兵頭朋子; 甲斐田勇人; 柳生行伸; 熊野正士; 鶴﨑正勝; 松木 充; 石井一成; 村上卓道
    第310回日本医学放射線学会関西地方会 2015年06月 口頭発表（一般）
  • Evaluation of the diagnostic performance of pancreatic carcinoma using CT pancreatic perfusion with three mathematical algorithms, Are they reliable as biomarker?  [通常講演]
    Kunou Y; Uchida M; Hirose Y; Kaida H; Okabe Y; Tokuyasu S; Abe T
    European Society of Gastrointestinal and Abdominal Radiology（ESGAR2015） 2015年06月 ポスター発表
  • The imaging of gastric mucosal associated lymphoid tissue lymphoma, endoscopic finding.  [通常講演]
    Hirose Y; Kaida H; Kunou Y; Uozumi J; Kurata S; Ohshima K; Abe T
    European Society of Gastrointestinal and Abdominal Radiology（ESGAR2015） 2015年06月 ポスター発表
  • The correlation of dual phase 18F-FDG PET/CT to immunohistochemical prognostic factors in breast cancer patients.  [通常講演]
    Kaida H; Toh U; Kawahara A; Kurta S; Hirose Y; Kage M; Ishii K; Murakami T; Ishibashi M
    SNMI annual meeting 2015 2015年06月 ポスター発表
  • Evaluation of Visceral and Subcutaneous Fat Volume and Metabolic Activity by 18F-Fluorodeoxyglucose-Positron Emission Tomography and Computed Tomography.  [通常講演]
    Sachiyo Igata; Nobuhiro Tahara; Shoichi Yamagishi; Norihiro Kodama; Atsuko Tahara; Akihiro Honda; Yoshikazu Nitta; Hayato Kaida; Masatoshi Ishibashi; Yoshihiro Fukumoto
    The79th Annual Scientific Meeting of the Japanese Circulation Society. 2015年04月 ポスター発表 大阪
  • Positive Correlation between Malondialdehyde-Modified Low-Density Lipoprotein Cholesterol and Vascular Inflammation Evaluated by 18F-FDG PET/CT.  [通常講演]
    Yoshikazu Nitta; Hayato Kaida; Nobuhiro Tahara; Atsuko Tahara; Akihiro Honda; Sachiyo Igata; Masatoshi Ishibashi; Shoichi Yamagishi; Yoshihiro Fukumoto
    The79th Annual Scientific Meeting of the Japanese Circulation Society. 2015年04月 ポスター発表 大阪
  • CT Perfusion Based Visualization and Quantification of Pancreatic Carcinoma Using 256 Slice CT-Feasibility on Predicting the Response in Combined Chemoradiotherapy or Chemotherapy.  [通常講演]
    Kunou Y; Uchida M; Kaida H; Hirose Y; Etou H; Okabe Y; Abe T
    Radiological Society of North America 2014 2014年11月 ポスター発表 Chicago，Illinois，U.S.A.
  • 卵巣癌患者における99mTc-MIBI SPECTと多剤耐性関連蛋白，アポトーシス関連蛋白との予備的研究．  [通常講演]
    倉田精二; 牛嶋公生; 河原明彦; 甲斐田勇人; 河野光一郎; 廣瀬靖光; 鹿毛政義; 嘉村敏治; 石橋正敏; 安陪等思
    第54回日本核医学会学術総会 2014年11月 ポスター発表 大阪
  • Palliative pain relief therapy for bone metastasis using concurrent therapy of Strontium-89 chloride with Zoledronic acid.  [通常講演]
    Baba K; Kaida H; Hattori C; Kugiyama T; Muraki K; Abe T; Ishibashi M
    Annual Congress of the European Association of Nuclear Medicine(EANM2014) 2014年10月 ポスター発表 Gothenburg，Sweden
  • Correlation between CT perfusion parameters and microvessel density in pancreatic cancer.  [通常講演]
    Kunou Y; Uchida M; Kaida H; Hirose Y; Abe T; Yasumoto M; Okabe Y
    European Society of Gastrointestinal and Abdominal Radiology（ESGAR2014） 2014年06月 ポスター発表 Salzburg,Austria
  • Mucosa-associated lymphoid tissue(MALT)lymphoma of the stomach with F- 18FDG PET:a comparison with endoscopic findings.  [通常講演]
    Hirose Y; Kaida H; Kunou Y; Uozumi J; Kurata S; Ohshima K; Abe T
    European Society of Gastrointestinal and Abdominal Radiology（ESGAR2014） 2014年06月 ポスター発表 Salzburg,Austria
  • 塩化ストロンチウムとゾレドロン酸を併用した転移性骨腫瘍に対する緩和療法．  [通常講演]
    馬場健吉; 石橋正敏; 甲斐田勇人; 服部睦行; 久木山智子; 村木宏一郎; 淡河恵津世; 安陪等思
    久留米メタストロン治療講演会 2014年05月 口頭発表（一般） 久留米
  • The relationship between FDG uptake and clinicopathological factors in DLBCL patients.  [通常講演]
    Yasumotsu Hirose; Hayato Kaida; Hiroaki Suefuji; Seiji Kurata; Masanobu Hayakawa; Satoshi Hattori; Takashi Okamura; Koichi Ohshima; Masatoshi Ishibashi; Toshi Abe
    第73回日本医学放射線学会総会 2014年04月 ポスター発表 横浜
  • Pancreatic perfusion computed tomography for predicting response and survival in concurrent chemoradiotherapy of unresectable pancreatic carcinoma.  [通常講演]
    Ykiko Kunou; Masafumi Uchida; Sunji Arikawa; Hayato Kaida; Yasumitu Hirose; Hiroaki Suefuji; Shinichi Tokuyasu; Toshi Abe
    第73回日本医学放射線学会総会 2014年04月 ポスター発表 横浜
  • 3D image quality of the liver using contrastenhanced CT with full iterative model reconstruction technique.  [通常講演]
    Ykiko Kunou; Masafumi Uchida; Shinichi Tokuyasu; Hayato Kaida; Yasumitu Hirose; Akiko Sumi; Toshi Abe
    第73回日本医学放射線学会総会 2014年04月 ポスター発表 横浜
  • 食道扁平上皮癌のFDG集積とGLUT-1,3, MVD, TAMとの関連性の検討.  [通常講演]
    廣瀬靖光; 甲斐田勇人; 倉田精二; 安陪等思; 石橋正敏; 河原明彦; 鹿毛正義; 田中寿明; 米本孝二
    第53回日本核医学会学術総会 2013年11月 口頭発表（一般） 福岡
  • 塩化ストロンチウムとゾレドロン酸を併用した転移性骨腫瘍に対する緩和療法．  [通常講演]
    馬場健吉; 石橋正敏; 甲斐田勇人; 服部睦行; 久木山智子; 村木宏一郎; 淡河恵津世; 安陪等思
    第51回日本癌治療学会学術集会 2013年10月 口頭発表（一般） 京都
  • Upregulated GABA inhibitory function in children with Child Behavior Checklist-Dysregulation Profile.  [通常講演]
    Nagamitsu S; Yamashita Y; Tanigawa H; Kaida H; Ishibashi M; Kakuma T; Matsuishi T
    60th Annual meeting of AACAP 2013年10月 ポスター発表 Orland, U.S.A.
  • Assessment of tumor cell proliferation in renal cell carcinoma using dual-phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging．  [通常講演]
    Rei Onishi; Fukuko Moriya; Katsuaki Chikui; Hayato Kaida; Seiji Kurata; Akihiko Kawahara; Masayoshi Kage; Masanori Noguchi; Masatoshi Ishibashi; Kei Matsuoka
    The 33rd the Congress of the Societe Internationale d’Urologie (SIU) 2013年09月 ポスター発表 Vancouver, Canada
  • 腎細胞癌に対するFDG-PET/CTを用いた治療前評価においてSUVの経時的集積増加は細胞増殖能と相関する．  [通常講演]
    大西 怜; 守屋普久子; 築井克聡; 甲斐田勇人; 倉田精二; 河原明彦; 鹿毛政義; 石橋正敏; 野口正典; 松岡 啓
    第101回日本泌尿器科学会総会 2013年04月 口頭発表（一般） 札幌
  • 腎細胞癌における〔18F〕FDG-PET の経時的集積増加は転移能及び腫瘍増殖能を予測し得る.  [通常講演]
    大西 怜; 守屋普久子; 甲斐田勇人; 倉田精二; 河原明彦; 鹿毛政義; 石橋正敏; 野口正典; 松岡 啓
    第50回日本癌治療学会学術集会 2012年10月 口頭発表（一般） 横浜
  • 18F-FDG uptake in primary gastric malignant lymphoma correlates with glucose transporter 1 expression and tumor aggressiveness.  [通常講演]
    Yuko Watanabe; Hiroaki Suefuji; Yasumitsu Hirose; Hayato Kaida; Chikayuki Hattori; Hidehiro Eto; Gen Suzuki; Etsuyo Ogo; Masatoshi Ishibashi; Takashi Okamura; Koichi Oshima; Naofumi Hayabuchi
    The XVI Meeting of the European Association for Haemato- pathology 2012 2012年10月 ポスター発表 Lisbon, Portugal
  • 発生臓器の異なる癌FDG集積とGLUT-1, Ki-67の関連の相違.  [通常講演]
    甲斐田勇人; 石橋正敏; 倉田精二; 廣瀬靖光; 藤本公則; 早渕尚文; 高森信三; 藤田博正; 中島 格; 河原明彦; 鹿毛政義; 早川正信; 服部 聡
    第52回日本核医学会学術総会 2012年10月 口頭発表（一般） 札幌
  • 切除不能膵癌のneoadjuvant chemoradiotherapyにおけるperfusion CTの有用性.  [通常講演]
    久能由記子; 内田政史; 有川俊二; 甲斐田勇人; 廣瀬靖光; 魚住 淳; 品川正治; 早渕尚文; 岡部義信; 福田圭助
    第71回日本医学放射線学会総会 2012年04月 ポスター発表 横浜
  • 食道扁平上皮癌における18F-FDG集積とbiological parameter関連性の検討.  [通常講演]
    廣瀬靖光; 甲斐田勇人; 倉田精二; 小林真衣子; 石橋正敏; 早渕尚文; 河原明彦; 鹿毛政義; 藤田博正; 米本孝二
    第71回日本医学放射線学会総会 2012年04月 ポスター発表 横浜
  • 膵癌切除例における FDG-PET （SUV 値）と予後との関連について.  [通常講演]
    北里雄平; 安永昌史; 木下壽文; 吉富宗宏; 赤須 玄; 御鍵和弘; 川原隆一; 石川博人; 久下 亨; 堀内彦之; 甲斐田勇人; 石橋正敏; 河原明彦; 鹿毛政義
    第112回日本外科学会定期学術集会 2012年04月 口頭発表（一般） 幕張
  • Relationship between clinicopathological factors and total lesion glycolysis in pancreatic cancer.  [通常講演]
    Masaharu Shinagawa; Hayato Kaida; Masatoshi Ishibashi; Yukiko Kuno; Makiko Yasumoto; Yoshiki Naito; Yasufumi Kinoshita; Masafumi Uchida; Naofumi Hayabuchi
    European Congress of Radiology (ECR) 2012 2012年03月 ポスター発表 Vienna, Austria
  • Relationship between clinicopathological factors and total lesion glycolysis in pancreatic cancer.  [通常講演]
    Masaharu Shinagawa; Hayato Kaida; Masatoshi Ishibashi; Yukiko Kuno; Makiko Yasumoto; Yoshiki Naito; Yasufumi Kinoshita; Masafumi Uchida; Naofumi Hayabuchi
    Radiological Society of North America 2011 2011年11月 ポスター発表 Chicago，Illinois，U.S.A.
  • Predicting the response of pancreatic cancer to combinedchemotherapy and radiotherapy by whole pancreatic perfusion computed tomography．  [通常講演]
    Kunou Y; Uchida M; Arikawa S; Kaida H; Sakoda J; Shinagawa M; Okabe Y; Yasumoto M; Hayabuchi N
    Radiological Society of North America 2011 2011年11月 ポスター発表 Chicago，Illinois，U.S.A.
  • 日本心臓病学会・日本心臓核医学会ジョイントシンポジウム“不安定プラークの病態と画像診断”炎症と動脈硬化 ‐FDG-PETを用いた動脈硬化活動性の可視化‐.  [通常講演]
    田原宣広; 本多亮博; 田原敦子; 新田良和; 児玉紀洋; 溝口ミノリ; 甲斐田勇人; 石橋正敏; 今泉 勉
    第59回日本心臓病学会学術集会 2011年09月 シンポジウム・ワークショップパネル（公募） 神戸
  • 心筋MIBI検査におけるアーチファクト軽減の取り組み.  [通常講演]
    馬場健吉; 石橋正敏; 甲斐田勇人; 服部睦行; 松田信彦; 早渕尚文
    第24回21世紀カンファランス 2011年09月 公開講演，セミナー，チュートリアル，講習，講義等 福岡
  • 第12回日本心臓核医学会賞受賞講演炎症と動脈硬化 ‐FDG-PETを用いた動脈硬化活動性の可視化‐.  [通常講演]
    田原宣広; 田原敦子; 新田良和; 児玉紀洋; 溝口ミノリ; 甲斐田勇人; 石橋正敏; 今泉 勉
    第21回日本心臓核医学会総会学術大 2011年06月 口頭発表（一般） 福岡
  • 教育講演“動脈硬化プラーク･イメージング”炎症と動脈硬化 ‐FDG-PETを用いた動脈硬化活動性の可視化‐.  [通常講演]
    田原宣広; 田原敦子; 新田良和; 児玉紀洋; 溝口ミノリ; 甲斐田勇人; 石橋正敏; 今泉 勉
    第10回日本頸部脳血管治療学会 2011年06月 口頭発表（一般） 大阪
  • FDG-PET検診で発見された腸間膜Inflammatory pseudotumorの一例.  [通常講演]
    廣瀬靖光; 甲斐田勇人; 小林真衣子; 倉田精二; 石橋正敏; 早渕尚文; 岡部義信; 木下壽文; 大島孝一; 田原宣広
    第173回日本医学放射線学会九州地方会 2011年06月 口頭発表（一般） 那覇
  • FDG-PET/CTで高集積を認めた傍神経節腫の一例.  [通常講演]
    小林真衣子; 廣瀬靖光; 甲斐田勇人; 倉田精二; 石橋正敏; 早渕尚文; 奥田康司; 木下壽文; 河原明彦; 鹿毛政義
    第173回日本医学放射線学会九州地方会 2011年06月 口頭発表（一般） 那覇
  • 18F-FDGが集積した直腸MALTリンパ腫の1例.  [通常講演]
    廣瀬靖光; 甲斐田勇人; 石橋正敏; 小林真衣子; 末藤大明; 早渕尚文; 鶴田 修; 岡村 孝; 河原明彦; 大島孝一
    第46回日本核医学会九州地方会 2011年02月 口頭発表（一般） 宮崎
  • 癌診療におけるFDG-PETの有効性  [通常講演]
    甲斐田勇人
    大法山病院院内研修会 2010年11月 公開講演，セミナー，チュートリアル，講習，講義等 田川
  • 乳癌におけるFDG集積とbiological factorとの関連性の検討.  [通常講演]
    甲斐田勇人; 石橋正敏; 倉田精二; 小林真衣子; 廣瀬靖光; 淡河恵津世; 早渕尚文; 唐 宇飛; 藤井輝彦; 河原明彦; 鹿毛政義; 服部 聡
    第50回日本核医学会学術総会 2010年11月 口頭発表（一般） 大宮
  • FDG-PETの臨床的有用性.  [通常講演]
    甲斐田勇人
    平成22年度結核指定医会学術講演会 2010年09月 公開講演，セミナー，チュートリアル，講習，講義等 大牟田
  • Detection of synchronous cancer using 18F-FDG-PET in hypopharyngeal cancer patients.  [通常講演]
    Hayato Kaida; Masatoshi Ishibashi; Seiji Kurata; Maiko Kobayashi; Norimitsu Tanaka; Toshi Abe; Tadashi Nakashima; Naofumi Hayabuchi
    Annual Congress of Australia and New Zealand Society of Nuclear Medicine 2010 2010年04月 ポスター発表 Auckland, New Zealand
  • The relationship between biologic factor and 18F-FDGuptake in esophageal squamous cell cancer patients.  [通常講演]
    Maiko Kobayashi; Hayato Kaida; Masatoshi Ishibashi; Seiji Kurata; Masafumi Uchida; Hiromasa Fujita; Satoshi Hattori; Akihiko Kawahara; Masayoshi Kage; Naofumi Hayabuchi
    Annual Congress of Australia and New Zealand Society of Nuclear Medicine 2010 2010年04月 ポスター発表 Auckland, New Zealand
  • 18F-FDGが集積した嫌色素性腎細胞癌の一例.  [通常講演]
    廣瀬靖光; 甲斐田勇人; 石橋正敏; 倉田精二; 小林真衣子; 内田政史; 淡河恵津世; 早渕尚文; 松岡 啓; 秋葉 純; 矢野博久
    第 45回日本核医学会九州地方会 2010年02月 口頭発表（一般） 大分
  • FDG-PETと分子病理学的手法による甲状腺乳頭癌の解析.  [通常講演]
    甲斐田勇人; 石橋正敏
    久留米佐賀甲状腺研究会 2009年11月 公開講演，セミナー，チュートリアル，講習，講義等 佐賀
  • Clinical assessment of 18F-FDG PET/CT and plasm a osteopontin levels in patients with asbestos-related pleural disease.  [通常講演]
    Seiji Kurata; Masatoshi Ishibashi; Hayato Kaida; Koichi Azuma; Maiko Kobayashi; Yasumitsu Hirose; Shinzo Takamori; Kiminori Fujimoto; Hisamichi Aizawa; Naofumi Hayabuchi
    Annual Congress of the European Association of Nuclear Medicine 2009 2009年10月 ポスター発表 Barcelona，Spain
  • 分子病理学的手法を用いての食道癌へのFDG集積の特性解析.  [通常講演]
    小林真衣子; 甲斐田勇人; 石橋正敏; 倉田精二; 内田政史; 早渕尚文; 田中優一; 藤田博正; 河原明彦; 鹿毛政義
    第49回日本核医学会学術総会 2009年10月 口頭発表（一般） 旭川
  • Staging of mediastinal and hilar lymph node metastases from nonsmall cell lung cancer:comparison of diagnostic accuracy of MRI and FDG-PET.  [通常講演]
    Kiminori Fujimoto; Hayato Kaida; Nestor L.Muller; Junko Sadohara; Ryouji Iwamoto; Naoko Fujimoto; Seiji Kurata; Fumihiko Muta; Toshihiro Matsuo; Shinzo Takamori; Masatoshi Ishibashi; Naofumi Hayabuchi
    The 13th World Conference on Lung Cancer 2009年07月 ポスター発表 San Francisco, U.S.A.
  • 乳管内乳頭腫へのFDG集積（Glucose transporterとの関連）.  [通常講演]
    廣瀬靖光; 甲斐田勇人; 石橋正敏; 倉田精二; 小林真衣子; 内田政史; 淡河恵津世; 早渕尚文
    第169回日本医学放射線学会九州地方会 2009年07月 口頭発表（一般） 福岡
  • 放射線治療後長期生存した進行肺癌の1例.  [通常講演]
    渡邉祐子; 淡河恵津世; 甲斐田勇人; 末藤大明; 江藤英博; 鈴木 弦; 辻 千代子; 服部睦行; 早渕尚文
    第169回日本医学放射線学会九州地方会 2009年07月 口頭発表（一般） 福岡
  • FDG-PET/CTで集積を認めた食道GISTの一例.  [通常講演]
    杠 美哉; 甲斐田勇人; 石橋正敏; 倉田精二; 小林真衣子; 有川俊二; 魚住 淳; 内田政史; 早渕尚文; 藤田博正; 河原明彦; 鹿毛政義
    第45回日本核医学会九州地方会 2009年02月 口頭発表（一般） 佐賀
  • 分子病理学的手法を用いての食道癌へのFDG集積の特性解析  [通常講演]
    小林真衣子; 甲斐田勇人; 石橋正敏; 倉田精二; 内田政史; 早渕尚文; 田中優一; 藤田博正; 河原明彦; 鹿毛政義; 服部 聡
    第45回日本核医学会九州地方会 2009年02月 口頭発表（一般） 佐賀
  • FDG-PETと分子病理学的手法を用いての甲状腺乳頭癌の細胞増殖の特性解析.  [通常講演]
    甲斐田勇人; 石橋正敏; 倉田精二; 小林真衣子; 貝原紘子; 早渕尚文; 広松雄治; 三橋択之; 中島 格; 河原明彦; 鹿毛政義
    第48回日本核医学会学術総会 2008年10月 口頭発表（一般） 千葉
  • 筋サルコイドーシス；治療効果判定におけるFDG-PETとGa67シンチグラフイーとの比較.  [通常講演]
    倉田精二; 石橋正敏; 甲斐田勇人; 小林真衣子; 貝原紘子; 田原宣広; 溝口ミノリ; 早渕尚文
    第48回日本核医学会学術総会 2008年10月 口頭発表（一般） 千葉
  • 非分泌型多発性骨髄腫のFDG-PETによる治療効果判定の一例.  [通常講演]
    貝原紘子; 甲斐田勇人; 石橋正敏; 倉田精二; 藤本公則; 内田政史; 早渕尚文; 大坪維範; 岡村 孝; 大島孝一
    第44回日本核医学会九州地方会 2008年02月 口頭発表（一般） 鹿児島
  • 乳癌術前化学療法の治療効果判定におけるFDG-PETの有効性の検討.  [通常講演]
    甲斐田勇人; 石橋正敏; 倉田精二; 淡河恵津世; 早渕尚文; 藤井輝彦
    第47回日本核医学会総会 2007年11月 口頭発表（一般） 仙台
  • Clinical usefulness of PET-CT imaging on staging and management of gastrointestinal tumor.  [通常講演]
    Naofumi Tomita; Masafumi Uchida; Sanae Azuma; Hayato Kaida; Masatoshi Ishibashi; Jun Uozumi; Naofumi Hayabuchi
    European Society of Gastrointestinal and Abdominal Radiology 2007年06月 ポスター発表 Lisbon, Portugal
  • Diffuse or combined uptake in the thyroid gland as an incidental finding in FDG-PET: Risks of thyroid cancer and subclinical hypothyroidism associated with Hashimoto's thyroiditis.  [通常講演]
    Seiji Kurata; Masatoshi Ishibashi; Hayato Kaida; Yuji Hiromatsu; Ikuyo Miyake; Naofumi Hayabuchi
    Society of Nuclear Medicine (SNM) 2007 Annual Meeting 2007年06月 ポスター発表 Washington D.C., U.S.A.
  • 退形成性膵管癌の1例.  [通常講演]
    有川俊二; 内田政史; 小金丸雅道; 甲斐田勇人; 内山大治; 吾妻佐奈江; 富田直史; 魚住 淳; 早渕尚文; 岡部義信; 菅 偉哉; 木下壽文; 内藤嘉紀; 枝光 理
    第21回腹部放射線研究会 2007年06月 口頭発表（一般） 宮崎
  • 食道癌進行度診断における心電図同期MDCTとFDG−PETの比較.  [通常講演]
    富田直史; 内田政史; 有川俊二; 魚住 淳; 甲斐田勇人; 倉田精二; 石橋正敏; 早渕尚文; 藤田博正
    第66回日本医学放射線学会総会 2007年04月 ポスター発表 横浜
  • 当センターのPET検診における乳癌の発見率に関する検討.  [通常講演]
    甲斐田勇人; 石橋正敏; 倉田精二; 淡河恵津世; 早渕尚文; 藤井輝彦; 田中真紀
    第24回筑後地区乳腺カンファランス 2007年03月 公開講演，セミナー，チュートリアル，講習，講義等 久留米
  • 脾臓原発悪性リンパ腫の（FDG-PET による経験）.  [通常講演]
    高田文香; 甲斐田勇人; 石橋正敏; 倉田精二; 魚住 淳; 内田政史; 早渕尚文; 岡村 孝; 内田信治; 大島孝一; 伴 茂樹
    第43回日本核医学会九州地方会 2007年02月 口頭発表（一般） 長崎
  • 肝胆膵領域におけるMulti- modality 3D Fusion Image作成の試み.  [通常講演]
    内田政史; 甲斐田勇人; 石橋正敏; 早渕尚文
    第12回三次元CT・MRI研究会 2007年02月 公開講演，セミナー，チュートリアル，講習，講義等 東京
  • PET検診における当センターの乳癌の発見率に関する検討.  [通常講演]
    甲斐田勇人; 石橋正敏; 倉田精二; 淡河恵津世; 早渕尚文; 藤井輝彦
    第46回日本核医学会学術総会 2006年11月 口頭発表（一般） 鹿児島
  • FDG-PETがん検診による甲状腺の異常集積の検出に関する検討.  [通常講演]
    倉田精二; 石橋正敏; 甲斐田勇人; 早渕尚文; 三宅育代; 広松雄治
    第46回日本核医学会学術総会 2006年11月 口頭発表（一般） 鹿児島
  • 18-FDG PETの甲状腺への集積に関する検討.  [通常講演]
    迎 徳範; 古賀寛久; 村石和久; 城谷克郎; 賀来寛雄; 三宅育代; 甲斐田勇人; 倉田精二; 石橋正敏; 広松雄治; 山田研太郎
    第49回日本甲状腺学会 2006年11月 口頭発表（一般） 高松
  • FDG-PETで発見された食道GISTの１例.  [通常講演]
    有川俊二; 魚住 淳; 田中法瑞; 甲斐田勇人; 富田直史; 内田政史; 石橋正敏; 早渕尚文; 岡部義信; 内藤嘉紀
    第42回日本医学放射線学会秋季臨床大会 2006年10月 ポスター発表 福岡
  • Evaluation of FDG-PET in patient with breast cancer using the novel device.  [通常講演]
    Hayato Kaida; Masatoshi Ishibashi; Seiji Kurata; Etsuyo Ogo; Teruhiko Fujii; Naofumi Hayabuchi
    Annual Congress Of The European Association of Nuclear Medicine 2006年09月 ポスター発表 Athen, Greek
  • Assessment of the relationship between bone scintigraphy and serum biochemical markers in hemodialysis patients.  [通常講演]
    Seiji Kurata; Masatoshi Ishibashi; Hayato Kaida; Hidemi Nishida; Yuji Hiromatsu; Seiya Okuda; Naofumi Hayabuchi
    Annual Congress Of The European Association Of Nuclear Medicine 2006年09月 ポスター発表 Athen, Greek
  • Prevalence of 18-FDG-PET uptake in the thyroid gland for cancer screening in 1444 healthy subjects and 4310 carcinoma patients.  [通常講演]
    Ikuyo Miyaka; Hayato Kaida; Kenkichi Baba; Tokunori Mukai; Seiji Kurata; Hiro Kaku; Hirohisa Koga; Masatoshi Ishibashi; Kentarou Yamada; Yuji Hiromatsu
    European thyroid association the 31st annual meeting 2006年09月 ポスター発表 Neples, Italy
  • MDCTにおける膵IPMTの描出能：主にERP, MRI／MRCPとの比較.  [通常講演]
    有川俊二; 内田政史; 品川正治; 甲斐田勇人; 石橋正敏; 早渕尚文; 岡部義信; 菅偉哉; 木下壽文; 内藤嘉紀
    第37回日本膵臓学会 2006年06月 口頭発表（一般） 横浜
  • FDG-PET検診で発見された十二指腸癌の一例.  [通常講演]
    牛尾いずみ; 甲斐田勇人; 倉田精二; 石橋正敏; 有川俊二; 富田直史; 魚住 淳; 内田政史; 早渕尚文; 宮城委史
    第163回日本医学放射線学会九州地方会 2006年06月 口頭発表（一般） 久留米
  • MPR,CPR imageを加えたMD-CTによる膵IPMT診断能の検討−MRCP,EUS,ERCP,FDG-PETとの比較−.  [通常講演]
    有川俊二; 内田政史; 品川正治; 甲斐田勇人; 石橋正敏; 早渕尚文; 岡部義信; 菅偉哉; 木下壽文; 内藤嘉紀
    第65回日本医学放射線学会総会 2006年04月 ポスター発表 横浜
  • The clinical application and exploitation using FDG PET mammography.  [通常講演]
    Hayato Kaida; Masatoshi Ishibashi; Kenkichi Baba; Etuyo Ogo; Teruhiko Fuji; Naofumi Hayabuchi
    第４５回日本核医学会総会 2005年11月 口頭発表（一般） 東京
  • 肺塞栓症の早期診断のための緊急核医学検査の試み.  [通常講演]
    馬場健吉; 石橋正敏; 甲斐田勇人; 早渕尚文
    第４５回日本核医学会総会 2005年11月 口頭発表（一般） 東京
  • CTやMRIをCD-Romを媒体として作成したGSO-PETとの融合画像診断の有用性．  [通常講演]
    馬場健吉; 石橋正敏; 甲斐田勇人; 早渕尚文
    第41回日本医学放射線学会秋季臨床大会 2005年10月 ポスター発表 広島
  • 腎性骨異栄養症における骨シンチと骨代謝マーカの有用性の検討．  [通常講演]
    甲斐田勇人
    海の中道RIカンファレンス 2005年07月 公開講演，セミナー，チュートリアル，講習，講義等 福岡
  • PET検診で二重癌が発見された一例.  [通常講演]
    中村真衣子; 甲斐田勇人; 石橋正敏; 馬場健吉; 有川俊二; 富田直史; 魚住 淳; 早渕尚文; 田原宣広; 矢野正次郎
    第161回日本医学放射線学会九州地方 2005年06月 口頭発表（一般） 宮崎
  • 消化器疾患におけるFDG-PETの役割.  [通常講演]
    甲斐田勇人
    筑後地区胃研究会 2005年03月 公開講演，セミナー，チュートリアル，講習，講義等 久留米
  • 肺塞栓症の早期診断のための緊急核医学検査の試み.  [通常講演]
    馬場健吉; 石橋正敏; 甲斐田勇人; 早渕尚文; 大内田昌直
    第11回肺塞栓症研究会学術集会 2004年11月 公開講演，セミナー，チュートリアル，講習，講義等 東京
  • 腎性骨異栄養症患者における骨シンチを用いてのwhole PTHの有用性.  [通常講演]
    甲斐田勇人; 石橋正敏; 馬場健吉; 早渕尚文
    第44回日本核医学会総会 2004年11月 口頭発表（一般） 京都
  • Relationship between Tc-99m tetrofosmin thyroid scintigraphy and the signal transfer system (MAPK) in patients with thyroid cancer.  [通常講演]
    Kenkichi Baba; Masatoshi Ishibashi; Hayato Kaida; Naofumi Hayabuchi; Kenta Koike; Teruhiko Fujii; Hideaki Yamana
    第44回日本核医学会総会 2004年11月 口頭発表（一般） 京都
  • 化学療法を施行中に突然の両側反回神経麻痺を呈したホジキンリンパ腫の1例.  [通常講演]
    辻 千代子; 鈴木 弦; 淡河恵津世; 江藤英博; 安元真紀子; 甲斐田勇人; 久能由記子; 早渕尚文; 千々和秀記; 中島 格
    第16回筑後放射線腫瘍談話会 2004年09月 公開講演，セミナー，チュートリアル，講習，講義等 久留米
  • 高アミラーゼ血症を呈した卵巣腫瘍の一例.  [通常講演]
    工藤桂子; 馬場健吉; 甲斐田勇人; 石橋正敏; 森田誠一郎; 早渕尚文; 牛嶋公生; 嘉村敏治
    第40 回日本核医学会九州地方会 2004年07月 口頭発表（一般） 大分
  • 甲状腺癌における99mTc-tetrofosminの集積とシグナル伝達系（MAPK）との関連.  [通常講演]
    馬場健吉; 石橋正敏; 甲斐田勇人; 森田誠一郎; 早渕尚文; 藤井輝彦; 小池健太
    第39回日本核医学会九州地方会 2004年02月 口頭発表（一般） 福岡
  • GSO-PETの初期使用経験.  [通常講演]
    甲斐田勇人; 石橋正敏; 馬場健吉; 森田誠一郎; 早渕尚文
    第39回日本核医学会九州地方会 2004年02月 口頭発表（一般） 福岡
  • Assessment of therapeutic effect in patients with secondary hyperparathyroidism using bone scintigraphy.  [通常講演]
    Hayato Kaida; Masatoshi Ishibashi; Seiji Kurata; Kenkichi Baba; Seiichirou Morita; Naofumi Hayabuchi
    第43回日本核医学会総会 2003年10月 口頭発表（一般） 大阪
  • 8slice MDCTの初期使用経験.  [通常講演]
    甲斐田勇人; 内田政史; 品川正治; 野崎 健; 西村 浩; 早渕尚文
    第154回日本医学放射線学会九州地方会 2002年02月 口頭発表（一般） 熊本
  • 直腸カルチノイドの一例.  [通常講演]
    甲斐田勇人; 稲吉康治; 原田英嗣; 溝手淑子; 高木重雄; 菊池 茂
    第153回日本医学放射線学会九州地方会 2001年06月 口頭発表（一般） 鹿児島
  • 男性多発嚢胞内乳癌の１例.  [通常講演]
    高木重雄; 稲吉康治; 長田周治; 甲斐田勇人; 菊池 茂; 魚住 淳; 西村 浩; 早渕尚文
    第152回日本医学放射線学会九州地方会 2001年02月 口頭発表（一般） 久留米
  • 大腸リンパ管拡張症の一例．  [通常講演]
    長田周治; 稲吉康治; 甲斐田勇人; 高木重雄; 菊池 茂; 西村 浩; 早渕尚文
    第152回日本医学放射線学会九州地方会 2001年02月 口頭発表（一般） 久留米
  • リザーバー動注後 ，合併症による抜去となった症例の検討.  [通常講演]
    富田直史; 内山大治; 甲斐田勇人; 藤松雅彦
    第17回長崎県北消化器癌研究会 2000年04月 公開講演，セミナー，チュートリアル，講習，講義等 佐世保
  • 高齢者のクローン病の一例.  [通常講演]
    甲斐田勇人; 溝手淑子; 富田直史; 藤松雅彦; 武内 稔
    第150回日本医学放射線学会九州地方会 2000年02月 口頭発表（一般） 宮崎

MISC

  • 心サルコイドーシスFDG PET/CT検査における呼吸同期・心電図同期収集の効果
    花岡宏平; 渡邊翔太; 石川大介; 甲斐田勇人; 安田昌和; 岩永善高; 中澤 学; 石井一成 心臓核医学 25 (2) 49 -49 2023年06月
  • Takahiro Yamada; Kohei Hanaoka; Yoshiyuki Yamakawa; Suzuka Minagawa; Atsushi Ohtani; Tetsuro Mizuta; Hayato Kaida; Kazunari Ishii JOURNAL OF NUCLEAR MEDICINE 63 2022年06月
  • 山口明乃; 根本充貴; 甲斐田勇人; 甲斐田勇人; 木村裕一; 永岡隆; 山田誉大; 花岡宏平; 北島一宏; 槌谷達也; 石井一成; 石井一成 日本生体医工学会大会プログラム・抄録集(Web) 61st 2022年
  • 瀬川新; 根本充貴; 甲斐田勇人; 甲斐田勇人; 山口明乃; 木村裕一; 永岡隆; 山田誉大; 北島一宏; 石井一成; 石井一成 日本生体医工学会大会プログラム・抄録集(Web) 61st 2022年
  • 渡邉綾; 山田誉大; 渡辺翔吾; 永岡隆; 根本充貴; 宮崎晃一; 花岡宏平; 甲斐田勇人; 甲斐田勇人; 石井一成; 石井一成; 木村裕一 日本生体医工学会大会プログラム・抄録集(Web) 60th 2021年
  • 山口明乃; 根本充貴; 甲斐田勇人; 甲斐田勇人; 木村裕一; 永岡隆; 山田誉大; 花岡宏平; 北島一宏; 槌谷達也; 石井一成; 石井一成 日本生体医工学会大会プログラム・抄録集(Web) 60th 2021年
  • 山口明乃; 根本充貴; 甲斐田勇人; 甲斐田勇人; 木村裕一; 永岡隆; 山田誉大; 花岡宏平; 北島一宏; 槌谷達也; 石井一成; 石井一成 核医学(Web) 58 (Supplement) 2021年
  • 渡邉綾; 木村裕一; 山田誉大; 渡辺翔吾; 永岡隆; 根本充貴; 宮崎晃一; 花岡宏平; 甲斐田勇人; 甲斐田勇人; 石井一成; 石井一成 核医学(Web) 58 (Supplement) 2021年
  • One-class SVMによる画素悪性度の集中性を用いたFDG-PET/CT上の病変自動検出
    田中 敦子; 根本 充貴; 甲斐田 勇人; 木村 裕一; 永岡 隆; 牛房 和之; 山田 誉大; 花岡 宏平; 北島 一宏; 槌谷 達也; 石井 一成 第39回日本医用画像工学会大会予稿集 153 -158 2020年09月
  • A. Tanaka; M. Nemoto; H. Kaida; Y. Kimura; T. Nagaoka; T. Yamada; K. Ushifusa; K. Hanaoka; K. Kitajima; T. Tsuchitani; K. Ishii International Journal of Computer Assisted Radiology and Surgery 15 (S1) 208 -209 2020年06月 [査読有り]
  • 横行結腸に生じたバンドによる絞扼性イレウスの1例 横行結腸軸捻転との比較
    沼本 勲男; 松木 充; 土居 秀平; 鈴木 絢子; 小田 晃義; 門場 智也; 藤谷 哲也; 松久保 祐子; 山田 穣; 兵頭 朋子; 任 誠雲; 甲斐田 勇人; 柳生 行伸; 小塚 健倫; 柏木 伸夫; 鶴崎 正勝; 細野 眞; 石井 一成 Japanese Journal of Radiology 38 (Suppl.) 42 -42 2020年02月
  • 田中敦子; 根本充貴; 甲斐田勇人; 木村裕一; 永岡隆; 山田誉大; 牛房和之; 花岡宏平; 北島一宏; 槌谷達也; 石井一成; 石井一成 電子情報通信学会技術研究報告 119 (399(MI2019 65-123)(Web)) 2020年
  • 渡邉綾; 木村裕一; 山田誉大; 渡辺翔吾; 永岡隆; 根本充貴; 宮崎晃一; 花岡宏平; 甲斐田勇人; 甲斐田勇人; 石井一成; 石井一成 核医学(Web) 57 (Supplement) 2020年
  • 田中敦子; 根本充貴; 甲斐田勇人; 甲斐田勇人; 木村裕一; 永岡隆; 牛房和之; 山田誉大; 花岡宏平; 北島一宏; 槌谷達也; 石井一成; 石井一成 核医学(Web) 57 (Supplement) 2020年
  • Kenji Suda; Nobuhiro Tahara; Akihiro Honda; Motofumi Iemura; Hironaga Yoshimoto; Shintaro Kishimoto; Yoshiyuki Kudo; Hiroyuki Tanaka; Hayato Kaida; Toshi Abe; Takafumi Ueno; Yoshihiro Fukumoto Circulation 140 A13320 2019年11月
  • AI異常検知に基づくPET/CT上の頸胸部病変の自動認識
    田中 敦子; 根本 充貴; 甲斐田 勇人; 木村 裕一; 山田 誉大; 牛房 和之; 花岡 宏平; 北島 一宏; 槌谷 達也; 石井 一成 核医学 56 (Suppl.) S154 2019年10月
  • FDG PET/CTによる食道癌術前化学療法の治療効果判定に関する検討
    甲斐田 勇人; 白石 治; 岩間 密; 加藤 寛章; 木村 豊; 花岡 宏平; 山田 穣; 北島 一宏; 安田 卓司; 石井 一成 核医学 56 (Suppl.) S155 2019年10月
  • 認知症自動診断AIアルゴリズム学習のための深層学習によるアミロイド画像の加増手法の検討
    渡邉 綾; 山田 誉大; 永岡 隆; 根本 充貴; 花岡 宏平; 甲斐田 勇人; 石井 一成; 木村 裕一 核医学 56 (Suppl.) S178 2019年10月
  • Nuclear protein in testis(NUT)midline carcinomaの一例
    山田 穣; 柏木 伸夫; 土居 秀平; 沼本 勲男; 浜川 岳文; 門場 智也; 松久保 祐子; 兵頭 朋子; 甲斐田 勇人; 任 誠雲; 柳生 行伸; 小塚 健倫; 岡野 意浩; 坂田 尚己; 松木 充; 石井 一成 日本小児放射線学会雑誌 35 (Suppl.) 28 2019年06月
  • 肺癌手術にて病理診断されたMultiple minute pulmonary meningothelial-like nodulesの1例
    和田 祐太郎; 松木 充; 土居 秀平; 鈴木 絢子; 沼本 勲男; 小田 晃義; 山田 穣; 兵頭 朋子; 任 誠雲; 甲斐田 勇人; 柳生 行伸; 細川 知紗; 小塚 健倫; 柏木 伸夫; 鶴崎 正勝; 今岡 いずみ; 細野 眞; 石井 一成; 村上 卓道; 榎木 英介 Japanese Journal of Radiology 37 (Suppl.) 40 2019年02月
  • 渡邉綾; 山田誉大; 永岡隆; 根本充貴; 花岡宏平; 甲斐田勇人; 石井一成; 石井一成; 木村裕一 核医学(Web) 56 (Supplement) 2019年
  • 田中敦子; 根本充貴; 甲斐田勇人; 甲斐田勇人; 木村裕一; 山田誉大; 牛房和之; 花岡宏平; 北島一宏; 槌谷達也; 石井一成; 石井一成 核医学(Web) 56 (Supplement) 2019年
  • 北島一宏; 南本亮吾; 平田健司; 山根登茂彦; 甲斐田勇人; 中條正豊; 森田敬裕; 中谷航也; 石橋 愛 核医学 56 (1) 45 -46 2019年01月 [査読有り]
  • 田中 敦子; 根本 充貴; 甲斐田 勇人; 木村 裕一; 永岡 隆; 山田 誉大; 花岡 宏平; 石井 一成 生体医工学 57 (0) S249_2 2019年
  • 甲斐田 勇人; 山田 穣; 松久保 祐子; 花岡 宏平; 任 誠雲; 柳生 行伸; 細野 眞; 石井 一成 核医学 56 (1) 153 2019年
  • SRTM法を用いたアミロイドイメージングに対する空間分解能を損なわないノイズ低減アルゴリズムの検討
    山田 誉大; 木村 裕一; 根本 充貴; 坂田 宗之; 永岡 隆; 花岡 宏平; 甲斐田 勇人; 石井 一成 核医学 55 (Suppl.) S168 2018年11月
  • AI異常検知を用いたFDG-PET/CT上の頸胸部原発性・転移性病変の検出
    根本 充貴; 甲斐田 勇人; 田中 敦子; 牛房 和之; 山田 誉大; 木村 裕一; 花岡 宏平; 石井 一成 核医学 55 (Suppl.) S196 2018年11月
  • FDG PET/CTによる食道癌術前化学療法の予後解析
    甲斐田 勇人; 白石 治; 岩間 密; 加藤 寛章; 木村 豊; 花岡 宏平; 山田 穣; 北島 一宏; 細野 眞; 安田 卓司; 石井 一成 核医学 55 (Suppl.) S200 2018年11月
  • 頭頸部扁平上皮癌からの骨転移
    鈴木 絢子; 柏木 伸夫; 沼本 勲男; 小田 晃義; 門場 智也; 兵頭 朋子; 山田 穣; 甲斐田 勇人; 柳生 行伸; 任 誠雲; 鶴崎 正勝; 小塚 健倫; 松木 充; 石井 一成; 中西 克之 第54回日本医学放射線学会秋季臨床大会抄録集 S470 2018年09月
  • 真性腸石のCT所見
    浜川 岳文; 松木 充; 鈴木 絢子; 沼本 勲男; 小田 晃義; 門場 智也; 土居 秀平; 松久保 祐子; 兵頭 朋子; 任 誠雲; 甲斐田 勇人; 柳生 行伸; 鶴崎 正勝; 小塚 健倫; 石井 一成 第54回日本医学放射線学会秋季臨床大会抄録集 S498 2018年09月
  • 頸部顔面救急疾患の画像診断：耳下腺、甲状腺
    柏木伸夫; 藤原良平; 甲斐田勇人; 鶴﨑正勝; 石井一成 画像診断 38 (7) 795 -804 2018年07月
  • 福井秀行; 松木充; 任誠雲; 甲斐田勇人; 柳生行伸; 小塚健倫; 細川知紗; 熊野正士; 柏木伸夫; 鶴崎正勝; 今岡いずみ; 細野眞; 石井一成; 村上卓道 Japanese Journal of Radiology 36 (Suppl) 34 2018年02月
  • 沼本 勲男; 松木 充; 福井 秀行; 若林 雄一; 日高 正二郎; 渡口 真史; 藤谷 哲也; 山川 美帆; 兵頭 朋子; 山田 穣; 任 誠雲; 甲斐田 勇人; 柳生 行伸; 柏木 伸夫; 細川 知紗; 小塚 健倫; 鶴崎 正勝; 今岡 いずみ; 細野 眞; 石井 一成; 村上 卓道 Japanese Journal of Radiology 36 (Suppl.) 27 2018年02月
  • 根本充貴; 甲斐田勇人; 田中敦子; 牛房和之; 山田誉大; 木村裕一; 花岡宏平; 石井一成; 石井一成 核医学(Web) 55 (Supplement) 2018年
  • 山田誉大; 木村裕一; 根本充貴; 坂田宗之; 永岡隆; 花岡宏平; 甲斐田勇人; 石井一成; 石井一成 核医学(Web) 55 (Suppl) 2018年
  • 山田 誉大; 木村 裕一; 藤井 康介; 渡辺 翔吾; 永岡 隆; 根本 充貴; 花岡 宏平; 甲斐田 勇人; 石井 一成 生体医工学 56 S294 2018年
  • Volumetric parameterを用いた食道癌切除患者の予後因子の検討
    甲斐田 勇人; 石井 一成; 細川 知紗; 柳生 行伸; 任 誠雲; 兵頭 朋子; 山田 穣; 細野 眞; 安田 卓司; 村上 卓道 核医学 54 (Suppl.) S193 2017年09月
  • Hayato Kaida; Koichi Azuma; Akihiko Kawahara; Eiji Sadashima; Satoshi Hattori; Jun Akiba; Axel Rominger; Shinzo Takamori; Kiminori Fujimoto; Makoto Hosono; Kazunari Ishii; Takamichi Murakami; Masatoshi Ishibashi Journal of Nuclear Medicine 58 (S1) 1047 2017年05月
  • FDG-PET/CTで集積を認めた異所性甲状腺癌の一例
    甲斐田 勇人; 石井 一成; 細川 知紗; 仁 誠雲; 細野 眞; 村上 卓道; 花岡 宏平; 乾 浩己 核医学 54 (1) 668 -669 2017年02月
  • 膀胱子宮内膜症の経過を追った2例
    沼本 勲男; 今岡 いずみ; 若林 雄一; 藤谷 哲也; 山川 美穂; 兵頭 朋子; 甲斐田 勇人; 柳生 行伸; 熊野 正士; 鶴崎 正勝; 松木 充; 石井 一成; 村上 卓道 Japanese Journal of Radiology 35 (Suppl.) 49 2017年02月
  • 上顎洞術後変化としての眼窩下管拡大
    福井 秀行; 柏木 伸夫; 任 誠雲; 甲斐田 勇人; 柳生 行伸; 小塚 健倫; 細川 知紗; 熊野 正士; 鶴崎 正勝; 松木 充; 今岡 いずみ; 石井 一成; 細野 眞; 村上 卓道 Japanese Journal of Radiology 35 (Suppl.) 54 2017年02月
  • 甲斐田 勇人; 石井 一成; 細川 知紗; 仁 誠雲; 細野 眞; 村上 卓道; 花岡 宏平; 乾 浩己 核医学 54 (1) 668 -669 2017年02月
  • 非小細胞肺癌のFDG集積とGlut-1、pStat-1、pStat-3での予後因子の検討
    甲斐田 勇人; 東 公一; 河原 明彦; 服部 聡; 倉田 精二; 高森 信三; 藤本 公則; 鹿毛 政義; 石井 一成; 村上 卓道; 石橋 正敏 核医学 53 (Suppl.) S283 2016年10月
  • 認知症患者における線条体アミロイド沈着の検討
    細川 知紗; 石井 一成; Sauerbeck Julia; Sheiwein Franziska; 甲斐田 勇人; 兵頭 朋子; 山田 穣; 細野 眞; 花岡 宏平; 村上 卓道 核医学 53 (Suppl.) S276 2016年10月
  • 上顎洞術後変化としての眼窩下管拡大
    福井 秀行; 柏木 伸夫; 任 誠雲; 甲斐田 勇人; 柳生 行伸; 小塚 健倫; 細川 知紗; 熊野 正士; 鶴崎 正勝; 松木 充; 今岡 いずみ; 細野 眞; 石井 一成; 村上 卓道 Japanese Journal of Diagnostic Imaging 34 (1) 116 2016年02月
  • 細川 知紗; 石井 一成; Sauerbeck Julia; Scheiwein Franziska; 甲斐田 勇人; 山田 穣; 兵頭 朋子; 細野 眞; 花岡 宏平; 村上 卓道 核医学 53 (1) 561 2016年02月
  • 甲斐田 勇人; 石井 一成; 村上 卓道; 田原 宣広; 本多 亮博; 福本 義弘; 石橋 正敏 核医学 52 (4) 403 2015年11月
  • H. Kaida; K. Azuma; A. Kawahara; S. Hattori; S. Takamori; E. Sadashima; K. Fujimoto; M. Kage; S. Kurata; Y. Hirose; K. Ishii; T. Murakami; M. Ishibashi EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 42 S298 2015年10月
  • K. Ishii; R. Takahashi; Y. Wakabyashi; C. Hosokawa; H. Kaida; T. Murakami EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 42 S546 2015年10月
  • 膵癌のFDG集積とmTOR関連マーカーとの相関性に関する分子病理学的検討
    甲斐田 勇人; 東 公一; 河原 明彦; 安永 昌史; 服部 聡; 倉田 精二; 廣瀬 靖光; 鹿毛 政義; 石井 一成; 村上 卓道; 石橋 正敏 核医学 52 (3) 248 2015年09月
  • PiB陰性例の18F-FDG PETによる脳代謝分布の検討
    細川 知紗; 石井 一成; 若林 雄一; 兵頭 朋子; 花田 一志; 甲斐田 勇人; 細野 眞; 木村 裕一; 村上 卓道 核医学 52 (3) 262 2015年09月
  • Statin Alleviates Persistent Coronary Arterial Inflammation Long After Kawasaki Disease - A Serial Fluorodeoxyglucose Positron Emission Tomography Study -
    Kenji Suda; Nobuhiro Tahara; Akihiro Honda; Hironaga Yoshimoto; Shintaro Kishimoto; Yoshiyuki Kudo; Hayato Kaida; Toshi Abe; Takafumi Ueno; Yoshihiro Fukumoto Circulation 131 (S2) AO74 2015年06月
  • Hayato Kaida; Uhi Toh; Akihiko Kawahara; Seiji Kurata; Yasumitsu Hirose; Masayoshi Kage; Kazunari Ishii; Takamichi Murakami; Masatoshi Ishibashi Journal of Nuclear Medicine 56 (3) 1309 2015年05月
  • Kenji Suda; Nobuhiro Tahara; Akihiro Honda; Motofumi Iemura; Hironaga Yoshimoto; Shintaro Kishimoto; Yoshiyuki Kudo; Hiroyuki Tanaka; Hayato Kaida; Toshi Abe; Takafumi Ueno; Yoshihiro Fukumoto Circulation 131 (suppl_2) 2015年04月
  • K. Baba; M. Ishibashi; H. Kaida; C. Hattori; T. Kugiyama; K. Muraki; T. Abe EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 41 S329 2014年10月
  • 長田周治; 江藤英博; 甲斐田勇人; 倉田精二; 鈴木 弦; 淡河恵津世; 安陪等思 画像診断 34 (9) 1055 -1063 2014年
  • 廣瀬 靖光; 甲斐田 勇人; 倉田 精二; 安陪 等思; 石橋 正敏; 河原 明彦; 鹿毛 正義; 田中 寿明; 米本 孝二 核医学 50 (3) S190 2013年09月
  • S. Kurata; K. Shizukuishi; U. Tateishi; T. Yoneyama; A. Hino; H. Kaida; M. Ishibashi; N. Hayabuchi; T. Inoue EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 39 S492 -S493 2012年10月
  • 北里 雄平; 安永 昌史; 木下 壽文; 吉富 宗宏; 赤須 玄; 御鍵 和弘; 川原 隆一; 石川 博人; 久下 亨; 堀内 彦之; 甲斐田 勇人; 石橋 正敏; 河原 明彦; 鹿毛 政義 日本外科学会雑誌 113 (2) 561 -561 2012年03月
  • 食道扁平上皮癌における18F-FDG集積とbiological parameter関連性の検討
    廣瀬 靖光; 甲斐田 勇人; 倉田 精二; 小林 真衣子; 石橋 正敏; 早渕 尚文; 河原 明彦; 鹿毛 正義; 藤田 博正; 米本 孝二 第71回日本医学放射線学会学術集会抄録集 S343 2012年02月
  • PET／CTによる肝胆膵の悪性腫瘍診断の有用性と位置づけ―国内外の文献報告に見る現状と可能性．
    甲斐田勇人; 廣瀬靖光; 倉田精二; 石橋正敏 インナービジョン 25 (25) 8 -11 2012年
  • 泌尿器科領域におけるPET テクノロジーの展望.
    倉田精二; 甲斐田勇人; 石橋正敏 Urology today 20 (20) 8 -11 2012年
  • Y. Hirose; H. Kaida; S. Kurata; M. Kobayashi; A. Kawahara; S. Hattori; M. Hayakawa; M. Kage; H. Fujita; N. Hayabuchi; M. Ishibashi EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 38 S361 -S362 2011年10月
  • 渡邉 祐子; 淡河 恵津世; 甲斐田 勇人; 鈴木 弦; 江藤 英博; 末藤 大明; 服部 睦行; 辻 千代子; 早渕 尚文 癌と化学療法 38 (9) 1503 -1505 2011年09月
  • 放射線治療後長期生存した進行肺癌の1例
    渡邉 祐子; 淡河 恵津世; 甲斐田 勇人; 末藤 大明; 江藤 英博; 鈴木 弦; 辻 千代子; 服部 睦行; 早渕 尚文 Japanese Journal of Radiology 29 (Suppl.I) 85 2011年01月
  • 次世代のクリニカルPET NaF PETイメージングの臨床.
    倉田精二; 甲斐田勇人; 石橋正敏; 雫石一也; 立石宇貴秀; 井上登美夫 Rad fan 9 (9) 62 -65 2011年
  • Shunji Arikawa; Masafumi Uchida; Etsuyo Ogoh; Jun Uozumi; Seigo Yoshida; Yuko Watanabe; Hayato Kaida; Nobuya Ishibashi; Kazuo Shirouzu; Naofumi Hayabuchi Gan to kagaku ryoho. Cancer & chemotherapy 37 (4) 727 -30 2010年04月
  • Yuji Hiromatsu; Hayato Kaida; Masatoshi Ishibashi; Seiji Kurata; Hirohito Umeno; Akihiko Kawahara; Masayoshi Kage; Satoshi Hattori ENDOCRINE JOURNAL 57 S456 -S456 2010年03月
  • 原発性・転移性肝癌におけるFDG-PETの有用性．
    甲斐田勇人; 小林真衣子; 倉田精二; 石橋正敏 インナービジョン 25 (25) 8 -11 2010年
  • Kiminori Fujimoto; Hayato Kaida; Nestor L. Mueller; Junko Sadohara; Ryouji Iwamoto; Naoko Fujimoto; Shuji Kurata; Fumihiko Muta; Toshihiro Matsuo; Shinzo Takamori; Masatoshi Ishibashi; Naofumi Hayabuchi JOURNAL OF THORACIC ONCOLOGY 4 (9) S478 -S478 2009年09月
  • S. Kurata; M. Ishibashi; H. Kaida; K. Azuma; M. Kobayashi; Y. Hirose; S. Takamori; H. Aizawa; N. Hayabuchi EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 36 S461 2009年09月
  • Hepatobiliary pancreatic MR imaging progresses at 3T improvement in gradient strength and parallel processing techniques boost diagnostic power of high-field dynamic studies.
    Kunou Y; Uchida M; Kaida H; Hayabuchi N Diagnostic Imaging 15 (15) 12 -13 2009年
  • 消化器がん転移診断におけるPETの意義(2)遠隔転移.
    石橋正敏; 甲斐田勇人; 倉田精二 臨床消化器内科 24 (3) 291 -300 2009年
  • 乳癌の画像診断におけるFDG-PETの有用性．
    田山光介; 唐 宇飛; 藤井輝彦; 白水和雄; 甲斐田勇人 日本臨床 65 373 -378 2007年
  • 三宅 育代; 馬場 健吉; 迎 徳範; 賀来 寛雄; 甲斐田 勇人; 石橋 正敏; 広松 雄治; 山田 研太郎 ホルモンと臨牀 54 105 -113 2006年09月
  • S. Kurata; M. Ishibashi; H. Kaida; H. Nishida; Y. Hiromatsu; S. Okuda; N. Hayabuchi EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 33 S361 2006年09月
  • H. Kaida; M. Ishibashi; S. Kurata; E. Ogo; T. Fujii; N. Hayabuchi EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 33 S253 2006年09月
  • 非小細胞癌における縦隔肺門リンパ節転移の診断
    藤本公則; 佐土原順子; 甲斐田勇人; 石橋正敏; 早渕尚文; 松尾敏弘; 高森信三 臨床画像 22 38 -51 2006年
  • 石橋正敏; 馬場健吉; 甲斐田勇人; 早渕尚文 久留米医学会誌 68 (1・2) 22 -27 2005年

受賞

  • 2023年06月 日本心臓核医学会 第12回学会賞技術部門
     心サルコイドーシスFDG PET/CT検査における呼吸同期・心電図同期収集の効果 
    受賞者: 花岡宏平;渡邊翔太;石川大介;甲斐田勇人;安田昌和;岩永善高;中澤 学;石井一成
  • 2023年05月 第62回日本生体医工学大会 Young Investigator's Award (YIA 2023) 優秀賞
     Pix2Pix画像スタイル変換を用いた教師無し異常検知によるFDG-PET/CT像上肺病変強調 
    受賞者: 大谷和暉;根本充貴;甲斐田勇人;瀬川新;中前有香子;村中皓紀;吉田昂平;木村裕一;永岡隆;山田誉大;花岡宏平;槌谷達也;北島一宏;石井一成
  • 2023年04月 日本医学放射線学会 教育展示優秀賞
     Clinical role of FDG-PET/CT for the diagnosis of Esophageal cancer 
    受賞者: Hayato Kaida;Minoru Yamada;Yuko Matsukubo;Hiroaki Kato;Sung-Woon Im;Osamu Shiraishi;Takenori Kozuka;Makoto Hosono;Takushi Yasuda;Kazunari Ishii
  • 2022年07月 近畿大学医学会 近畿大学医学会賞
     Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan. 
    受賞者: Kaida H;Kitajima K;Nakajo M;Ishibashi M;Matsunaga T;Minamimoto R;Hirata K;Nakatani K;Hung A;Hattori S;Yasuda T;Ishii K
  • 2022年06月 Society of Nuclear Medicine & Molecular Imaging (SNMMI 2022 Annual Meeting） SNMMI-TS Professional Development Grant Award
     Comparison between the μ-maps of different PET tracers: 18F-FDG and 18F-flutemetamol, generated by the attenuation correction method without external radiation source. 
    受賞者: Takahiro Yamada;Kohei Hanaoka;Yoshiyuki Yamakawa;Suzuka Minagawa;Atsushi Ohtani;Tetsuro Mizuta;Hayato Kaida;Kazunari Ishii
  • 2019年06月 Society of Nuclear Medicine & Molecular Imaging (SNMMI 2019 Annual Meeting） TECHNOLOGIST BEST POSTER AWARD 3RD PLACE (SNMMI 2019)
     Optimization of respiratory gated 18F-FDG PET/CT scan protocol for cardiac sarcoidosis. 
    受賞者: Kohei Hanaoka;Shota Watanabe;Yusuke Shibata;Hayato Kaida;Makoto Hosono;Kazunari Ishii
  • 2012年04月 日本医学放射線学会 Silver Medal
     食道扁平上皮癌における18F-FDG集積とbiological parameter関連性の検討. 
    受賞者: 廣瀬靖光;甲斐田勇人;倉田精二;小林真衣子;石橋正敏;早渕尚文;河原明彦;鹿毛政義;藤田博正;米本孝二
  • 2011年04月 日本医学放射線学会 第8回日本医学放射線学会研究助成
     乳癌のFDG集積と癌増殖シグナル伝達系との関連性の研究 
    受賞者: 甲斐田勇人

共同研究・競争的資金等の研究課題

  • 日本学術振興会：科学研究費助成事業 基盤研究(C)
    研究期間 : 2022年04月 -2026年03月 
    代表者 : 北島 一宏; 山門亨一郎; 甲斐田勇人; 渡部直史; 大崎洋充
  • 食道癌術前化学療法の治療効果予測－低酸素イメージングと癌シグナル伝達因子との相関
    日本学術振興会：科学研究費助成事業 基盤研究(C)
    研究期間 : 2021年04月 -2025年03月 
    代表者 : 甲斐田勇人, 石井一成, 安田卓司, 伊藤彰彦, 細野 眞, 服部 聡, 河原明彦
  • アミノ酸イメージングと癌シグナル伝達因子による脳腫瘍患者の予後予測マーカーの解明
    GEヘルスケアファーマ：GEヘルスケアファーマ奨学寄付プログラム
    研究期間 : 2021年04月 -2022年03月 
    代表者 : 甲斐田勇人
  • 日本学術振興会：科学研究費助成事業 基盤研究(C)
    研究期間 : 2019年04月 -2022年03月 
    代表者 : 北島 一宏; 山門 亨一郎; 甲斐田 勇人; 伊藤 公輝; 関根 鉄朗; 大崎 洋充
     
    初年度は、FDG-PET/CTで得られる 悪性腫瘍（癌、肉腫）のバイオマーカーとして期待されている SUV（standardized uptake value ) やMTV（metabolic tumor volume）やTLG （total lesion glycolysis）などの定量値を、異なる施設や異なる装置間で同列に扱えるように、4施設9つのPET/CT装置のハーモナイゼーションの調整を、ファントム実験により下記の手順で行った。 ①各施設のPET/CT装置の撮影条件と再構成条件の確認 ・撮影条件：FDGの投与量、待機時間、撮影モード、1ベッドあたりの収集時間、TOFの有無の確認 ・再構成条件：再構成法、再構成パラメーター、平滑化フィルター、マトリックスサイズ、ピクセルサイズ、PSF補正の有無を確認する。 ②NEMAボディファントムを用いたファントム実験の実施 本研究に使用する各施設のPET/CT装置に対し、NEMAボディファントムを用いたファントム実験を行う。 ③SUVmaxの標準化と検証 各施設のPET/CT装置に対し、日本核医学会が構築した「18F-FDGを用いた全身PET撮像のためのファントム試験手順書」から各球体サイズ（直径10～37mm）の陽性像におけるSUVmaxの標準化の値を比較し、標準化されたSUVmaxが同じになるか否かを検討する。 以上の検証を行って、4施設9つのPET/CT装置のハーモナイゼーションが可能な事を確認した。 今後は、臨床データを用いた臨床的有用性を検討していく。
  • The clinical application of artifical intelligence based computer-aid diagnosis algorithm for 18F-FDG PET/CT for the staging of primary lung cancer
    GEヘルスケアファーマ：GEヘルスケアファーマ奨学寄付プログラム
    研究期間 : 2020年04月 -2021年03月 
    代表者 : 甲斐田勇人
  • FDG-PET/CTによる食道癌術前化学療法の効果判定－PERCISTの有効性の検討
    エーザイ株式会社：エーザイ奨学寄付金
    研究期間 : 2019年04月 -2021年03月 
    代表者 : 甲斐田勇人
  • 日本学術振興会：科学研究費助成事業 基盤研究(C)
    研究期間 : 2016年04月 -2021年03月 
    代表者 : 甲斐田 勇人; 加藤 天美; 河原 明彦; 村上 卓道; 服部 聡; 石井 一成; 伊藤 彰彦
     
    この研究の目的は11C-methionine (MET) PETと神経膠腫で手術を受けた患者を対象に、アミノ酸代謝や細胞増殖シグナル伝達因子（LAT1, mTOR, HIF1-α，VEGF, EGFR)とMET集積との相関性を明らかにし、MET集積パラメータ(T/N ratio,SUVmax, SUVmean, TLA, MTV)と、細胞増殖シグナル伝達因子を用いて予後予測因子を前向き研究で明らかし、脳腫瘍の腫瘍増殖とアミノ酸代謝の関係について病理学的解明も試みる。令和元年度も当施設の脳神経外科と密接に連携し、研究参加可能な脳腫瘍患者の登録を継続している。年度末までにMET PET/CTを受けた32例の脳腫瘍患者を登録できた。これらの患者は当施設で手術や放射線治療などの集学的治療やその後の経過観察も行っている。現在、そのうち17例の病理標本染色を共同研究機関である久留米大学の病院病理部で開始し、染色を行っている途中である。また、収集したMET PET/CTデータのパラメータに関する解析も同時に遂行中で、その結果の一部を第79回日本医学放射線学会総会で発表する予定である。来年度も対象患者のデータ収集を第一に努めていきたいと考える。PET/CTデータ収集と解析、手術を行った患者の病理標本の染色に関して円滑に進めていけるよう、関係各所との連携を再確認し、随時打ち合わせを実施する。次年度は最終年度に該当するため、データのとりまとめを行っていく予定である。
  • FDG-PET/CTとMRIによる血管炎症と脳白質病変や海馬体積との関連性の検討
    第一三共株式会社：第一三共奨学寄付プログラム
    研究期間 : 2018年04月 -2019年03月 
    代表者 : 甲斐田勇人
  • 日本学術振興会：科学研究費助成事業 基盤研究(C)
    研究期間 : 2014年04月 -2017年03月 
    代表者 : 田原 宣広; 本多 亮博; 甲斐田 勇人; 知花 英俊
     
    肺動脈性肺高血圧症 (PAH)例の肺血管障害や右心負荷の程度をFDG-PET/CTを用いて定量評価し、PAHの疾患重症度との関連性について検討した。健常例と比較して、肺野や右心室のFDG集積はPAH例で有意に高値であり、肺血管障害や右心負荷を反映していると考えられた。また、肺血管拡張薬による治療介入により肺血行動態の改善が認められ、右室FDG集積は減弱、肺野FDG集積は肺血管抵抗の改善が不十分な例においてのみ増加した。肺動脈平均圧、右室駆出率、NT-pro-BNPは右室FDG集積に独立して関連する因子であり、治療による右室FDG集積の変化が、右室駆出率の変化に独立して関連する因子であった。
  • 日本学術振興会：科学研究費助成事業 基盤研究(C)
    研究期間 : 2012年04月 -2015年03月 
    代表者 : 甲斐田 勇人; 藤本 公則; 東 公一; 早渕 尚文; 石橋 正敏; 高森 信三; 服部 聡; 鹿毛 政義; 倉田 精二; 服部 聡; 早渕 尚文; 石橋 正敏; 高森 信三
     
    研究の目的は非小細胞肺癌で手術を受けた患者150名の摘出標本に癌増殖シグナル伝達因子の免疫染色を行い、FDG集積と癌増殖シグナル伝達因子との相関性を明らかにし、非小細胞肺癌の生存率に関係する最適なFDG集積の評価方法(SUV max, MTV, TLG)とシグナル伝達因子を明らかにする事で再発や転移リスク患者の層別化が可能か検討した。Western blotでFDGの集積規定因子のGlut-1に関するシグナル伝達因子はStat-1, Stat-3であり、FDG集積との相関性が見られたのはGlut-1, Stat-3で関連性が見られた。予後はSUV max, MTV, TLG共に関連が見られた。
  • 日本学術振興会：科学研究費助成事業 基盤研究(C)
    研究期間 : 2011年 -2013年 
    代表者 : 田原 宣広; 石橋 正敏; 児玉 紀洋; 上野 高史; 光武 良亮; 甲斐田 勇人
     
    我々は、ステント留置後の局所炎症をFDG-PETと多列化CTを用いて描出し、ステント留置後に生じる種々の問題点との関連について検討した。心筋のFDG集積を抑制する目的で12時間以上の絶食とヘパリン前投与を行ったが、心筋のFDG集積を完全に抑制することはできなかった。冠動脈におけるFDG集積の評価が可能な例でステント留置部のFDG集積が強い例では、慢性期の冠動脈造影において狭窄が進行し、黄色調病変が多く、血管内皮機能が低下していた。また、遅発性ステント圧着不良やステント部位の付着血栓を認め、ステント部位にFDG集積が確認された。ステント留置局所の炎症がこれらの事象に関与していることが推察された。
  • 日本学術振興会：科学研究費助成事業 基盤研究(C)
    研究期間 : 2011年 -2013年 
    代表者 : 石橋 正敏; 甲斐 田勇人; 倉田 精二; 藤井 輝彦; 鹿毛 政義; 安永 昌文; 北里 雄平; 内田 政史; 土居 亮介; 早渕 尚文; 木下 壽文
     
    分子病理学的手法を用い膵癌増殖に関与するシグナル伝達因子とGLUT-1との関連を調べFDG集積やこれらシグナル伝達因子との相関性を検討した。cell line ではEGFR, P70, mTOR,P-riboprotein, riboproteinがGLUT-1が関係する因子と判明した。膵癌術前にFDG-PET/CTを施行した44例にこれら癌シグナル伝達因子の免疫染色を行った。FDG集積の評価にSUV maxを用い、SUV maxはEGFR, GLUT-3, GLUT-1, P70と有意な相関を認めた。膵癌のFDG集積機序にGLUT-1やmTOR関連シグナル伝達因子やEGFRが関与していた。
  • 日本学術振興会：科学研究費助成事業 基盤研究(C)
    研究期間 : 2011年 -2013年 
    代表者 : 倉田 精二; 甲斐 田勇人; 石橋 正敏; 牛嶋 公生; 嘉村 敏治; 早渕 尚文; 鹿毛 政義
     
    卵巣癌における99mTc-MIBI SPECTと多剤耐性関連蛋白の発現の関係を検討した。卵巣癌疑いの13例の患者に、99mTc-MIBI 740MBqを投与して早期と後期にSPECT撮影を行い、腫瘍軟部組織比（早期、後期）及び洗い出し率を算出した。摘出標本を用いて免疫組織化学染色を行い、99mTc-MIBIと多剤耐性関連蛋白の発現の関連を検討した。術後病理診断で6例が卵巣癌と診断された。99mTc-MIBI SPECTで5例に集積を認め、多剤耐性関連蛋白の発現を認めた。99mTc-MIBIの洗い出し率はYB-1と強い正の相関を認めた。また、早期の腫瘍軟部比はBaxと強い正の相関を認めた。
  • 乳癌のFDG集積と癌増殖シグナル伝達系との関 連性の研究
    日本医学放射線学会：日本医学放射線学会研究助成金
    研究期間 : 2010年04月 -2011年03月 
    代表者 : 甲斐田勇人
  • 日本学術振興会：科学研究費助成事業 若手研究(B)
    研究期間 : 2009年04月 -2011年03月 
    代表者 : 甲斐田 勇人
     
    頚動脈の不安定プラークが疑われるPET/CT検診者対象に高分解能心臓CTを施行し、頚動脈の不安定プラークへのFDG集積と冠動脈の不安定プラークの関係を検討し、これらとプラーク形成や破綻に関与する血清サイトカイン(MPO, PTX, ADMA,高感度CRP, MDA-LDL)との関係を調べた。頸動脈のFDG集積の評価法はtarget-to-background ratio(TBR)を用いた。TBRは高感度CRPやMDA-LDLと有意な相関を認め、特にMDA-LDLとの関連が強かった。心臓CTは80例中3名の負荷心電図で異常が見られ、3名に心臓CTをおこない、1名の冠動脈に50%狭窄と不安定プラークが見られた。しかし、頸動脈のFDG集積と冠動脈不安定プラークとの関連ははっきりとした結論は得られなかった。
  • 日本学術振興会：科学研究費助成事業 基盤研究(C)
    研究期間 : 2008年04月 -2010年03月 
    代表者 : 石橋 正敏; 甲斐田 勇人; 倉田 精二; 鹿毛 政義; 山名 秀明; 藤井 輝彦; 藤田 博正; 早渕 尚文
     
    食道癌のF-18 FDG PET/CTの結果とVEGF(vasoendothelial growth factor)とGLUT-1(glucose transporter)の関係を評価するために本研究を施行した。本研究に、57例の食道癌を検討した。内訳は、男性52例、女性5例であった。食道癌摘出手術前に、全例、PET/CT施行した。摘出標本を用いて、免疫染色が行われた。免疫染色の結果の評価は、視覚的に行われた。FDG PET/CTで得られたパラメータであるSUVmaxとGLUT-1/VEGF,p-T stageとGLUT-1/VEGF、SUVmax,さらにp-N stageとGLUT-1/VEGF、SUVmaxとの関係を調べた。結果:SUV maxは、GLUT-1/VEGFとp-tumor lengthと有意に相関した。原発巣のSUVmaxはp-T stage,p-N stage,VEGF発現と相関した。結語として、FDG uptakeはGLUT-1とVEGF発現に関連した。SUVmaxは、食道癌の予後およびリンパ節転移との関連性を見いだした。
  • 日本学術振興会：科学研究費助成事業 基盤研究(C)
    研究期間 : 2007年04月 -2009年03月 
    代表者 : 倉田 精二; 甲斐田 勇人; 石橋 正敏; 早渕 尚文; 高森 信三; 相沢 久道
     
    アスベスト曝露歴を有し、悪性胸膜中皮腫が疑われた患者に対する18F-FDG PET/CT検査およびSUVmaxを使った半定量的評価、血漿オステオポンチン濃度の測定が終了した。症例の内訳は悪性胸膜中皮腫、胸膜炎、胸膜プラークであった。悪性胸膜中皮腫を有する群と胸膜炎を有する群の比較では、オステオポンチン濃度での判別は困難であったが、SUVmax値を用いることにより判別できる可能性が示唆された。また、胸膜炎と胸膜プラークの群での血漿オステオポンチン濃度とSUVmax値との間に相関関係が見られ、炎症の活動性の指標となる可能性が示唆された。
  • 日本学術振興会：科学研究費助成事業 基盤研究(C)
    研究期間 : 2005年04月 -2007年03月 
    代表者 : 石橋 正敏; 甲斐田 勇人; 山名 秀明; 藤井 輝彦; 早渕 尚文
     
    1.^<18>F-FDG PETにおける腫瘍集積性と乳癌細胞増殖動態の比較 対象は初発乳癌患者である。対象患者数は約118名で、対象患者の範疇に入るのは手術、化学療法、放射線治療等の治療適応のある患者であった。また、対象患者の範疇に入るが糖尿病に罹患していた場合は血糖値200mg/dl以下にコントロールされている患者とした。対象患者全てに^<18>F-FDGPETを施行した。放射線医薬品は^<18>F-FDGを用いた。投与量は0.12mCi/kgで行い、PETの機種はAllegro(Philps/ADAC)であり,GSO-PETである。FDG投与後1時間安静とし、撮像を開始した。撮像方法は、全身を撮像し、我々で開発したPETマンモ用治具を用いて、腹臥位(supine position:SP)と仰臥位(prone position:PP)にて撮像した。全身像とPPと比較し、前者よりPPで8.8%乳癌を指摘できた。結論として、乳癌のFDG-PETには、PPの追加が必要であった。またPETで再発または転移が疑われた症例では、PET以外にCTやMRI等の他の検査でも再発や転移の評価を行い、病変の存在が確定した後に再発や転移症例に関してbiopsyが可能であればできるだけ施行した。また、初発乳癌全例で手術を施行した場合、得られた摘出標本の癌組織におけるERK MAPKのリン酸化を免疫染色で検討した。すなわち、リン酸化したERK MAPKを特異的に認識する抗体を用い免疫染色をおこなった。細胞質が染色された癌細胞をERK MAPK陽性細胞とし、癌細胞の40%以上陽性を示した症例をERK MAPK陽性とした。免疫染色により得られた乳癌細胞におけるERK MAPKのリン酸化、すなわち、乳癌の細胞増殖動態と^<18>F-FDG PETの解析データとの比較検討を開始した。118例中の73例に解析を行ったその結果、MAPK(+)群 SUVmax 4.02±2.76 vs.MAPK(-)SUVmax 3.87±2.70(P=0.25)には有意差を認めなかった。ER,PgR,Her2のいずれとも有意差はなかった。乳癌に関するFDGの取り込みと細胞増殖との関係は、免疫染色の抗体の再検討を行う必要があると結論づけられた。
  • FDG-PETと分子病理学による甲状腺癌の細胞増殖能の特性解析
    久留米大学医学部同窓会：久留米大学医学部同窓会研究補助金
    研究期間 : 2007年 
    代表者 : 甲斐田勇人

委員歴

  • 2021年11月 - 現在   日本核医学会   日本核医学会 編集委員
  • 2017年10月 - 現在   日本核医学会   日本核医学会 評議員

その他のリンク

researchmap


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.